<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:aemd="http://aethlonmedical.com/20240331"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="aemd-20240331.xsd" xlink:type="simple"/>
    <context id="From2023-04-01to2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
        </entity>
        <period>
            <instant>2023-09-29</instant>
        </period>
    </context>
    <context id="AsOf2024-06-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
        </entity>
        <period>
            <instant>2024-06-25</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2022-04-012023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_MelanomaCancerContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">aemd:MelanomaCancerContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_CashInUSBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">aemd:CashInUSBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_CashInUSBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">aemd:CashInUSBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_CashEquivalentsInUSTreasuryBillsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">aemd:CashEquivalentsInUSTreasuryBillsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_CashEquivalentsInUSTreasuryBillsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">aemd:CashEquivalentsInUSTreasuryBillsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_CashInAustralianBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">aemd:CashInAustralianBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_CashInAustralianBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">aemd:CashInAustralianBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_StockBasedCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">aemd:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_StockBasedCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">aemd:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-032023-10-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
        </entity>
        <period>
            <startDate>2023-10-03</startDate>
            <endDate>2023-10-04</endDate>
        </period>
    </context>
    <context id="From2022-03-232022-03-24_custom_ATM2022AgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">aemd:ATM2022AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-23</startDate>
            <endDate>2022-03-24</endDate>
        </period>
    </context>
    <context id="From2022-09-282022-09-29_custom_ATM2022AgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">aemd:ATM2022AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-28</startDate>
            <endDate>2022-09-29</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_ATM2022AgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">aemd:ATM2022AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_ATM2022AgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">aemd:ATM2022AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_ATM2022AgreementMember_custom_HcWainwrightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aemd:HcWainwrightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">aemd:ATM2022AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_Director1Member_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aemd:Director1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_Director2Member_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aemd:Director2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_Director3Member_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aemd:Director3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_ATM2022AgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">aemd:ATM2022AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_ATM2022AgreementMember_custom_HcWainwrightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aemd:HcWainwrightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">aemd:ATM2022AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_EligibleDirectorsEachMember_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aemd:EligibleDirectorsEachMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_NewlyAppointedDirectorMember_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aemd:NewlyAppointedDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2022-09-012022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_OptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_OptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_RSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">aemd:RSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aemd:RangeOfExercisePrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aemd:RangeOfExercisePrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aemd:RangeOfExercisePrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aemd:RangeOfExercisePrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aemd:RangeOfExercisePrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aemd:RangeOfExercisePrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aemd:RangeOfExercisePrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aemd:RangeOfExercisePrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_OptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_OptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_OptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_OptionMember_custom_ExercisePrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aemd:ExercisePrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_OptionMember_custom_ExercisePrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aemd:ExercisePrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_OptionMember_custom_ExercisePrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aemd:ExercisePrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_OptionMember_custom_ExercisePrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aemd:ExercisePrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_OptionMember_custom_ExercisePrice3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aemd:ExercisePrice3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_OptionMember_custom_ExercisePrice3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aemd:ExercisePrice3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_NonEmployeeDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aemd:NonEmployeeDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_Dr.FisherMember_custom_SeparationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">aemd:Dr.FisherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aemd:SeparationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-12-012024-03-31_custom_SeparationAgreementMember_custom_Dr.FisherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">aemd:Dr.FisherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aemd:SeparationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_AccruedBoardFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aemd:AccruedBoardFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_AccruedBoardFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aemd:AccruedBoardFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_AccruedVacationToAllEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aemd:AccruedVacationToAllEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_AccruedVacationToAllEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aemd:AccruedVacationToAllEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_AccruedSeparationExpensesForFormerExecutiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aemd:AccruedSeparationExpensesForFormerExecutiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_AccruedSeparationExpensesForFormerExecutiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aemd:AccruedSeparationExpensesForFormerExecutiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_FederalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">aemd:FederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_StateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">aemd:StateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_OfficeAndLaboratorySpaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">aemd:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_ManufacturingSpaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">aemd:ManufacturingSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_OfficeLabAndManufacturingLeasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">aemd:OfficeLabAndManufacturingLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2023-04-01to2024-03-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2023-04-01to2024-03-31" id="Fact000004">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-04-01to2024-03-31" id="Fact000005">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2023-04-01to2024-03-31" id="Fact000006">0000882291</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-03-31"
      id="xdx2ixbrl0118"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-03-31"
      id="xdx2ixbrl0119"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-04-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0241"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-04-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0242"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-04-012023-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0243"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-04-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0250"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-04-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0251"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-04-012023-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0252"
      unitRef="USD"
      xsi:nil="true"/>
    <aemd:LossOnDissolutionOfSubsidiary
      contextRef="From2022-04-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0257"
      unitRef="USD"
      xsi:nil="true"/>
    <aemd:LossOnDissolutionOfSubsidiary
      contextRef="From2022-04-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0258"
      unitRef="USD"
      xsi:nil="true"/>
    <aemd:LossOnDissolutionOfSubsidiary
      contextRef="From2022-04-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0259"
      unitRef="USD"
      xsi:nil="true"/>
    <aemd:LossOnDissolutionOfSubsidiary
      contextRef="From2022-04-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0260"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-04-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0264"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-04-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-04-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-04-012023-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0268"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0271"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-04-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-04-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-04-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0280"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-04-012023-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012024-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <aemd:StockIssuedDuringPeriodValueRoundingForReverseSplit
      contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <aemd:StockIssuedDuringPeriodValueRoundingForReverseSplit
      contextRef="From2023-04-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <aemd:StockIssuedDuringPeriodValueRoundingForReverseSplit
      contextRef="From2023-04-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <aemd:StockIssuedDuringPeriodValueRoundingForReverseSplit
      contextRef="From2023-04-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <aemd:StockIssuedDuringPeriodValueRoundingForReverseSplit
      contextRef="From2023-04-012024-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <aemd:StockIssuedDuringPeriodValueRoundingForReverseSplit
      contextRef="From2023-04-01to2024-03-31"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <aemd:IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsValue
      contextRef="From2023-04-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <aemd:IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsValue
      contextRef="From2023-04-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <aemd:IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsValue
      contextRef="From2023-04-012024-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <aemd:ReversalOfAccruedCommissionLiability
      contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <aemd:ReversalOfAccruedCommissionLiability
      contextRef="From2023-04-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <aemd:ReversalOfAccruedCommissionLiability
      contextRef="From2023-04-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <aemd:ReversalOfAccruedCommissionLiability
      contextRef="From2023-04-012024-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012024-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0340"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012024-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0341"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0344"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-04-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-04-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-04-012024-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="xdx2ixbrl0483"
      unitRef="USD">-12208174</us-gaap:NetIncomeLoss>
    <dei:DocumentType contextRef="From2023-04-01to2024-03-31" id="Fact000012">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2023-04-01to2024-03-31" id="Fact000013">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-04-01to2024-03-31" id="Fact000014">2024-03-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-04-01to2024-03-31" id="Fact000016">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="From2023-04-01to2024-03-31" id="Fact000017">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-04-01to2024-03-31" id="Fact000018">001-37487</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-04-01to2024-03-31" id="Fact000019">Aethlon Medical, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-04-01to2024-03-31" id="Fact000020">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-04-01to2024-03-31" id="Fact000021">13-3632859</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-04-01to2024-03-31" id="Fact000022">11555 Sorrento Valley Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-04-01to2024-03-31" id="Fact000023">Suite 203</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-04-01to2024-03-31" id="Fact000024">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-04-01to2024-03-31" id="Fact000025">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-04-01to2024-03-31" id="Fact000026">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-04-01to2024-03-31" id="Fact000027">619</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-04-01to2024-03-31" id="Fact000028">941-0360</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-04-01to2024-03-31" id="Fact000030">COMMON STOCK, $0.001 PAR VALUE</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-04-01to2024-03-31" id="Fact000032">AEMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-04-01to2024-03-31" id="Fact000034">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2023-04-01to2024-03-31" id="Fact000035">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2023-04-01to2024-03-31" id="Fact000036">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2023-04-01to2024-03-31" id="Fact000037">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-04-01to2024-03-31" id="Fact000038">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-04-01to2024-03-31" id="Fact000039">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-04-01to2024-03-31" id="Fact000040">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-04-01to2024-03-31" id="Fact000041">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2023-04-01to2024-03-31" id="Fact000042">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2023-04-01to2024-03-31" id="Fact000043">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2023-04-01to2024-03-31" id="Fact000044">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2023-09-29"
      decimals="0"
      id="Fact000046"
      unitRef="USD">5500000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-06-25"
      decimals="INF"
      id="Fact000047"
      unitRef="Shares">13899725</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="From2023-04-01to2024-03-31" id="Fact000049">23</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2023-04-01to2024-03-31" id="Fact000051">Baker Tilly US, LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2023-04-01to2024-03-31" id="Fact000053">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000061"
      unitRef="USD">5441978</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000062"
      unitRef="USD">14532943</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000064"
      unitRef="USD">277827</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000065"
      unitRef="USD">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000067"
      unitRef="USD">505983</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000068"
      unitRef="USD">557623</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000070"
      unitRef="USD">6225788</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000071"
      unitRef="USD">15090566</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000073"
      unitRef="USD">1015229</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000074"
      unitRef="USD">1144004</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000076"
      unitRef="USD">883054</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000077"
      unitRef="USD">1151909</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000079"
      unitRef="USD">1100</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000080"
      unitRef="USD">1650</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:RestrictedCash
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000082"
      unitRef="USD">87506</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000083"
      unitRef="USD">87506</us-gaap:RestrictedCash>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000085"
      unitRef="USD">33305</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000086"
      unitRef="USD">33305</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000088"
      unitRef="USD">8245982</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000089"
      unitRef="USD">17508940</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000097"
      unitRef="USD">777862</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000098"
      unitRef="USD">432889</us-gaap:AccountsPayableCurrent>
    <aemd:DueToRelatedParties
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000100"
      unitRef="USD">546434</aemd:DueToRelatedParties>
    <aemd:DueToRelatedParties
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000101"
      unitRef="USD">214221</aemd:DueToRelatedParties>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000103"
      unitRef="USD">290565</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000104"
      unitRef="USD">269386</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000106"
      unitRef="USD">215038</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000107"
      unitRef="USD">588592</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000109"
      unitRef="USD">1829899</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000110"
      unitRef="USD">1505088</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000112"
      unitRef="USD">649751</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000113"
      unitRef="USD">939642</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000115"
      unitRef="USD">2479650</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000116"
      unitRef="USD">2444730</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000127"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-03-31"
      decimals="INF"
      id="Fact000129"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000131"
      unitRef="Shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-03-31"
      decimals="INF"
      id="Fact000133"
      unitRef="Shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000135"
      unitRef="Shares">2629725</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000137"
      unitRef="Shares">2629725</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-03-31"
      decimals="INF"
      id="Fact000139"
      unitRef="Shares">2299259</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-03-31"
      decimals="INF"
      id="Fact000141"
      unitRef="Shares">2299259</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000124"
      unitRef="USD">2629</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000125"
      unitRef="USD">2299</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000143"
      unitRef="USD">160337371</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000144"
      unitRef="USD">157426606</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000146"
      unitRef="USD">-6940</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000147"
      unitRef="USD">-6141</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000149"
      unitRef="USD">-154566728</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000150"
      unitRef="USD">-142358554</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000152"
      unitRef="USD">5766332</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000153"
      unitRef="USD">15064210</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000155"
      unitRef="USD">5766332</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000156"
      unitRef="USD">15064210</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000158"
      unitRef="USD">8245982</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000159"
      unitRef="USD">17508940</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000164"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000165"
      unitRef="USD">574245</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000167"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000168"
      unitRef="USD">574245</us-gaap:Revenues>
    <us-gaap:ProfessionalFees
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000173"
      unitRef="USD">3526926</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000174"
      unitRef="USD">3548028</us-gaap:ProfessionalFees>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000176"
      unitRef="USD">5206451</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000177"
      unitRef="USD">4443552</us-gaap:LaborAndRelatedExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000179"
      unitRef="USD">3903191</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000180"
      unitRef="USD">4481303</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000182"
      unitRef="USD">12636568</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000183"
      unitRef="USD">12472883</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000185"
      unitRef="USD">-12636568</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000186"
      unitRef="USD">-11898638</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainOrLossOnSaleOfStockInSubsidiary
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000191"
      unitRef="USD">-0</us-gaap:GainOrLossOnSaleOfStockInSubsidiary>
    <us-gaap:GainOrLossOnSaleOfStockInSubsidiary
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000192"
      unitRef="USD">-142121</us-gaap:GainOrLossOnSaleOfStockInSubsidiary>
    <us-gaap:InterestIncomeOther
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000194"
      unitRef="USD">428394</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000195"
      unitRef="USD">10973</us-gaap:InterestIncomeOther>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000197"
      unitRef="USD">428394</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000198"
      unitRef="USD">-131148</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000200"
      unitRef="USD">-12208174</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000201"
      unitRef="USD">-12029786</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-04-01to2024-03-31"
      decimals="INF"
      id="Fact000203"
      unitRef="USDPShares">-4.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-04-01to2024-03-31"
      decimals="INF"
      id="Fact000205"
      unitRef="USDPShares">-4.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-04-012023-03-31"
      decimals="INF"
      id="Fact000207"
      unitRef="USDPShares">-5.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-04-012023-03-31"
      decimals="INF"
      id="Fact000209"
      unitRef="USDPShares">-5.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-04-01to2024-03-31"
      decimals="INF"
      id="Fact000211"
      unitRef="Shares">2512774</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-04-01to2024-03-31"
      decimals="INF"
      id="Fact000213"
      unitRef="Shares">2512774</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-04-012023-03-31"
      decimals="INF"
      id="Fact000215"
      unitRef="Shares">2053744</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-04-012023-03-31"
      decimals="INF"
      id="Fact000217"
      unitRef="Shares">2053744</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000219"
      unitRef="USD">-12208174</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000220"
      unitRef="USD">-12029786</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000222"
      unitRef="USD">799</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000223"
      unitRef="USD">6141</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000225"
      unitRef="USD">-12208973</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000226"
      unitRef="USD">-12035927</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000235"
      unitRef="Shares">1541926</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000228"
      unitRef="USD">1542</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000237"
      unitRef="USD">1542</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000229"
      unitRef="USD">147460747</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000230"
      unitRef="USD">-130329181</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000231"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000232"
      unitRef="USD">-141708</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31"
      decimals="0"
      id="Fact000233"
      unitRef="USD">16991400</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-04-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000246"
      unitRef="Shares">748084</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-04-012023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000239"
      unitRef="USD">748</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-04-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000240"
      unitRef="USD">8926463</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000244"
      unitRef="USD">8927211</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2022-04-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000255"
      unitRef="Shares">9249</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-04-012023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000248"
      unitRef="USD">9</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-04-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000249"
      unitRef="USD">-12502</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000253"
      unitRef="USD">-12493</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <aemd:LossOnDissolutionOfSubsidiary
      contextRef="From2022-04-012023-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000261"
      unitRef="USD">142121</aemd:LossOnDissolutionOfSubsidiary>
    <aemd:LossOnDissolutionOfSubsidiary
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000262"
      unitRef="USD">142121</aemd:LossOnDissolutionOfSubsidiary>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-04-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000265"
      unitRef="USD">1051898</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000269"
      unitRef="USD">1051898</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000273"
      unitRef="USD">-12029373</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012023-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000275"
      unitRef="USD">-413</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000276"
      unitRef="USD">-12029786</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-04-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000281"
      unitRef="USD">6141</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000283"
      unitRef="USD">6141</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000292"
      unitRef="Shares">2299259</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000285"
      unitRef="USD">2299</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000294"
      unitRef="USD">2299</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000286"
      unitRef="USD">157426606</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000287"
      unitRef="USD">-142358554</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000288"
      unitRef="USD">-6141</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000289"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000290"
      unitRef="USD">15064210</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000303"
      unitRef="Shares">296056</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000296"
      unitRef="USD">296</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000297"
      unitRef="USD">1322087</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000301"
      unitRef="USD">1322383</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000312"
      unitRef="Shares">32</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <aemd:IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares
      contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000321"
      unitRef="Shares">34378</aemd:IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares>
    <aemd:IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsValue
      contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000314"
      unitRef="USD">34</aemd:IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsValue>
    <aemd:IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsValue
      contextRef="From2023-04-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000315"
      unitRef="USD">-34812</aemd:IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsValue>
    <aemd:IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsValue
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000319"
      unitRef="USD">-34778</aemd:IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsValue>
    <aemd:ReversalOfAccruedCommissionLiability
      contextRef="From2023-04-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000324"
      unitRef="USD">404120</aemd:ReversalOfAccruedCommissionLiability>
    <aemd:ReversalOfAccruedCommissionLiability
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000328"
      unitRef="USD">404120</aemd:ReversalOfAccruedCommissionLiability>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000331"
      unitRef="USD">1219370</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000335"
      unitRef="USD">1219370</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000339"
      unitRef="USD">-12208174</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000342"
      unitRef="USD">-12208174</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-04-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000347"
      unitRef="USD">799</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000349"
      unitRef="USD">799</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000358"
      unitRef="Shares">2629725</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000351"
      unitRef="USD">2629</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000360"
      unitRef="USD">2629</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000352"
      unitRef="USD">160337371</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000353"
      unitRef="USD">-154566728</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000354"
      unitRef="USD">-6940</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000355"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000356"
      unitRef="USD">5766332</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000365"
      unitRef="USD">-12208174</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000366"
      unitRef="USD">-12029786</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000371"
      unitRef="USD">359057</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000372"
      unitRef="USD">240892</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000374"
      unitRef="USD">1219370</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000375"
      unitRef="USD">1051898</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000377"
      unitRef="USD">-21135</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000378"
      unitRef="USD">-0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainOrLossOnSaleOfStockInSubsidiary
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000380"
      unitRef="USD">-0</us-gaap:GainOrLossOnSaleOfStockInSubsidiary>
    <us-gaap:GainOrLossOnSaleOfStockInSubsidiary
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000381"
      unitRef="USD">-142121</us-gaap:GainOrLossOnSaleOfStockInSubsidiary>
    <us-gaap:OtherNoncashExpense
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000383"
      unitRef="USD">143</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000384"
      unitRef="USD">24408</us-gaap:OtherNoncashExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000389"
      unitRef="USD">-0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000390"
      unitRef="USD">-127965</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000392"
      unitRef="USD">10232</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000393"
      unitRef="USD">-398169</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000395"
      unitRef="USD">156678</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000396"
      unitRef="USD">-174727</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000398"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000399"
      unitRef="USD">-344547</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000401"
      unitRef="USD">332213</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000402"
      unitRef="USD">58479</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000404"
      unitRef="USD">-10129810</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000405"
      unitRef="USD">-10505128</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000410"
      unitRef="USD">250867</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000411"
      unitRef="USD">943109</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000413"
      unitRef="USD">-250867</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000414"
      unitRef="USD">-943109</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000419"
      unitRef="USD">34778</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000420"
      unitRef="USD">12493</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000422"
      unitRef="USD">1322383</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000423"
      unitRef="USD">8927211</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000425"
      unitRef="USD">1287605</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000426"
      unitRef="USD">8914718</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000428"
      unitRef="USD">2107</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000429"
      unitRef="USD">-5957</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000431"
      unitRef="USD">-9090965</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000432"
      unitRef="USD">-2539476</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000434"
      unitRef="USD">14620449</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-03-31"
      decimals="0"
      id="Fact000435"
      unitRef="USD">17159925</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000437"
      unitRef="USD">5529484</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000438"
      unitRef="USD">14620449</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <aemd:InitialRecognitionOfRightofuseLeaseAssetAndLeaseLiability
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000443"
      unitRef="USD">0</aemd:InitialRecognitionOfRightofuseLeaseAssetAndLeaseLiability>
    <aemd:InitialRecognitionOfRightofuseLeaseAssetAndLeaseLiability
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000444"
      unitRef="USD">625471</aemd:InitialRecognitionOfRightofuseLeaseAssetAndLeaseLiability>
    <aemd:IssuanceOfSharesUnderVestedRestrictedStockUnitsNetStockOptionExercisesAndUnvestedShareIssuanceForServices
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000446"
      unitRef="USD">35</aemd:IssuanceOfSharesUnderVestedRestrictedStockUnitsNetStockOptionExercisesAndUnvestedShareIssuanceForServices>
    <aemd:IssuanceOfSharesUnderVestedRestrictedStockUnitsNetStockOptionExercisesAndUnvestedShareIssuanceForServices
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000447"
      unitRef="USD">92</aemd:IssuanceOfSharesUnderVestedRestrictedStockUnitsNetStockOptionExercisesAndUnvestedShareIssuanceForServices>
    <aemd:ReversalOfAccruedCommissionLiability
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000449"
      unitRef="USD">404120</aemd:ReversalOfAccruedCommissionLiability>
    <aemd:ReversalOfAccruedCommissionLiability
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000450"
      unitRef="USD">0</aemd:ReversalOfAccruedCommissionLiability>
    <aemd:DeferredOfferingCostsNotYetPaid
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000452"
      unitRef="USD">219117</aemd:DeferredOfferingCostsNotYetPaid>
    <aemd:DeferredOfferingCostsNotYetPaid
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000453"
      unitRef="USD">0</aemd:DeferredOfferingCostsNotYetPaid>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000458"
      unitRef="USD">5441978</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000459"
      unitRef="USD">14532943</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000461"
      unitRef="USD">87506</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000462"
      unitRef="USD">87506</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000464"
      unitRef="USD">5529484</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000465"
      unitRef="USD">14620449</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000467">&lt;p id="xdx_80C_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zGuxuItqChz9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;1. &lt;span id="xdx_821_zHtI9ynFRzLi"&gt;ORGANIZATION, LIQUIDITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--BusinessDescriptionAndAccountingPoliciesTextBlock_z8mgq1twUlJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_863_zGIOw7knt1Jj"&gt;ORGANIZATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Aethlon Medical, Inc., or Aethlon, the Company, we
or us, is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device designed to
combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, 164 sessions with 38 patients,
the Hemopurifier was safely utilized and demonstrated the potential to remove life-threatening viruses. In pre-clinical studies, the Hemopurifier
has demonstrated the potential to remove harmful exosomes and exosomal particles from biological fluids, utilizing its proprietary lectin-based
technology. This action has potential applications in cancer, where exosomes and exosomal particles may promote immune suppression and
metastasis, and in life-threatening infectious diseases. The U.S. Food and Drug Administration, or FDA, has designated the Hemopurifier
as a &#x201c;Breakthrough Device&#x201d; for two independent indications:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 2pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 20pt"&gt;&lt;/td&gt;&lt;td style="width: 20pt; text-align: left"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;the treatment of individuals with advanced or metastatic cancer
who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to
participate in the development or severity of the disease; and&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 2pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 20pt"&gt;&lt;/td&gt;&lt;td style="width: 20pt; text-align: left"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;the treatment of life-threatening viruses that are not addressed
with approved therapies.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Oncology&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We believe the Hemopurifier may be a substantial advancement
in the treatment of patients with advanced and metastatic cancer through its design to bind to and remove harmful exosomes and exosomal
particles that promote the growth and spread of tumors. In October 2022, we formed a wholly-owned subsidiary in Australia to initially
conduct oncology-related clinical research, then seek regulatory approval and commercialize our Hemopurifier in Australia. We are currently
working with our contract research organization, or CRO, on preparations to conduct a clinical trial in Australia in patients with solid
tumors, including head and neck cancer, and gastrointestinal cancers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January 2023, we entered into an agreement with
North American Science Associates, LLC, or NAMSA, a world leading medical technology CRO offering global end-to-end development services,
to oversee our planned clinical trials investigating the Hemopurifier for oncology indications. Pursuant to the agreement, NAMSA agreed
to manage our planned clinical trials of the Hemopurifier for patients in the United States and Australia with various types of cancer
tumors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We recently completed an &lt;i&gt;in vitro&lt;/i&gt; binding study of relevant oncology
targets, to provide pre-clinical evidence to support our trial design and translational endpoints. Our study indicated positive results
from this study, providing evidence that our Hemopurifier removes extracellular vesicles, or EVs, from plasma. This translational study
provides pre-clinical evidence to support our planned phase 1 safety, feasibility and dose-finding clinical trials of our Hemopurifier
in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda&#xae; or
Opdivo&#xae;. In addition to an interested initial trial site in India, we had three interested sites in Australia that were awaiting our
completion of this &lt;i&gt;in vitro&lt;/i&gt; binding study. We added the data from this study to our Clinical Investigator Brochure and submitted
that brochure to the Ethics Committee of Royal Adelaide Hospital in Australia and in June 2024, we received approval for our proposed
phase 1 oncology trial from the Ethics Committee from Royal Adelaide Hospital. We are currently in the process of applying to the Ethics
Committees of the two additional interested clinical trial sites in Australia and the site in India.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Life-Threatening Viral Infections&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We also believe that the Hemopurifier can be part
of the broad-spectrum treatment of life-threatening highly glycosylated, or carbohydrate coated, viruses that are not addressed with an
already approved treatment. In small-scale or early feasibility human studies, the Hemopurifier has been used in the past to treat individuals
infected with human immunodeficiency virus, or HIV, hepatitis-C and Ebola.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Additionally, in vitro, the Hemopurifier has been
demonstrated to capture Zika virus, Lassa virus, MERS-CoV, cytomegalovirus, Epstein-Barr virus, Herpes simplex virus, Chikungunya virus,
Dengue virus, West Nile virus, smallpox-related viruses, H1N1 swine flu virus, H5N1 bird flu virus, Monkeypox virus and the reconstructed
Spanish flu virus of 1918. In several cases, these studies were conducted in collaboration with leading government or non-government research
institutes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We believe the Hemopurifier can be part of the treatment of severe SARS-CoV-2
viremia/COVID-19, or COVID-19, cases. COVID viremia is detected in approximately 34% of patients and is associated with severity, requirement
for intensive care unit, or ICU, stay, development of multi-organ failure and poor outcomes. EVs and exosomal miRNAs may play a role in
the spread of infection as well as ongoing inflammation, development of coagulopathy and lung injury. Our proprietary &lt;i&gt;Galanthus nivalis&lt;/i&gt;
agglutinin, or GNA, affinity resin has been shown to bind multiple clinically relevant SARS-CoV-2 variants. Furthermore, studies have
demonstrated &lt;i&gt;in vitro&lt;/i&gt; removal of seven SARS-CoV2 variants (104 PFU/mL) in phosphate buffered saline passed over a column of GNA
affinity resin (1g) three times, with capture efficiencies between 53% and 89%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 17, 2020, the FDA approved a supplement to
our open Investigational Device Exemption, or IDE, for the Hemopurifier in viral disease to allow for the testing of the Hemopurifier
in patients with SARS-CoV-2/COVID-19, or COVID-19, in a new feasibility study. That study was designed to enroll up to 40 subjects at
up to 20 centers in the United States. Subjects were to have established laboratory diagnosis of COVID-19, be admitted to an intensive
care unit, or ICU, and have acute lung injury and/or severe or life-threatening disease, among other criteria. Endpoints for this study,
in addition to safety, included reduction in circulating virus as well as clinical outcomes (NCT # 04595903). In January 2021, the Hemopurifier
was used to treat a viremic patient, under our emergency use approval, with a predicted risk of mortality of 80% and the Hemopurifier
was able to reduce the patient&#x2019;s SARS-CoV-2 plasma viral load by 58.4%.&#160;In June 2022, the first patient in this study was enrolled
and completed the Hemopurifier treatment phase of the protocol. Due to the lack of COVID-19 patients in the ICUs of our trial sites, we
terminated this study in 2022. However, our IDE for this indication remains open, as we have an active COVID-19 trial in India and wish
to preserve the option of enrolling patients if the situation with COVID-19 changes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Under Single Patient
Emergency Use regulations, Aethlon has treated two patients with COVID-19 with the Hemopurifier, in addition to the COVID-19 patient treated
with our Hemopurifier in our COVID-19 clinical trial discussed above&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We previously reported a disruption in our Hemopurifier supply, as our
then existing supply of Hemopurifiers expired on September 30, 2022 and, also as previously disclosed, we are dependent on FDA approval
of qualified suppliers to manufacture our Hemopurifier. We recently completed final testing in order to begin manufacturing Hemopurifiers
at our new manufacturing facility in San Diego, California for use in planned U.S. clinical trials, using GNA from our current supplier.
In April 2024, we received a notice of approval from the FDA for our IDE supplement to add our San Diego manufacturing facility and we
now are able to manufacture Hemopurifiers at this site. We also have sufficient Hemopurifiers on hand for use in our planned Australia
and India oncology trials. Our intended transition to a new supplier for GNA, a component of our Hemopurifier, continues to be delayed
as we work with the FDA for approval of our supplement to our IDE, which is required to make this manufacturing supplier change. We are
working with the FDA to qualify this second supplier of our GNA.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We also obtained ethics review board, or ERB, approval from and entered
into a clinical trial agreement with Medanta Medicity Hospital, a multi-specialty hospital in Delhi NCR, India, for a COVID-19 clinical
trial at that location.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2023, we received ERB approval from the MAMC, for a second site
for our clinical trial in India to treat severe COVID-19. MAMC was established in 1958 and is located in New Delhi, India. MAMC is affiliated
with the University of Delhi and is operated by the Delhi government.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We now have two sites in India for this trial with the Medanta Medicity
Hospital and Maulana Azad Medical College, or MAMC. One patient has been treated to date; however, we have been informed by our CRO that
a new COVID-19 subvariant was detected in India recently. Our COVID-19 trial in India remains open in the event that there are COVID-19
admissions to the ICUs at our sites in India.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Organ Transplantation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Additionally, based on preclinical data with acellular
kidney perfusates, we believe that the Hemopurifier has potential applications in organ transplantation. We are investigating whether
the Hemopurifier, when incorporated into a machine perfusion organ preservation circuit, can remove harmful viruses, exosomes, RNA molecules,
cytokines, chemokines and other inflammatory molecules from recovered organs. We initially are focused on recovered kidneys from deceased
donors. We have previously demonstrated the removal of multiple viruses and exosomes and exosomal particles from buffer solutions, &lt;i&gt;in
vitro&lt;/i&gt;, utilizing a scaled-down version of our Hemopurifier and believe this process could reduce transplantation complications by
improving graft function, reducing graft rejection, maintaining or improving organ viability prior to transplantation, and potentially
reducing the number of kidneys rejected for transplant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Successful outcomes of human trials will also
be required by the regulatory agencies of certain foreign countries where we plan to market and sell the Hemopurifier. Some of our patents
may expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain patent applications
and/or other patents issued to us more recently will help protect the proprietary nature of our Hemopurifier treatment technology.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition to the foregoing, we are monitoring closely
the impact of inflation, recent bank failures and the war between Russia and Ukraine and the military conflicts in Israel and the surrounding
areas, as well as related political and economic responses and counter-responses by various global factors on our business. Given the
level of uncertainty regarding the duration and impact of these events on capital markets and the U.S. economy, we are unable to assess
the impact on our timelines and future access to capital. The full extent to which inflation, recent bank failures and the ongoing military
conflicts will impact our business, results of operations, financial condition, clinical trials and preclinical research will depend on
future developments, as well as the economic impact on national and international markets that are highly uncertain.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our executive offices are located at 11555 Sorrento
Valley Road, Suite 203, San Diego, California 92121. Our telephone number is (619) 941-0360. Our website address is www.aethlonmedical.com.
The information contained on, or that can be accessed through, our website is not part of, and is not incorporated into, this Annual Report
on Form 10-K.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our common stock is listed on the Nasdaq Capital Market
under the symbol &#x201c;AEMD.&#x201d;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_ecustom--LiquidityAndGoingConcernPolicyTextBlock_zw1QKCA0G3O6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86F_zMdmWZXaQOv6"&gt;LIQUIDITY AND GOING CONCERN&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has incurred losses since inception in devoting substantially
all of its efforts toward research and development and has an accumulated deficit of $&lt;span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20240331_zbkI8ufMY9Xf" title="Accumulated deficit"&gt;154,566,728&lt;/span&gt; as of March 31, 2024. During the year
ended March 31, 2024, the Company generated a net loss of approximately $&lt;span id="xdx_903_eus-gaap--NetIncomeLoss_dxL_c20230401__20240331_zYN4AEcuhwsd" title="Net loss::XDX::-12208174"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0483"&gt;12,208,000&lt;/span&gt;&lt;/span&gt; and the Company expects that it will continue to generate
operating losses for the foreseeable future. While the Company currently has over $&lt;span id="xdx_90F_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20240331_ztlSmQIWEnC6" title="Cash and cash equivalents"&gt;9.1&lt;/span&gt; million in cash and cash equivalents and have been
carrying out certain expense reductions since November 2023; our planned additional expense reductions may not materialize and/or our
patient recruitment may occur more rapidly than expected along with the concomitant increases in expenses, therefore there is substantial
doubt that our cash on hand will carry the company for 12 months beyond the filing date of the financial statements included in this Annual
Report.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s ability to execute its current operating plan depends
on its ability to reduce expenses and obtain additional funding via the sale of equity, or other sources of capital. The Company plans
to continue actively pursuing financing alternatives, however, there can be no assurance that it will obtain the necessary funding, raising
substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year of the date these financial statements
are issued. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_z7yN2wO3e5bd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86F_zowRJMHh99I5"&gt;PRINCIPLES OF CONSOLIDATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial statements
include the accounts of Aethlon Medical, Inc. and its wholly owned subsidiary, Aethlon Medical Australia Pty Ltd, as well as its previously
majority-owned subsidiary, ESI, which dissolved in September 2022. Operations in our Australian subsidiary is recorded in their functional
currency. The results of operations for our Australian subsidiary are translated from functional currency into U.S. dollars using the
current exchange rate on the date the expense was recognized. Assets and liabilities are translated using the period end exchange rates.
The U.S dollar effects that arise from translating the net assets of are recorded in other comprehensive income (loss). All significant
inter-company transactions and balances have been eliminated in consolidation. The consolidated financial statements contain all normal
recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the consolidated financial statements
as of and for the fiscal years ended March 31, 2024 and 2023, and the consolidated statement of cash flows for the fiscal years ended
March 31, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--RisksAndUncertaintiesPolicyTextBlock_zwLcqnFwAW86" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_861_zSYm8J8ttRei"&gt;RISKS AND UNCERTAINTIES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We operate in an industry that is subject to intense
competition, government regulation and rapid technological change. Our operations are subject to significant risk and uncertainties including
financial, operational, technological, regulatory, and including the potential risk of business failure.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--UseOfEstimates_ziNL2ODx0Eue" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_864_z08AYAFA8nel"&gt;USE OF ESTIMATES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We prepare our consolidated financial statements in
conformity with accounting principles generally accepted in the United States of America, or GAAP, which requires us to make a number
of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
at the date of the financial statements. Such estimates and assumptions affect the reported amounts of expenses during the reporting period.
On an ongoing basis, we evaluate estimates and assumptions based upon historical experience and various other factors and circumstances.
We believe our estimates and assumptions are reasonable in the circumstances; however, actual results may differ from these estimates
under different future conditions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We believe that the estimates and assumptions that
are most important to the portrayal of our financial condition and results of operations, in that they require the most difficult, subjective
or complex judgments, form the basis for the accounting policies deemed to be most critical to us.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z5fgrZZlaxCd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86A_zIbkaHoyIn08"&gt;CASH AND CASH EQUIVALENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounting standards define &#x201c;cash and cash equivalents&#x201d;
as any short-term, highly liquid investment that is both readily convertible to known amounts of cash and so near their maturity that
they present insignificant risk of changes in value because of changes in interest rates. For the purpose of financial statement presentation,
we consider all highly liquid investment instruments with original maturities of three months or less when purchased, or any investment
redeemable without penalty or loss of interest to be cash equivalents. Cash is carried at cost, which approximates fair value, and cash
equivalents are carried at fair value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the fiscal years ended March 31, 2024 and March
31, 2023 our cash and cash equivalents were comprised of the following instruments:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zCj1Kr8QwWD1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ORGANIZATION, LIQUIDITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Cash and cash equivalents)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B2_zojazZQi4w5a" style="display: none"&gt;Schedule of cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the year ended&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Cash in US bank checking account&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20240331__us-gaap--CashAndCashEquivalentsAxis__custom--CashInUSBankMember_ztzbUfCdPIm3" style="width: 13%; text-align: right" title="Cash and cash equivalents"&gt;697,908&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__custom--CashInUSBankMember_zcNn4ihS7G8c" style="width: 13%; text-align: right" title="Cash and cash equivalents"&gt;575,766&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Cash equivalents held in US Treasury bills&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20240331__us-gaap--CashAndCashEquivalentsAxis__custom--CashEquivalentsInUSTreasuryBillsMember_zYKszzOUTeH1" style="text-align: right" title="Cash and cash equivalents"&gt;4,736,469&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__custom--CashEquivalentsInUSTreasuryBillsMember_z6KvUveYmZR3" style="text-align: right" title="Cash and cash equivalents"&gt;13,910,973&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Cash in Australian bank checking account&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20240331__us-gaap--CashAndCashEquivalentsAxis__custom--CashInAustralianBankMember_zTTEni0i0zvh" style="border-bottom: Black 1pt solid; text-align: right" title="Cash and cash equivalents"&gt;7,601&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__custom--CashInAustralianBankMember_z5tvCO3Aszu6" style="border-bottom: Black 1pt solid; text-align: right" title="Cash and cash equivalents"&gt;46,204&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total cash and cash equivalents&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20240331_zGY5sXYR7Bnh" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash and cash equivalents"&gt;5,441,978&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230331_zqC5rG24mr35" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash and cash equivalents"&gt;14,532,943&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zArdsPbBI6Xd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86A_z3EoK5FH2iqi"&gt;CONCENTRATIONS OF CREDIT RISKS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cash is maintained at one US financial institution
in a checking account. Accounts at this institution are secured by the Federal Deposit Insurance Corporation up to $250,000. Our March
31, 2024 cash balances were approximately $&lt;span id="xdx_90E_eus-gaap--CashUninsuredAmount_pp0p0_c20240331_zI1lv8MmPmnh" title="Cash balances over insured amount"&gt;568,000&lt;/span&gt; over such insured amount. &lt;span style="background-color: white"&gt;We do not believe that
the Company is exposed to any significant risk with respect to its cash in that checking account.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;At March 31,
2024, we maintained cash equivalents of approximately $&lt;span id="xdx_904_eus-gaap--USGovernmentSecuritiesAtCarryingValue_iI_pn5n6_c20240331_zCt2aRU3zVwl" title="Cash equivalents of US treasury bills"&gt;4.7&lt;/span&gt; million in US Treasury bills with maturities of less than three months. We
do not believe that the Company is exposed to any significant risk with respect to its cash equivalents since they represent US government
risk.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cash is maintained at one Australian financial institution
in checking accounts. Accounts at this institution are secured by the Financial Claims Scheme for up to Australian $250,000. Our March
31, 2024 Australian cash balance was below that threshold.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We did not have any revenue in fiscal year ended March
31, 2024. All of our revenue in the fiscal year ended March 31, 2023 related to our government contracts. We did not have any accounts
receivable at March 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zh7yth2uYs86" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86D_zG9n2GZhpPBg"&gt;RESTRICTED CASH&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;To comply with the terms of our laboratory, office,
and manufacturing space leases, we caused our bank to issue two standby letters of credit, or the L/Cs, in the amount of $&lt;span id="xdx_900_eus-gaap--RestrictedCash_iI_pp0p0_c20240331_zLH3I3gSgkA4" title="Restricted cash"&gt;87,506&lt;/span&gt; in favor
of the landlord. The L/Cs are in lieu of a security deposit. In order to support the L/Cs, we agreed to have our bank withdraw $87,506
from our operating accounts and to place that amount in restricted certificates of deposit. We have classified that amount as restricted
cash, a long-term asset, on our balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zmhKDB01aWc2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_865_zkeTwgHA8tJ8"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Property and equipment are stated at cost. Depreciation
is computed using the straight-line method over the estimated useful lives of the related assets, which range from two to five years.
Repairs and maintenance are charged to expense as incurred while improvements are capitalized. Upon the sale or retirement of property
and equipment, the accounts are relieved of the cost and the related accumulated depreciation with any gain or loss included in the consolidated
statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zLplOXYE6dkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_869_zx4giJ0t3lya"&gt;INCOME TAXES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Deferred tax assets and liabilities are recognized for the future tax consequences
attributable to the difference between the consolidated financial statements and their respective tax basis. Deferred income taxes reflect
the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes
and the amounts reported for income tax purposes, and (b) tax credit carryforwards. We record a valuation allowance for deferred tax assets
when, based on our best estimate of taxable income (if any) in the foreseeable future, it is more likely than not that some portion of
the deferred tax assets may not be realized. Management has provided a full valuation allowance against the Company&#x2019;s net deferred
tax asset. Tax positions taken or expected to be taken in the course of preparing tax returns are required to be evaluated to determine
whether the tax positions are more-likely-than-not to be sustained by the applicable tax authority. Tax positions deemed to not meet a
more-likely-than-not threshold would be recorded as tax expense in the current year. There were &lt;span id="xdx_90D_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20240331_zVkd0MC7J2tc" title="Uncertain tax positions"&gt;&lt;span id="xdx_905_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20230331_z05QyNg6bASi" title="Uncertain tax positions"&gt;no&lt;/span&gt;&lt;/span&gt; uncertain tax positions that require
accrual to or disclosure in the consolidated financial statements as of March 31, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zhwSfpD9GeB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86A_zXoRmHSULYF4"&gt;LONG-LIVED ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Long-lived assets are reviewed for impairment whenever
events or changes in circumstances indicate that their carrying amounts may not be recoverable. If the cost basis of a long-lived asset
is greater than the projected future undiscounted net cash flows from such asset, an impairment loss is recognized. We believe &lt;span id="xdx_909_eus-gaap--AssetImpairmentCharges_pp0p0_do_c20230401__20240331_zjbkgQE0hMR8" title="Asset impairment charges"&gt;&lt;span id="xdx_907_eus-gaap--AssetImpairmentCharges_pp0p0_do_c20220401__20230331_zAE4f3U7ZRL2" title="Asset impairment charges"&gt;no&lt;/span&gt;&lt;/span&gt; impairment
charges were necessary during the fiscal years ended March 31, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_z4TTVp4K6gfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_866_zt122nDAHudj"&gt;LOSS PER SHARE&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic loss per share is computed by dividing net loss
available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted
loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional
common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive.
Since we had net losses for all periods presented, basic and diluted loss per share are the same, and additional potential common shares
have been excluded as their effect would be antidilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2024 and 2023, a total of &lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230401__20240331_zagM1gZ8dYk" title="Antidilutive shares"&gt;124,028&lt;/span&gt;
and &lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220401__20230331_zwqlVCfsyWE5" title="Antidilutive shares"&gt;204,501&lt;/span&gt; potential common shares, consisting of shares underlying outstanding stock options, restricted stock units, or RSUs, and warrants
were excluded as their inclusion would be antidilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--DebtPolicyTextBlock_zfKW2lEJj5Ma" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86D_zvANLp0QcQKb"&gt;DEFERRED OFFERING COSTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Specific incremental costs directly attributable to
an actual offering of securities may be deferred and charged against the gross proceeds of the offering. As of March 31, 2024, approximately
$&lt;span id="xdx_903_eus-gaap--DeferredCosts_iI_c20240331_zUBEn55UZ6Xd" title="Deferred offering costs"&gt;278,000&lt;/span&gt; of costs have been deferred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--RevenueRecognitionPolicyTextBlock_zLhW8ATE10x9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_867_zdYu5C3pYSXj"&gt;REVENUE RECOGNITION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We did not recognize revenue in fiscal year ended
March 31, 2024. Our revenues in the fiscal year ended March 31, 2023 consisted entirely of amounts earned under contracts and grants with
the National Institutes of Health, or NIH. During the fiscal year ended March 31, 2023, we recognized revenues totaling $&lt;span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331_zK1EKBeu0mC1" title="Contract revenue"&gt;574,245&lt;/span&gt; under
such contracts. We have concluded that these agreements are not within the scope of ASC Topic, 606, Revenue from Contracts with Customers,
or Topic 606, as the NIH grants and contracts do not meet the definition of a &#x201c;customer&#x201d; as defined by Topic 606. Prior to
the effective date of ASC Topic 606, which for the Company was April 1, 2018, we accounted for our grant/contract revenues under the Milestone
Method as prescribed by the legacy guidance of ASC 605-28, Revenue Recognition &#x2013; Milestone Method, or Milestone Method. In the absence
of other applicable guidance under US GAAP, effective April 1, 2018, we elected to continue to use the Milestone Method by analogy to
recognize revenue under these grants/contracts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We identify the deliverables included within these
agreements and evaluate which deliverables represent separate units of accounting based on if certain criteria are met, including whether
the delivered element has standalone value to the collaborator. The consideration received is allocated among the separate units of accounting,
and the applicable revenue recognition criteria are applied to each of the separate units.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A milestone is an event having all of the following
characteristics:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(1) There is substantive uncertainty at the date the
arrangement is entered into that the event will be achieved. A vendor&#x2019;s assessment that it expects to achieve a milestone does not
necessarily mean that there is not substantive uncertainty associated with achieving the milestone.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(2) The event can only be achieved based in whole
or in part on either: (a) the vendor&#x2019;s performance; or (b) a specific outcome resulting from the vendor&#x2019;s performance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(3) If achieved, the event would result in additional
payments being due to the vendor.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A milestone does not include events for which the
occurrence is either: (a) contingent solely upon the passage of time; or (b) the result of a counterparty&#x2019;s performance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The policy for recognizing deliverable consideration
contingent upon achievement of a milestone must be applied consistently to similar deliverables.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The assessment of whether a milestone is substantive
is performed at the inception of the arrangement. The consideration earned from the achievement of a milestone must meet all of the following
for the milestone to be considered substantive:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(1) The consideration is commensurate with either:
(a) the vendor&#x2019;s performance to achieve the milestone; or (b) the enhancement of the value of the delivered item or items as a result
of a specific outcome resulting from the vendor&#x2019;s performance to achieve the milestone;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(2) The consideration relates solely to past performance;
and&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(3) The consideration is reasonable relative to all
of the deliverables and payment terms (including other potential milestone consideration) within the arrangement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A milestone is not considered substantive if any portion
of the associated milestone consideration relates to the remaining deliverables in the unit of accounting (i.e., it does not relate solely
to past performance). To recognize the milestone consideration in its entirety as revenue in the period in which the milestone is achieved,
the milestone must be substantive in its entirety. Milestone consideration cannot be bifurcated into substantive and nonsubstantive components.
In addition, if a portion of the consideration earned from achieving a milestone may be refunded or adjusted based on future performance,
the related milestone is not considered substantive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We have recognized revenue under the following contract/grant:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Phase 2 Melanoma Cancer Contract&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 12, 2019, the National Cancer Institute,
or NCI, part of the NIH, awarded to us a SBIR Phase II Award Contract, for NIH/NCI Topic 359, entitled &#x201c;A Device Prototype for Isolation
of Melanoma Exosomes for Diagnostics and Treatment Monitoring&#x201d;, or the Award Contract. The Award Contract amount was $1,860,561
and, as amended, ran for the period from September 16, 2019 through September 15, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The work performed pursuant to this Award Contract
was focused on melanoma exosomes. This work followed from our completion of a Phase I contract for the Topic 359 solicitation that ran
from September 2017 through June 2018, as described below. Following on the Phase I work, the deliverables in the Phase II program involved
the design and testing of a pre-commercial prototype of a more advanced version of the exosome isolation platform.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Award Contract ended on September 15, 2022 and
we presented the required final report to the NCI. As the NCI completed its close out review of the contract, we recognized as revenue
$&lt;span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220401__20230331__us-gaap--TransactionTypeAxis__custom--MelanomaCancerContractMember_zbCK03hmTvj2" title="Revenue recognized from contract"&gt;574,245&lt;/span&gt; in fiscal year ended March 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zSG0jYLMlUm1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86D_zC6BjQdwI7yf"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Employee stock options and rights to purchase shares
under stock participation plans are accounted for under the fair value method. Accordingly, share-based compensation is measured when
all granting activities have been completed, generally the grant date, based on the fair value of the award. The exercise price of options
is generally equal to the market price of the Company&#x2019;s common stock (defined as the closing price as quoted on the Nasdaq Capital
Market or OTCBB on the date of grant). Compensation cost recognized by the Company includes (a) compensation cost for all equity incentive
awards granted prior to April 1, 2006, but not yet vested, based on the grant-date fair value estimated in accordance with the original
provisions of the then current accounting standards, and (b) compensation cost for all equity incentive awards granted subsequent to March
31, 2006, based on the grant-date fair value estimated in accordance with the provisions of subsequent accounting standards. We use a
Binomial Lattice option pricing model for estimating fair value of options granted (see Note 4).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table summarizes share-based compensation
expenses relating to shares and options granted and the effect on loss per common share during the years ended March 31, 2024 and 2023:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zZcl5mzexuh4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ORGANIZATION, LIQUIDITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Stock compensation)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BD_z1wkUgvdYp3j" style="display: none"&gt;Schedule of share-based compensation expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230401__20240331_znW0e3MKqtT5" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20220401__20230331_zegqj2dGYCU4" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Fiscal Years Ended&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_i_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left; padding-bottom: 1pt"&gt;Vesting of Stock Options and Restricted Stock Units&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 13%; text-align: right"&gt;1,219,370&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 13%; text-align: right"&gt;1,051,898&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ShareBasedCompensation_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total Stock-Based Compensation Expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,219,370&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,051,898&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Weighted average number of common shares outstanding &#x2013; basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20240331_zBjzResuM7y4"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20240331_zRcyRVLAt4aj"&gt;2,512,774&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220401__20230331_zARx0WNRhjx6"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220401__20230331_zmaF9cPa8Q8k"&gt;2,053,744&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Basic and diluted loss per common share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareBasic_c20230401__20240331__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zuRoesZvDJN9" title="Basic loss per common share"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20230401__20240331__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zAkA5blKXvYf" title="Diluted loss per common share"&gt;(0.49&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20220401__20230331__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zkx9gocAsC1d" title="Basic loss per common share"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20220401__20230331__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zYrc87xr3Eg5" title="Diluted loss per common share"&gt;(0.51&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We record share-based compensation expenses for awards
of stock options and RSUs under ASC 718, Share-based compensation, or ASC 718. For awards to non-employees for periods prior to the adoption
of ASU 2018-07, Compensation-Stock Compensation: Improvements to Non-employee Share-Based Payment Accounting, on April 1, 2019, the Company
had applied ASC 505-50, Equity &#x2013; Equity-based payments to non-employees, or ASC 505-50. ASC 718 establishes guidance for the recognition
of expenses arising from the issuance of share-based compensation awards at their fair value at the grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We recognize share-based compensation expense related
to stock options and stock appreciation rights granted to employees, directors and consultants based on the estimated fair value of the
awards on the date of grant. We estimate the grant date fair value, and the resulting share-based compensation expense, for stock options
that only have service vesting requirements or performance-based vesting requirements without market conditions using the binomial lattice
option-pricing model. The grant date fair value of the share-based awards with service vesting requirements is generally recognized on
a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. Determining the
appropriate amount to expense for performance-based awards based on the achievement of stated goals requires judgment. The estimate of
expense is revised periodically based on the probability of achieving the required performance targets and adjustments are made as appropriate.
The cumulative impact of any revisions is reflected in the period of change. If any applicable financial performance goals are not met,
no compensation cost is recognized and any previously recognized compensation cost is reversed. For performance-based awards with market
conditions, we determine the fair value of awards as of the grant date using a Monte Carlo simulation model.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We review share-based compensation on a quarterly
basis for changes to the estimate of expected award forfeitures based on actual forfeiture experience. The effect of adjusting the forfeiture
rate for all expense amortization after March 31, 2007 is recognized in the period the forfeiture estimate is changed. The effect of forfeiture
adjustments for the fiscal year ended March 31, 2024 was insignificant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_z0OD2KeQmMXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86D_z2J3od3XLig5"&gt;PATENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Patents include both foreign and domestic patents.
We capitalize the cost of patents, some of which were acquired, and amortize such costs over the shorter of the remaining legal life or
their estimated economic life, upon issuance of the patent. The unamortized costs of patents are subject to our review for impairment
under our long-lived asset policy above.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--StockPurchaseWarrantsPolicyTextBlock_zHl0sCMz91Lg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86F_zcv2HnDFLzY7"&gt;STOCK PURCHASE WARRANTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In the past we issued warrants for the purchase of
shares of our common stock in connection with the issuance of common stock for cash. Warrants issued in connection with common stock for
cash, if classified as equity, are considered issued in connection with equity transactions and the warrant fair value is recorded to
additional paid-in-capital.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--ResearchAndDevelopmentExpensePolicy_zg3uc4SrzZOf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_863_zny89c3c1yvh"&gt;RESEARCH AND DEVELOPMENT EXPENSES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our research and development costs are expensed as
incurred. We incurred approximately $&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230401__20240331_zHzf5mDUa13a" title="Research and development expenses"&gt;2,520,000&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220401__20230331_zlHQIhByHa26" title="Research and development expenses"&gt;2,745,000&lt;/span&gt; of research and development expenses for the years ended March 31, 2024
and 2023, respectively, which are included in various operating expenses in the accompanying consolidated statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--OffBalanceSheetCreditExposurePolicyPolicyTextBlock_zQ6HOVrmtpo1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86C_z8Sny2iDWeIj"&gt;OFF-BALANCE SHEET ARRANGEMENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We have not entered into any off-balance sheet arrangements
that have or are reasonably likely to have a current or future material effect on our consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zN3ia16zZhJ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86A_zgZEqGDZyIIj"&gt;SIGNIFICANT RECENT ACCOUNTING PRONOUNCEMENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2023, the FASB issued Accounting Standards
Update 2023-09, Improvements to Income Tax Disclosures (&#x201c;ASU 2023-09&#x201d;), which requires enhanced annual disclosures for specific
categories in the rate reconciliation and income taxes paid disaggregated by federal, state and foreign taxes. ASU 2023-09 is effective
for public business entities for annual periods beginning after December 15, 2024. The Company is evaluating if the adoption of this new
standard will have a material effect on our disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial
Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The adoption of ASU No. 2016-13 for smaller
reporting companies that did not previously early adopt was January 1, 2023. &lt;span&gt;The Company maintained
US Treasury bills with maturities of less than three months&lt;/span&gt; and expects zero credit losses from these securities. As a result,
the Company did not record an allowance for expected credit losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;











</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000469">&lt;p id="xdx_84D_eus-gaap--BusinessDescriptionAndAccountingPoliciesTextBlock_z8mgq1twUlJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_863_zGIOw7knt1Jj"&gt;ORGANIZATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Aethlon Medical, Inc., or Aethlon, the Company, we
or us, is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device designed to
combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, 164 sessions with 38 patients,
the Hemopurifier was safely utilized and demonstrated the potential to remove life-threatening viruses. In pre-clinical studies, the Hemopurifier
has demonstrated the potential to remove harmful exosomes and exosomal particles from biological fluids, utilizing its proprietary lectin-based
technology. This action has potential applications in cancer, where exosomes and exosomal particles may promote immune suppression and
metastasis, and in life-threatening infectious diseases. The U.S. Food and Drug Administration, or FDA, has designated the Hemopurifier
as a &#x201c;Breakthrough Device&#x201d; for two independent indications:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 2pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 20pt"&gt;&lt;/td&gt;&lt;td style="width: 20pt; text-align: left"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;the treatment of individuals with advanced or metastatic cancer
who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to
participate in the development or severity of the disease; and&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 2pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 20pt"&gt;&lt;/td&gt;&lt;td style="width: 20pt; text-align: left"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;the treatment of life-threatening viruses that are not addressed
with approved therapies.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Oncology&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We believe the Hemopurifier may be a substantial advancement
in the treatment of patients with advanced and metastatic cancer through its design to bind to and remove harmful exosomes and exosomal
particles that promote the growth and spread of tumors. In October 2022, we formed a wholly-owned subsidiary in Australia to initially
conduct oncology-related clinical research, then seek regulatory approval and commercialize our Hemopurifier in Australia. We are currently
working with our contract research organization, or CRO, on preparations to conduct a clinical trial in Australia in patients with solid
tumors, including head and neck cancer, and gastrointestinal cancers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January 2023, we entered into an agreement with
North American Science Associates, LLC, or NAMSA, a world leading medical technology CRO offering global end-to-end development services,
to oversee our planned clinical trials investigating the Hemopurifier for oncology indications. Pursuant to the agreement, NAMSA agreed
to manage our planned clinical trials of the Hemopurifier for patients in the United States and Australia with various types of cancer
tumors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We recently completed an &lt;i&gt;in vitro&lt;/i&gt; binding study of relevant oncology
targets, to provide pre-clinical evidence to support our trial design and translational endpoints. Our study indicated positive results
from this study, providing evidence that our Hemopurifier removes extracellular vesicles, or EVs, from plasma. This translational study
provides pre-clinical evidence to support our planned phase 1 safety, feasibility and dose-finding clinical trials of our Hemopurifier
in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda&#xae; or
Opdivo&#xae;. In addition to an interested initial trial site in India, we had three interested sites in Australia that were awaiting our
completion of this &lt;i&gt;in vitro&lt;/i&gt; binding study. We added the data from this study to our Clinical Investigator Brochure and submitted
that brochure to the Ethics Committee of Royal Adelaide Hospital in Australia and in June 2024, we received approval for our proposed
phase 1 oncology trial from the Ethics Committee from Royal Adelaide Hospital. We are currently in the process of applying to the Ethics
Committees of the two additional interested clinical trial sites in Australia and the site in India.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Life-Threatening Viral Infections&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We also believe that the Hemopurifier can be part
of the broad-spectrum treatment of life-threatening highly glycosylated, or carbohydrate coated, viruses that are not addressed with an
already approved treatment. In small-scale or early feasibility human studies, the Hemopurifier has been used in the past to treat individuals
infected with human immunodeficiency virus, or HIV, hepatitis-C and Ebola.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Additionally, in vitro, the Hemopurifier has been
demonstrated to capture Zika virus, Lassa virus, MERS-CoV, cytomegalovirus, Epstein-Barr virus, Herpes simplex virus, Chikungunya virus,
Dengue virus, West Nile virus, smallpox-related viruses, H1N1 swine flu virus, H5N1 bird flu virus, Monkeypox virus and the reconstructed
Spanish flu virus of 1918. In several cases, these studies were conducted in collaboration with leading government or non-government research
institutes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We believe the Hemopurifier can be part of the treatment of severe SARS-CoV-2
viremia/COVID-19, or COVID-19, cases. COVID viremia is detected in approximately 34% of patients and is associated with severity, requirement
for intensive care unit, or ICU, stay, development of multi-organ failure and poor outcomes. EVs and exosomal miRNAs may play a role in
the spread of infection as well as ongoing inflammation, development of coagulopathy and lung injury. Our proprietary &lt;i&gt;Galanthus nivalis&lt;/i&gt;
agglutinin, or GNA, affinity resin has been shown to bind multiple clinically relevant SARS-CoV-2 variants. Furthermore, studies have
demonstrated &lt;i&gt;in vitro&lt;/i&gt; removal of seven SARS-CoV2 variants (104 PFU/mL) in phosphate buffered saline passed over a column of GNA
affinity resin (1g) three times, with capture efficiencies between 53% and 89%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 17, 2020, the FDA approved a supplement to
our open Investigational Device Exemption, or IDE, for the Hemopurifier in viral disease to allow for the testing of the Hemopurifier
in patients with SARS-CoV-2/COVID-19, or COVID-19, in a new feasibility study. That study was designed to enroll up to 40 subjects at
up to 20 centers in the United States. Subjects were to have established laboratory diagnosis of COVID-19, be admitted to an intensive
care unit, or ICU, and have acute lung injury and/or severe or life-threatening disease, among other criteria. Endpoints for this study,
in addition to safety, included reduction in circulating virus as well as clinical outcomes (NCT # 04595903). In January 2021, the Hemopurifier
was used to treat a viremic patient, under our emergency use approval, with a predicted risk of mortality of 80% and the Hemopurifier
was able to reduce the patient&#x2019;s SARS-CoV-2 plasma viral load by 58.4%.&#160;In June 2022, the first patient in this study was enrolled
and completed the Hemopurifier treatment phase of the protocol. Due to the lack of COVID-19 patients in the ICUs of our trial sites, we
terminated this study in 2022. However, our IDE for this indication remains open, as we have an active COVID-19 trial in India and wish
to preserve the option of enrolling patients if the situation with COVID-19 changes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Under Single Patient
Emergency Use regulations, Aethlon has treated two patients with COVID-19 with the Hemopurifier, in addition to the COVID-19 patient treated
with our Hemopurifier in our COVID-19 clinical trial discussed above&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We previously reported a disruption in our Hemopurifier supply, as our
then existing supply of Hemopurifiers expired on September 30, 2022 and, also as previously disclosed, we are dependent on FDA approval
of qualified suppliers to manufacture our Hemopurifier. We recently completed final testing in order to begin manufacturing Hemopurifiers
at our new manufacturing facility in San Diego, California for use in planned U.S. clinical trials, using GNA from our current supplier.
In April 2024, we received a notice of approval from the FDA for our IDE supplement to add our San Diego manufacturing facility and we
now are able to manufacture Hemopurifiers at this site. We also have sufficient Hemopurifiers on hand for use in our planned Australia
and India oncology trials. Our intended transition to a new supplier for GNA, a component of our Hemopurifier, continues to be delayed
as we work with the FDA for approval of our supplement to our IDE, which is required to make this manufacturing supplier change. We are
working with the FDA to qualify this second supplier of our GNA.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We also obtained ethics review board, or ERB, approval from and entered
into a clinical trial agreement with Medanta Medicity Hospital, a multi-specialty hospital in Delhi NCR, India, for a COVID-19 clinical
trial at that location.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2023, we received ERB approval from the MAMC, for a second site
for our clinical trial in India to treat severe COVID-19. MAMC was established in 1958 and is located in New Delhi, India. MAMC is affiliated
with the University of Delhi and is operated by the Delhi government.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We now have two sites in India for this trial with the Medanta Medicity
Hospital and Maulana Azad Medical College, or MAMC. One patient has been treated to date; however, we have been informed by our CRO that
a new COVID-19 subvariant was detected in India recently. Our COVID-19 trial in India remains open in the event that there are COVID-19
admissions to the ICUs at our sites in India.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Organ Transplantation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Additionally, based on preclinical data with acellular
kidney perfusates, we believe that the Hemopurifier has potential applications in organ transplantation. We are investigating whether
the Hemopurifier, when incorporated into a machine perfusion organ preservation circuit, can remove harmful viruses, exosomes, RNA molecules,
cytokines, chemokines and other inflammatory molecules from recovered organs. We initially are focused on recovered kidneys from deceased
donors. We have previously demonstrated the removal of multiple viruses and exosomes and exosomal particles from buffer solutions, &lt;i&gt;in
vitro&lt;/i&gt;, utilizing a scaled-down version of our Hemopurifier and believe this process could reduce transplantation complications by
improving graft function, reducing graft rejection, maintaining or improving organ viability prior to transplantation, and potentially
reducing the number of kidneys rejected for transplant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Successful outcomes of human trials will also
be required by the regulatory agencies of certain foreign countries where we plan to market and sell the Hemopurifier. Some of our patents
may expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain patent applications
and/or other patents issued to us more recently will help protect the proprietary nature of our Hemopurifier treatment technology.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition to the foregoing, we are monitoring closely
the impact of inflation, recent bank failures and the war between Russia and Ukraine and the military conflicts in Israel and the surrounding
areas, as well as related political and economic responses and counter-responses by various global factors on our business. Given the
level of uncertainty regarding the duration and impact of these events on capital markets and the U.S. economy, we are unable to assess
the impact on our timelines and future access to capital. The full extent to which inflation, recent bank failures and the ongoing military
conflicts will impact our business, results of operations, financial condition, clinical trials and preclinical research will depend on
future developments, as well as the economic impact on national and international markets that are highly uncertain.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our executive offices are located at 11555 Sorrento
Valley Road, Suite 203, San Diego, California 92121. Our telephone number is (619) 941-0360. Our website address is www.aethlonmedical.com.
The information contained on, or that can be accessed through, our website is not part of, and is not incorporated into, this Annual Report
on Form 10-K.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our common stock is listed on the Nasdaq Capital Market
under the symbol &#x201c;AEMD.&#x201d;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <aemd:LiquidityAndGoingConcernPolicyTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000479">&lt;p id="xdx_840_ecustom--LiquidityAndGoingConcernPolicyTextBlock_zw1QKCA0G3O6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86F_zMdmWZXaQOv6"&gt;LIQUIDITY AND GOING CONCERN&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has incurred losses since inception in devoting substantially
all of its efforts toward research and development and has an accumulated deficit of $&lt;span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20240331_zbkI8ufMY9Xf" title="Accumulated deficit"&gt;154,566,728&lt;/span&gt; as of March 31, 2024. During the year
ended March 31, 2024, the Company generated a net loss of approximately $&lt;span id="xdx_903_eus-gaap--NetIncomeLoss_dxL_c20230401__20240331_zYN4AEcuhwsd" title="Net loss::XDX::-12208174"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0483"&gt;12,208,000&lt;/span&gt;&lt;/span&gt; and the Company expects that it will continue to generate
operating losses for the foreseeable future. While the Company currently has over $&lt;span id="xdx_90F_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20240331_ztlSmQIWEnC6" title="Cash and cash equivalents"&gt;9.1&lt;/span&gt; million in cash and cash equivalents and have been
carrying out certain expense reductions since November 2023; our planned additional expense reductions may not materialize and/or our
patient recruitment may occur more rapidly than expected along with the concomitant increases in expenses, therefore there is substantial
doubt that our cash on hand will carry the company for 12 months beyond the filing date of the financial statements included in this Annual
Report.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s ability to execute its current operating plan depends
on its ability to reduce expenses and obtain additional funding via the sale of equity, or other sources of capital. The Company plans
to continue actively pursuing financing alternatives, however, there can be no assurance that it will obtain the necessary funding, raising
substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year of the date these financial statements
are issued. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</aemd:LiquidityAndGoingConcernPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000481"
      unitRef="USD">-154566728</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2024-03-31"
      decimals="-5"
      id="Fact000485"
      unitRef="USD">9100000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000491">&lt;p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_z7yN2wO3e5bd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86F_zowRJMHh99I5"&gt;PRINCIPLES OF CONSOLIDATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial statements
include the accounts of Aethlon Medical, Inc. and its wholly owned subsidiary, Aethlon Medical Australia Pty Ltd, as well as its previously
majority-owned subsidiary, ESI, which dissolved in September 2022. Operations in our Australian subsidiary is recorded in their functional
currency. The results of operations for our Australian subsidiary are translated from functional currency into U.S. dollars using the
current exchange rate on the date the expense was recognized. Assets and liabilities are translated using the period end exchange rates.
The U.S dollar effects that arise from translating the net assets of are recorded in other comprehensive income (loss). All significant
inter-company transactions and balances have been eliminated in consolidation. The consolidated financial statements contain all normal
recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the consolidated financial statements
as of and for the fiscal years ended March 31, 2024 and 2023, and the consolidated statement of cash flows for the fiscal years ended
March 31, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <aemd:RisksAndUncertaintiesPolicyTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000493">&lt;p id="xdx_84B_ecustom--RisksAndUncertaintiesPolicyTextBlock_zwLcqnFwAW86" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_861_zSYm8J8ttRei"&gt;RISKS AND UNCERTAINTIES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We operate in an industry that is subject to intense
competition, government regulation and rapid technological change. Our operations are subject to significant risk and uncertainties including
financial, operational, technological, regulatory, and including the potential risk of business failure.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</aemd:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2023-04-01to2024-03-31" id="Fact000495">&lt;p id="xdx_845_eus-gaap--UseOfEstimates_ziNL2ODx0Eue" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_864_z08AYAFA8nel"&gt;USE OF ESTIMATES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We prepare our consolidated financial statements in
conformity with accounting principles generally accepted in the United States of America, or GAAP, which requires us to make a number
of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
at the date of the financial statements. Such estimates and assumptions affect the reported amounts of expenses during the reporting period.
On an ongoing basis, we evaluate estimates and assumptions based upon historical experience and various other factors and circumstances.
We believe our estimates and assumptions are reasonable in the circumstances; however, actual results may differ from these estimates
under different future conditions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We believe that the estimates and assumptions that
are most important to the portrayal of our financial condition and results of operations, in that they require the most difficult, subjective
or complex judgments, form the basis for the accounting policies deemed to be most critical to us.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000497">&lt;p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z5fgrZZlaxCd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86A_zIbkaHoyIn08"&gt;CASH AND CASH EQUIVALENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounting standards define &#x201c;cash and cash equivalents&#x201d;
as any short-term, highly liquid investment that is both readily convertible to known amounts of cash and so near their maturity that
they present insignificant risk of changes in value because of changes in interest rates. For the purpose of financial statement presentation,
we consider all highly liquid investment instruments with original maturities of three months or less when purchased, or any investment
redeemable without penalty or loss of interest to be cash equivalents. Cash is carried at cost, which approximates fair value, and cash
equivalents are carried at fair value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the fiscal years ended March 31, 2024 and March
31, 2023 our cash and cash equivalents were comprised of the following instruments:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zCj1Kr8QwWD1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ORGANIZATION, LIQUIDITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Cash and cash equivalents)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B2_zojazZQi4w5a" style="display: none"&gt;Schedule of cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the year ended&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Cash in US bank checking account&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20240331__us-gaap--CashAndCashEquivalentsAxis__custom--CashInUSBankMember_ztzbUfCdPIm3" style="width: 13%; text-align: right" title="Cash and cash equivalents"&gt;697,908&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__custom--CashInUSBankMember_zcNn4ihS7G8c" style="width: 13%; text-align: right" title="Cash and cash equivalents"&gt;575,766&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Cash equivalents held in US Treasury bills&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20240331__us-gaap--CashAndCashEquivalentsAxis__custom--CashEquivalentsInUSTreasuryBillsMember_zYKszzOUTeH1" style="text-align: right" title="Cash and cash equivalents"&gt;4,736,469&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__custom--CashEquivalentsInUSTreasuryBillsMember_z6KvUveYmZR3" style="text-align: right" title="Cash and cash equivalents"&gt;13,910,973&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Cash in Australian bank checking account&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20240331__us-gaap--CashAndCashEquivalentsAxis__custom--CashInAustralianBankMember_zTTEni0i0zvh" style="border-bottom: Black 1pt solid; text-align: right" title="Cash and cash equivalents"&gt;7,601&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__custom--CashInAustralianBankMember_z5tvCO3Aszu6" style="border-bottom: Black 1pt solid; text-align: right" title="Cash and cash equivalents"&gt;46,204&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total cash and cash equivalents&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20240331_zGY5sXYR7Bnh" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash and cash equivalents"&gt;5,441,978&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230331_zqC5rG24mr35" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash and cash equivalents"&gt;14,532,943&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000503">&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zCj1Kr8QwWD1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ORGANIZATION, LIQUIDITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Cash and cash equivalents)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B2_zojazZQi4w5a" style="display: none"&gt;Schedule of cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the year ended&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Cash in US bank checking account&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20240331__us-gaap--CashAndCashEquivalentsAxis__custom--CashInUSBankMember_ztzbUfCdPIm3" style="width: 13%; text-align: right" title="Cash and cash equivalents"&gt;697,908&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__custom--CashInUSBankMember_zcNn4ihS7G8c" style="width: 13%; text-align: right" title="Cash and cash equivalents"&gt;575,766&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Cash equivalents held in US Treasury bills&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20240331__us-gaap--CashAndCashEquivalentsAxis__custom--CashEquivalentsInUSTreasuryBillsMember_zYKszzOUTeH1" style="text-align: right" title="Cash and cash equivalents"&gt;4,736,469&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__custom--CashEquivalentsInUSTreasuryBillsMember_z6KvUveYmZR3" style="text-align: right" title="Cash and cash equivalents"&gt;13,910,973&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Cash in Australian bank checking account&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20240331__us-gaap--CashAndCashEquivalentsAxis__custom--CashInAustralianBankMember_zTTEni0i0zvh" style="border-bottom: Black 1pt solid; text-align: right" title="Cash and cash equivalents"&gt;7,601&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230331__us-gaap--CashAndCashEquivalentsAxis__custom--CashInAustralianBankMember_z5tvCO3Aszu6" style="border-bottom: Black 1pt solid; text-align: right" title="Cash and cash equivalents"&gt;46,204&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total cash and cash equivalents&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20240331_zGY5sXYR7Bnh" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash and cash equivalents"&gt;5,441,978&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230331_zqC5rG24mr35" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash and cash equivalents"&gt;14,532,943&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-03-31_custom_CashInUSBankMember"
      decimals="0"
      id="Fact000505"
      unitRef="USD">697908</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-03-31_custom_CashInUSBankMember"
      decimals="0"
      id="Fact000507"
      unitRef="USD">575766</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-03-31_custom_CashEquivalentsInUSTreasuryBillsMember"
      decimals="0"
      id="Fact000509"
      unitRef="USD">4736469</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-03-31_custom_CashEquivalentsInUSTreasuryBillsMember"
      decimals="0"
      id="Fact000511"
      unitRef="USD">13910973</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-03-31_custom_CashInAustralianBankMember"
      decimals="0"
      id="Fact000513"
      unitRef="USD">7601</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-03-31_custom_CashInAustralianBankMember"
      decimals="0"
      id="Fact000515"
      unitRef="USD">46204</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000517"
      unitRef="USD">5441978</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000519"
      unitRef="USD">14532943</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2023-04-01to2024-03-31" id="Fact000521">&lt;p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zArdsPbBI6Xd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86A_z3EoK5FH2iqi"&gt;CONCENTRATIONS OF CREDIT RISKS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cash is maintained at one US financial institution
in a checking account. Accounts at this institution are secured by the Federal Deposit Insurance Corporation up to $250,000. Our March
31, 2024 cash balances were approximately $&lt;span id="xdx_90E_eus-gaap--CashUninsuredAmount_pp0p0_c20240331_zI1lv8MmPmnh" title="Cash balances over insured amount"&gt;568,000&lt;/span&gt; over such insured amount. &lt;span style="background-color: white"&gt;We do not believe that
the Company is exposed to any significant risk with respect to its cash in that checking account.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;At March 31,
2024, we maintained cash equivalents of approximately $&lt;span id="xdx_904_eus-gaap--USGovernmentSecuritiesAtCarryingValue_iI_pn5n6_c20240331_zCt2aRU3zVwl" title="Cash equivalents of US treasury bills"&gt;4.7&lt;/span&gt; million in US Treasury bills with maturities of less than three months. We
do not believe that the Company is exposed to any significant risk with respect to its cash equivalents since they represent US government
risk.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cash is maintained at one Australian financial institution
in checking accounts. Accounts at this institution are secured by the Financial Claims Scheme for up to Australian $250,000. Our March
31, 2024 Australian cash balance was below that threshold.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We did not have any revenue in fiscal year ended March
31, 2024. All of our revenue in the fiscal year ended March 31, 2023 related to our government contracts. We did not have any accounts
receivable at March 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000523"
      unitRef="USD">568000</us-gaap:CashUninsuredAmount>
    <us-gaap:USGovernmentSecuritiesAtCarryingValue
      contextRef="AsOf2024-03-31"
      decimals="-5"
      id="Fact000525"
      unitRef="USD">4700000</us-gaap:USGovernmentSecuritiesAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="From2023-04-01to2024-03-31" id="Fact000527">&lt;p id="xdx_84A_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zh7yth2uYs86" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86D_zG9n2GZhpPBg"&gt;RESTRICTED CASH&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;To comply with the terms of our laboratory, office,
and manufacturing space leases, we caused our bank to issue two standby letters of credit, or the L/Cs, in the amount of $&lt;span id="xdx_900_eus-gaap--RestrictedCash_iI_pp0p0_c20240331_zLH3I3gSgkA4" title="Restricted cash"&gt;87,506&lt;/span&gt; in favor
of the landlord. The L/Cs are in lieu of a security deposit. In order to support the L/Cs, we agreed to have our bank withdraw $87,506
from our operating accounts and to place that amount in restricted certificates of deposit. We have classified that amount as restricted
cash, a long-term asset, on our balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCash
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000529"
      unitRef="USD">87506</us-gaap:RestrictedCash>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000531">&lt;p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zmhKDB01aWc2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_865_zkeTwgHA8tJ8"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Property and equipment are stated at cost. Depreciation
is computed using the straight-line method over the estimated useful lives of the related assets, which range from two to five years.
Repairs and maintenance are charged to expense as incurred while improvements are capitalized. Upon the sale or retirement of property
and equipment, the accounts are relieved of the cost and the related accumulated depreciation with any gain or loss included in the consolidated
statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000537">&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zLplOXYE6dkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_869_zx4giJ0t3lya"&gt;INCOME TAXES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Deferred tax assets and liabilities are recognized for the future tax consequences
attributable to the difference between the consolidated financial statements and their respective tax basis. Deferred income taxes reflect
the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes
and the amounts reported for income tax purposes, and (b) tax credit carryforwards. We record a valuation allowance for deferred tax assets
when, based on our best estimate of taxable income (if any) in the foreseeable future, it is more likely than not that some portion of
the deferred tax assets may not be realized. Management has provided a full valuation allowance against the Company&#x2019;s net deferred
tax asset. Tax positions taken or expected to be taken in the course of preparing tax returns are required to be evaluated to determine
whether the tax positions are more-likely-than-not to be sustained by the applicable tax authority. Tax positions deemed to not meet a
more-likely-than-not threshold would be recorded as tax expense in the current year. There were &lt;span id="xdx_90D_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20240331_zVkd0MC7J2tc" title="Uncertain tax positions"&gt;&lt;span id="xdx_905_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20230331_z05QyNg6bASi" title="Uncertain tax positions"&gt;no&lt;/span&gt;&lt;/span&gt; uncertain tax positions that require
accrual to or disclosure in the consolidated financial statements as of March 31, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000539"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000541"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000543">&lt;p id="xdx_849_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zhwSfpD9GeB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86A_zXoRmHSULYF4"&gt;LONG-LIVED ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Long-lived assets are reviewed for impairment whenever
events or changes in circumstances indicate that their carrying amounts may not be recoverable. If the cost basis of a long-lived asset
is greater than the projected future undiscounted net cash flows from such asset, an impairment loss is recognized. We believe &lt;span id="xdx_909_eus-gaap--AssetImpairmentCharges_pp0p0_do_c20230401__20240331_zjbkgQE0hMR8" title="Asset impairment charges"&gt;&lt;span id="xdx_907_eus-gaap--AssetImpairmentCharges_pp0p0_do_c20220401__20230331_zAE4f3U7ZRL2" title="Asset impairment charges"&gt;no&lt;/span&gt;&lt;/span&gt; impairment
charges were necessary during the fiscal years ended March 31, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000545"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000547"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000549">&lt;p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_z4TTVp4K6gfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_866_zt122nDAHudj"&gt;LOSS PER SHARE&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic loss per share is computed by dividing net loss
available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted
loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional
common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive.
Since we had net losses for all periods presented, basic and diluted loss per share are the same, and additional potential common shares
have been excluded as their effect would be antidilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2024 and 2023, a total of &lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230401__20240331_zagM1gZ8dYk" title="Antidilutive shares"&gt;124,028&lt;/span&gt;
and &lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220401__20230331_zwqlVCfsyWE5" title="Antidilutive shares"&gt;204,501&lt;/span&gt; potential common shares, consisting of shares underlying outstanding stock options, restricted stock units, or RSUs, and warrants
were excluded as their inclusion would be antidilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-04-01to2024-03-31"
      decimals="INF"
      id="Fact000551"
      unitRef="Shares">124028</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-04-012023-03-31"
      decimals="INF"
      id="Fact000553"
      unitRef="Shares">204501</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DebtPolicyTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000555">&lt;p id="xdx_844_eus-gaap--DebtPolicyTextBlock_zfKW2lEJj5Ma" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86D_zvANLp0QcQKb"&gt;DEFERRED OFFERING COSTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Specific incremental costs directly attributable to
an actual offering of securities may be deferred and charged against the gross proceeds of the offering. As of March 31, 2024, approximately
$&lt;span id="xdx_903_eus-gaap--DeferredCosts_iI_c20240331_zUBEn55UZ6Xd" title="Deferred offering costs"&gt;278,000&lt;/span&gt; of costs have been deferred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:DebtPolicyTextBlock>
    <us-gaap:DeferredCosts
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000557"
      unitRef="USD">278000</us-gaap:DeferredCosts>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000559">&lt;p id="xdx_846_eus-gaap--RevenueRecognitionPolicyTextBlock_zLhW8ATE10x9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_867_zdYu5C3pYSXj"&gt;REVENUE RECOGNITION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We did not recognize revenue in fiscal year ended
March 31, 2024. Our revenues in the fiscal year ended March 31, 2023 consisted entirely of amounts earned under contracts and grants with
the National Institutes of Health, or NIH. During the fiscal year ended March 31, 2023, we recognized revenues totaling $&lt;span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331_zK1EKBeu0mC1" title="Contract revenue"&gt;574,245&lt;/span&gt; under
such contracts. We have concluded that these agreements are not within the scope of ASC Topic, 606, Revenue from Contracts with Customers,
or Topic 606, as the NIH grants and contracts do not meet the definition of a &#x201c;customer&#x201d; as defined by Topic 606. Prior to
the effective date of ASC Topic 606, which for the Company was April 1, 2018, we accounted for our grant/contract revenues under the Milestone
Method as prescribed by the legacy guidance of ASC 605-28, Revenue Recognition &#x2013; Milestone Method, or Milestone Method. In the absence
of other applicable guidance under US GAAP, effective April 1, 2018, we elected to continue to use the Milestone Method by analogy to
recognize revenue under these grants/contracts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We identify the deliverables included within these
agreements and evaluate which deliverables represent separate units of accounting based on if certain criteria are met, including whether
the delivered element has standalone value to the collaborator. The consideration received is allocated among the separate units of accounting,
and the applicable revenue recognition criteria are applied to each of the separate units.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A milestone is an event having all of the following
characteristics:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(1) There is substantive uncertainty at the date the
arrangement is entered into that the event will be achieved. A vendor&#x2019;s assessment that it expects to achieve a milestone does not
necessarily mean that there is not substantive uncertainty associated with achieving the milestone.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(2) The event can only be achieved based in whole
or in part on either: (a) the vendor&#x2019;s performance; or (b) a specific outcome resulting from the vendor&#x2019;s performance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(3) If achieved, the event would result in additional
payments being due to the vendor.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A milestone does not include events for which the
occurrence is either: (a) contingent solely upon the passage of time; or (b) the result of a counterparty&#x2019;s performance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The policy for recognizing deliverable consideration
contingent upon achievement of a milestone must be applied consistently to similar deliverables.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The assessment of whether a milestone is substantive
is performed at the inception of the arrangement. The consideration earned from the achievement of a milestone must meet all of the following
for the milestone to be considered substantive:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(1) The consideration is commensurate with either:
(a) the vendor&#x2019;s performance to achieve the milestone; or (b) the enhancement of the value of the delivered item or items as a result
of a specific outcome resulting from the vendor&#x2019;s performance to achieve the milestone;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(2) The consideration relates solely to past performance;
and&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(3) The consideration is reasonable relative to all
of the deliverables and payment terms (including other potential milestone consideration) within the arrangement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A milestone is not considered substantive if any portion
of the associated milestone consideration relates to the remaining deliverables in the unit of accounting (i.e., it does not relate solely
to past performance). To recognize the milestone consideration in its entirety as revenue in the period in which the milestone is achieved,
the milestone must be substantive in its entirety. Milestone consideration cannot be bifurcated into substantive and nonsubstantive components.
In addition, if a portion of the consideration earned from achieving a milestone may be refunded or adjusted based on future performance,
the related milestone is not considered substantive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We have recognized revenue under the following contract/grant:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Phase 2 Melanoma Cancer Contract&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 12, 2019, the National Cancer Institute,
or NCI, part of the NIH, awarded to us a SBIR Phase II Award Contract, for NIH/NCI Topic 359, entitled &#x201c;A Device Prototype for Isolation
of Melanoma Exosomes for Diagnostics and Treatment Monitoring&#x201d;, or the Award Contract. The Award Contract amount was $1,860,561
and, as amended, ran for the period from September 16, 2019 through September 15, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The work performed pursuant to this Award Contract
was focused on melanoma exosomes. This work followed from our completion of a Phase I contract for the Topic 359 solicitation that ran
from September 2017 through June 2018, as described below. Following on the Phase I work, the deliverables in the Phase II program involved
the design and testing of a pre-commercial prototype of a more advanced version of the exosome isolation platform.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Award Contract ended on September 15, 2022 and
we presented the required final report to the NCI. As the NCI completed its close out review of the contract, we recognized as revenue
$&lt;span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220401__20230331__us-gaap--TransactionTypeAxis__custom--MelanomaCancerContractMember_zbCK03hmTvj2" title="Revenue recognized from contract"&gt;574,245&lt;/span&gt; in fiscal year ended March 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000561"
      unitRef="USD">574245</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-04-012023-03-31_custom_MelanomaCancerContractMember"
      decimals="0"
      id="Fact000571"
      unitRef="USD">574245</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2023-04-01to2024-03-31" id="Fact000573">&lt;p id="xdx_844_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zSG0jYLMlUm1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86D_zC6BjQdwI7yf"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Employee stock options and rights to purchase shares
under stock participation plans are accounted for under the fair value method. Accordingly, share-based compensation is measured when
all granting activities have been completed, generally the grant date, based on the fair value of the award. The exercise price of options
is generally equal to the market price of the Company&#x2019;s common stock (defined as the closing price as quoted on the Nasdaq Capital
Market or OTCBB on the date of grant). Compensation cost recognized by the Company includes (a) compensation cost for all equity incentive
awards granted prior to April 1, 2006, but not yet vested, based on the grant-date fair value estimated in accordance with the original
provisions of the then current accounting standards, and (b) compensation cost for all equity incentive awards granted subsequent to March
31, 2006, based on the grant-date fair value estimated in accordance with the provisions of subsequent accounting standards. We use a
Binomial Lattice option pricing model for estimating fair value of options granted (see Note 4).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table summarizes share-based compensation
expenses relating to shares and options granted and the effect on loss per common share during the years ended March 31, 2024 and 2023:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zZcl5mzexuh4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ORGANIZATION, LIQUIDITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Stock compensation)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BD_z1wkUgvdYp3j" style="display: none"&gt;Schedule of share-based compensation expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230401__20240331_znW0e3MKqtT5" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20220401__20230331_zegqj2dGYCU4" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Fiscal Years Ended&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_i_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left; padding-bottom: 1pt"&gt;Vesting of Stock Options and Restricted Stock Units&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 13%; text-align: right"&gt;1,219,370&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 13%; text-align: right"&gt;1,051,898&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ShareBasedCompensation_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total Stock-Based Compensation Expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,219,370&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,051,898&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Weighted average number of common shares outstanding &#x2013; basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20240331_zBjzResuM7y4"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20240331_zRcyRVLAt4aj"&gt;2,512,774&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220401__20230331_zARx0WNRhjx6"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220401__20230331_zmaF9cPa8Q8k"&gt;2,053,744&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Basic and diluted loss per common share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareBasic_c20230401__20240331__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zuRoesZvDJN9" title="Basic loss per common share"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20230401__20240331__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zAkA5blKXvYf" title="Diluted loss per common share"&gt;(0.49&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20220401__20230331__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zkx9gocAsC1d" title="Basic loss per common share"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20220401__20230331__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zYrc87xr3Eg5" title="Diluted loss per common share"&gt;(0.51&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We record share-based compensation expenses for awards
of stock options and RSUs under ASC 718, Share-based compensation, or ASC 718. For awards to non-employees for periods prior to the adoption
of ASU 2018-07, Compensation-Stock Compensation: Improvements to Non-employee Share-Based Payment Accounting, on April 1, 2019, the Company
had applied ASC 505-50, Equity &#x2013; Equity-based payments to non-employees, or ASC 505-50. ASC 718 establishes guidance for the recognition
of expenses arising from the issuance of share-based compensation awards at their fair value at the grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We recognize share-based compensation expense related
to stock options and stock appreciation rights granted to employees, directors and consultants based on the estimated fair value of the
awards on the date of grant. We estimate the grant date fair value, and the resulting share-based compensation expense, for stock options
that only have service vesting requirements or performance-based vesting requirements without market conditions using the binomial lattice
option-pricing model. The grant date fair value of the share-based awards with service vesting requirements is generally recognized on
a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. Determining the
appropriate amount to expense for performance-based awards based on the achievement of stated goals requires judgment. The estimate of
expense is revised periodically based on the probability of achieving the required performance targets and adjustments are made as appropriate.
The cumulative impact of any revisions is reflected in the period of change. If any applicable financial performance goals are not met,
no compensation cost is recognized and any previously recognized compensation cost is reversed. For performance-based awards with market
conditions, we determine the fair value of awards as of the grant date using a Monte Carlo simulation model.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We review share-based compensation on a quarterly
basis for changes to the estimate of expected award forfeitures based on actual forfeiture experience. The effect of adjusting the forfeiture
rate for all expense amortization after March 31, 2007 is recognized in the period the forfeiture estimate is changed. The effect of forfeiture
adjustments for the fiscal year ended March 31, 2024 was insignificant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000575">&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zZcl5mzexuh4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ORGANIZATION, LIQUIDITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Stock compensation)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BD_z1wkUgvdYp3j" style="display: none"&gt;Schedule of share-based compensation expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230401__20240331_znW0e3MKqtT5" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20220401__20230331_zegqj2dGYCU4" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Fiscal Years Ended&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_i_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left; padding-bottom: 1pt"&gt;Vesting of Stock Options and Restricted Stock Units&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 13%; text-align: right"&gt;1,219,370&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 13%; text-align: right"&gt;1,051,898&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ShareBasedCompensation_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total Stock-Based Compensation Expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,219,370&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,051,898&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Weighted average number of common shares outstanding &#x2013; basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20240331_zBjzResuM7y4"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20240331_zRcyRVLAt4aj"&gt;2,512,774&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220401__20230331_zARx0WNRhjx6"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220401__20230331_zmaF9cPa8Q8k"&gt;2,053,744&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Basic and diluted loss per common share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareBasic_c20230401__20240331__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zuRoesZvDJN9" title="Basic loss per common share"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20230401__20240331__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zAkA5blKXvYf" title="Diluted loss per common share"&gt;(0.49&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20220401__20230331__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zkx9gocAsC1d" title="Basic loss per common share"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20220401__20230331__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zYrc87xr3Eg5" title="Diluted loss per common share"&gt;(0.51&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000577"
      unitRef="USD">1219370</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000578"
      unitRef="USD">1051898</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000580"
      unitRef="USD">1219370</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000581"
      unitRef="USD">1051898</us-gaap:ShareBasedCompensation>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-04-01to2024-03-31"
      decimals="INF"
      id="Fact000582"
      unitRef="Shares">2512774</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-04-01to2024-03-31"
      decimals="INF"
      id="Fact000583"
      unitRef="Shares">2512774</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-04-012023-03-31"
      decimals="INF"
      id="Fact000584"
      unitRef="Shares">2053744</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-04-012023-03-31"
      decimals="INF"
      id="Fact000585"
      unitRef="Shares">2053744</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-04-012024-03-31_custom_StockBasedCompensationMember"
      decimals="INF"
      id="Fact000587"
      unitRef="USDPShares">-0.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-04-012024-03-31_custom_StockBasedCompensationMember"
      decimals="INF"
      id="Fact000589"
      unitRef="USDPShares">-0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-04-012023-03-31_custom_StockBasedCompensationMember"
      decimals="INF"
      id="Fact000591"
      unitRef="USDPShares">-0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-04-012023-03-31_custom_StockBasedCompensationMember"
      decimals="INF"
      id="Fact000593"
      unitRef="USDPShares">-0.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000599">&lt;p id="xdx_845_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_z0OD2KeQmMXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86D_z2J3od3XLig5"&gt;PATENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Patents include both foreign and domestic patents.
We capitalize the cost of patents, some of which were acquired, and amortize such costs over the shorter of the remaining legal life or
their estimated economic life, upon issuance of the patent. The unamortized costs of patents are subject to our review for impairment
under our long-lived asset policy above.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <aemd:StockPurchaseWarrantsPolicyTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000601">&lt;p id="xdx_845_ecustom--StockPurchaseWarrantsPolicyTextBlock_zHl0sCMz91Lg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86F_zcv2HnDFLzY7"&gt;STOCK PURCHASE WARRANTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In the past we issued warrants for the purchase of
shares of our common stock in connection with the issuance of common stock for cash. Warrants issued in connection with common stock for
cash, if classified as equity, are considered issued in connection with equity transactions and the warrant fair value is recorded to
additional paid-in-capital.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</aemd:StockPurchaseWarrantsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2023-04-01to2024-03-31" id="Fact000603">&lt;p id="xdx_84D_eus-gaap--ResearchAndDevelopmentExpensePolicy_zg3uc4SrzZOf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_863_zny89c3c1yvh"&gt;RESEARCH AND DEVELOPMENT EXPENSES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our research and development costs are expensed as
incurred. We incurred approximately $&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230401__20240331_zHzf5mDUa13a" title="Research and development expenses"&gt;2,520,000&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220401__20230331_zlHQIhByHa26" title="Research and development expenses"&gt;2,745,000&lt;/span&gt; of research and development expenses for the years ended March 31, 2024
and 2023, respectively, which are included in various operating expenses in the accompanying consolidated statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000605"
      unitRef="USD">2520000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000607"
      unitRef="USD">2745000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000609">&lt;p id="xdx_849_eus-gaap--OffBalanceSheetCreditExposurePolicyPolicyTextBlock_zQ6HOVrmtpo1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86C_z8Sny2iDWeIj"&gt;OFF-BALANCE SHEET ARRANGEMENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We have not entered into any off-balance sheet arrangements
that have or are reasonably likely to have a current or future material effect on our consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000611">&lt;p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zN3ia16zZhJ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_86A_zgZEqGDZyIIj"&gt;SIGNIFICANT RECENT ACCOUNTING PRONOUNCEMENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2023, the FASB issued Accounting Standards
Update 2023-09, Improvements to Income Tax Disclosures (&#x201c;ASU 2023-09&#x201d;), which requires enhanced annual disclosures for specific
categories in the rate reconciliation and income taxes paid disaggregated by federal, state and foreign taxes. ASU 2023-09 is effective
for public business entities for annual periods beginning after December 15, 2024. The Company is evaluating if the adoption of this new
standard will have a material effect on our disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial
Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The adoption of ASU No. 2016-13 for smaller
reporting companies that did not previously early adopt was January 1, 2023. &lt;span&gt;The Company maintained
US Treasury bills with maturities of less than three months&lt;/span&gt; and expects zero credit losses from these securities. As a result,
the Company did not record an allowance for expected credit losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;











</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000617">&lt;p id="xdx_804_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zhLJGb1jGluc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;2. &lt;span id="xdx_82F_zs0byjDdOPsi"&gt;PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Property and equipment, net, consist of the following:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--PropertyPlantAndEquipmentTextBlock_zln2UgHRXZP3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT, NET (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B5_zo8wVtnFYGuf" style="display: none"&gt;Schedule of property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240331_zZdykByitOEj" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230331_zBlzKeSp8MZ7" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_maPPAENzbUG_z8vkwjYY1DB8" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Furniture and office equipment, at cost&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,112,648&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;989,987&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LeaseholdImprovementsGross_iI_pp0p0_d0_maPPAENzbUG_z06AujCRZsYe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;893,131&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;888,224&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzbUG_zQpIcvX4IRXh" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(990,550&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(734,207&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzbUG_zQeaCJKY6fmh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Fixed Assets, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,015,229&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,144,004&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Depreciation expense for the fiscal years ended March 31, 2024 and 2023
was $&lt;span id="xdx_903_eus-gaap--Depreciation_pp0p0_c20230401__20240331_zqWQ2zNZ1Bb2" title="Depreciation expense"&gt;358,507&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--Depreciation_pp0p0_c20220401__20230331_z95jHykjoxe6" title="Depreciation expense"&gt;240,342&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000619">&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--PropertyPlantAndEquipmentTextBlock_zln2UgHRXZP3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT, NET (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B5_zo8wVtnFYGuf" style="display: none"&gt;Schedule of property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240331_zZdykByitOEj" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230331_zBlzKeSp8MZ7" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_maPPAENzbUG_z8vkwjYY1DB8" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Furniture and office equipment, at cost&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,112,648&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;989,987&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LeaseholdImprovementsGross_iI_pp0p0_d0_maPPAENzbUG_z06AujCRZsYe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;893,131&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;888,224&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzbUG_zQpIcvX4IRXh" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(990,550&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(734,207&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzbUG_zQeaCJKY6fmh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Fixed Assets, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,015,229&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,144,004&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000621"
      unitRef="USD">1112648</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000622"
      unitRef="USD">989987</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000624"
      unitRef="USD">893131</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000625"
      unitRef="USD">888224</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000627"
      unitRef="USD">990550</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000628"
      unitRef="USD">734207</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000630"
      unitRef="USD">1015229</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000631"
      unitRef="USD">1144004</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000633"
      unitRef="USD">358507</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000635"
      unitRef="USD">240342</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000637">&lt;p id="xdx_803_eus-gaap--IntangibleAssetsDisclosureTextBlock_zSs0f4oYaFJ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;3. &lt;span id="xdx_82B_zWBgiD6gT4Ic"&gt;PATENTS, NET&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Patents, net consist of the following:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zFks3mXFMqGg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PATENTS, NET (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BA_zAT0pJOob5Yk" style="display: none"&gt;Schedule of patents, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240331_z5qECch51Ck1" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20230331_zVcecokKjpWe" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FiniteLivedPatentsGross_iI_pp0p0_maFLIAGzTN2_zWZIUlTzMHNe" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Issued patents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;157,442&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;157,442&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_msFLIAGzTN2_zQ3wI8Re1tgl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(156,342&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(155,792&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsGross_iTI_pp0p0_mtFLIAGzTN2_maFLIANzcFT_z7lgapWM3Uo3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;Issued patents, net of accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,100&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,650&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANzcFT_zhVMvCaTvW75" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Patents, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,650&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Amortization expense for our capitalized issued patents
for each of the fiscal years ended March 31, 2024 and 2023 was $&lt;span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20230401__20240331_zwH94qAJymOb" title="Amortization of patents"&gt;&lt;span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20220401__20230331_zx25JVzVJxbi" title="Amortization of patents"&gt;550&lt;/span&gt;&lt;/span&gt;. As only one capitalized patent remains to be amortized, future amortization
expense on patents is estimated to be approximately $550 per year based on the estimated life of the patent. The weighted average remaining
life of our remaining capitalized patent is approximately &lt;span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240331_zCaqFm5PEkA" title="Weighted average remaining life of patents"&gt;2.0&lt;/span&gt; years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000639">&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zFks3mXFMqGg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PATENTS, NET (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BA_zAT0pJOob5Yk" style="display: none"&gt;Schedule of patents, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240331_z5qECch51Ck1" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20230331_zVcecokKjpWe" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FiniteLivedPatentsGross_iI_pp0p0_maFLIAGzTN2_zWZIUlTzMHNe" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Issued patents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;157,442&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;157,442&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_msFLIAGzTN2_zQ3wI8Re1tgl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(156,342&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(155,792&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsGross_iTI_pp0p0_mtFLIAGzTN2_maFLIANzcFT_z7lgapWM3Uo3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;Issued patents, net of accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,100&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,650&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANzcFT_zhVMvCaTvW75" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Patents, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,650&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedPatentsGross
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000641"
      unitRef="USD">157442</us-gaap:FiniteLivedPatentsGross>
    <us-gaap:FiniteLivedPatentsGross
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000642"
      unitRef="USD">157442</us-gaap:FiniteLivedPatentsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000644"
      unitRef="USD">156342</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000645"
      unitRef="USD">155792</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000647"
      unitRef="USD">1100</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000648"
      unitRef="USD">1650</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000650"
      unitRef="USD">1100</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000651"
      unitRef="USD">1650</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000653"
      unitRef="USD">550</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000655"
      unitRef="USD">550</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="AsOf2024-03-31" id="Fact000657">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000659">&lt;p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zyV6DykUyvid" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;4. &lt;span id="xdx_82C_zKpdchTY56Qb"&gt;EQUITY TRANSACTIONS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;REVERSE
STOCK SPLIT&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;On
October 4, 2023, we effected a&lt;span id="xdx_909_eus-gaap--StockholdersEquityReverseStockSplit_c20231003__20231004_zG05uaWNuu06" title="Reverse stock split"&gt;&#160;1-for-10&lt;/span&gt;&#160;reverse stock split of our then outstanding shares of common stock. Accordingly, each
10 shares of outstanding common stock then held by our stockholders were combined into one share of common stock. Any fractional shares
resulting from the reverse split were rounded up to the next whole share. Authorized common stock remained at&#160;&lt;span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20240331_zDy93Wg2CBba" title="Common stock, shares authorized"&gt;60,000,000&lt;/span&gt;&#160;shares
following the stock split. The accompanying consolidated financial statements and accompanying notes have been retroactively revised to
reflect such reverse stock split as if it had occurred on April 1, 2022. All shares and per share amounts have been revised accordingly.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;ISSUANCES OF COMMON STOCK AND WARRANTS&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Equity Transactions in the Fiscal Year Ended March 31, 2024.&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;2022 At The Market Offering Agreement with H.C. Wainwright &amp;amp; Co.,
LLC&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 24, 2022, we entered into an At The Market
Offering Agreement, or the 2022 ATM Agreement, with H.C. Wainwright &amp;amp; Co., LLC, or Wainwright, which established an at-the-market
equity program pursuant to which we may offer and sell shares of our common stock from time to time as set forth in the 2022 ATM Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The offering was registered under the Securities Act
of 1933, as amended, or the Securities Act, pursuant to our shelf registration statement on Form S-3 (Registration Statement No. 333-259909),
as previously filed with the Securities and Exchange Commission, or SEC, and declared effective on October 21, 2021. We filed a prospectus
supplement, dated March 24, 2022, with the SEC that provides for the sale of shares of our common stock, or the 2022 ATM Shares, having
an aggregate offering price of up to $&lt;span id="xdx_905_ecustom--AggregateOfferingPrice_c20220323__20220324__us-gaap--SecuritiesFinancingTransactionAxis__custom--ATM2022AgreementMember_zIKYVabdSlyh" title="Aggregate offering price"&gt;15,000,000&lt;/span&gt;, which was subsequently and most recently updated pursuant to our prospectus supplement,
dated September 29, 2022, filed with the SEC that provides for the sale of 2022 ATM Shares having an aggregate offering price of up to
$&lt;span id="xdx_90E_ecustom--AggregateOfferingPrice_c20220928__20220929__us-gaap--SecuritiesFinancingTransactionAxis__custom--ATM2022AgreementMember_zGkluvUPxgac" title="Aggregate offering price"&gt;6,625,000&lt;/span&gt;. As of March 31, 2024, $&lt;span id="xdx_909_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_c20240331__us-gaap--SecuritiesFinancingTransactionAxis__custom--ATM2022AgreementMember_zFukF17yQUgc" title="Securities remained available for sale"&gt;5,302,617&lt;/span&gt; of 2022 ATM Shares remained available for sale under the 2022 ATM Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Under the 2022 ATM Agreement, Wainwright may sell
the 2022 ATM Shares by any method permitted by law and deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule 415 promulgated
under the Securities Act, including sales made directly on the Nasdaq Capital Market, or on any other existing trading market for the
2022 ATM Shares. In addition, under the 2022 ATM Agreement, Wainwright may sell the 2022 ATM Shares in privately negotiated transactions
with our consent and in block transactions. Under certain circumstances, we may instruct Wainwright not to sell the 2022 ATM Shares if
the sales cannot be effected at or above the price designated by us from time to time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We are not obligated to make any further sales of
the 2022 ATM Shares under the 2022 ATM Agreement. The offering of the 2022 ATM Shares pursuant to the 2022 ATM Agreement will terminate
upon the termination of the 2022 ATM Agreement by Wainwright or us, as permitted therein.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The 2022 ATM Agreement contains customary representations,
warranties and agreements by us, and customary indemnification and contribution rights and obligations of the parties. We agreed to pay
Wainwright a placement fee of up to 3.0% of the aggregate gross proceeds from each sale of the 2022 ATM Shares. We also agreed to reimburse
Wainwright for certain specified expenses in connection with entering into the 2022 ATM Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In the fiscal year ended March 31, 2024, we raised
aggregate net proceeds of $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230401__20240331__us-gaap--SecuritiesFinancingTransactionAxis__custom--ATM2022AgreementMember_zfdsYrpNsoea" title="Proceeds from sale of common stock"&gt;1,322,383&lt;/span&gt; net of $&lt;span id="xdx_902_eus-gaap--PaymentsOfStockIssuanceCosts_c20230401__20240331__us-gaap--SecuritiesFinancingTransactionAxis__custom--ATM2022AgreementMember__srt--CounterpartyNameAxis__custom--HcWainwrightMember_zTKSmvmhQURe" title="Payment of stock issuance costs"&gt;34,118&lt;/span&gt; in commissions to Wainwright and $&lt;span id="xdx_90C_eus-gaap--PaymentsOfDebtIssuanceCosts_c20230401__20240331__us-gaap--SecuritiesFinancingTransactionAxis__custom--ATM2022AgreementMember_zQxrMkQnxF61" title="Payment of other stock issuance costs"&gt;8,202&lt;/span&gt; in other offering expense, through the sale
of &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230401__20240331__us-gaap--SecuritiesFinancingTransactionAxis__custom--ATM2022AgreementMember_zwRIReQCsCz7" title="Stock issued new, shares issued"&gt;296,056&lt;/span&gt; shares of our common stock at an average price of $&lt;span id="xdx_908_ecustom--SharesIssuedPricePerShare1_c20230401__20240331__us-gaap--SecuritiesFinancingTransactionAxis__custom--ATM2022AgreementMember_zEvXvXoVELv6" title="Average per share sale price"&gt;4.47&lt;/span&gt; per share under the 2022 ATM Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;RSU Grants to Non-Employee Directors &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;In
April 2023, the Compensation Committee of the Board, or Compensation Committee, approved, pursuant to the terms of the Company&#x2019;s
Amended and Restated Non-Employee Director Compensation Policy, or the Director Compensation Policy, the grant of the annual RSUs under
the Director Compensation Policy to each of the three non-employee directors of the Company then serving on the Board of Directors of
the Company, or Board. The Director Compensation Policy provides for a grant of stock options or $50,000 worth of RSUs at the beginning
of each fiscal year for current non-employee directors then serving on the Board, and for a grant of stock options or $75,000 worth of
RSUs for a newly elected non-employee director, with each RSU priced at the average for the closing prices for the five days preceding
and including the date of grant, or $4.30 per share for the April 2023 RSU grants. As a result, in April 2023 the three eligible directors
were each granted an RSU in the amount of &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230401__20240331__srt--CounterpartyNameAxis__custom--Director1Member__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBVNT699t1w2" title="RSU's granted"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230401__20240331__srt--CounterpartyNameAxis__custom--Director2Member__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRqXRtKC8Yu7" title="RSU's granted"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230401__20240331__srt--CounterpartyNameAxis__custom--Director3Member__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zulJh6RweoKh" title="RSU's granted"&gt;11,628&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; shares under the 2020 Plan. &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxIYJ2c9GYf" title="Terms of awards"&gt;The RSUs are subject to vesting in four equal installments,
with 25% of the restricted stock units vesting on each of June 30, 2023, September 30, 2023, December 31, 2023, and March 31, 2024, subject
in each case to the director&#x2019;s Continuous Service (as defined in the 2020 Plan), through such dates. Vesting will terminate upon
the director&#x2019;s termination of Continuous Service prior to any vesting date.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Unvested RSUs covering &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgqwdMeZqa37" title="Unvested stock outstanding"&gt;4,885&lt;/span&gt;
shares of common stock were outstanding as of March 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Equity Transactions in the Fiscal Year Ended March 31, 2023.&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the fiscal year ended March 31, 2023, we raised
net proceeds of $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220401__20230331__us-gaap--SecuritiesFinancingTransactionAxis__custom--ATM2022AgreementMember_zfDrEvKITCzl" title="Proceeds from sale of common stock"&gt;8,927,211&lt;/span&gt;, net of $&lt;span id="xdx_905_eus-gaap--PaymentsOfStockIssuanceCosts_c20220401__20230331__us-gaap--SecuritiesFinancingTransactionAxis__custom--ATM2022AgreementMember__srt--CounterpartyNameAxis__custom--HcWainwrightMember_zaO9Aav022ol" title="Payment of stock issuance costs"&gt;229,610&lt;/span&gt; in commissions to Wainwright and $&lt;span id="xdx_90E_eus-gaap--PaymentsOfDebtIssuanceCosts_c20220401__20230331__us-gaap--SecuritiesFinancingTransactionAxis__custom--ATM2022AgreementMember_zKBPwwHJLu8f" title="Payment of other stock issuance costs"&gt;27,153&lt;/span&gt; in other offering expense, through the sale of &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220401__20230331__us-gaap--SecuritiesFinancingTransactionAxis__custom--ATM2022AgreementMember_zreqcJurpF7f" title="Stock issued new, shares issued"&gt;748,084&lt;/span&gt;
shares of our common stock at an average price of $&lt;span id="xdx_907_ecustom--SharesIssuedPricePerShare1_c20220401__20230331__us-gaap--SecuritiesFinancingTransactionAxis__custom--ATM2022AgreementMember_zU96BLxqNN6d" title="Average per share sale price"&gt;11.90&lt;/span&gt; per share under the 2022 ATM Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;RSU Grants to Non-Employee Directors&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Compensation
Committee approved, effective as of April 1, 2022, pursuant to the terms of the Director Compensation Policy, the grant of the
annual RSUs to each of the two non-employee directors of the Company then serving on the Board, and the grant of an RSU for the then
newly appointed non-employee director. The RSU grants were made subject to stockholder approval of an increase of&#160;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaue7tcWoHn7" title="Number of shares authorized"&gt;1,800,000&lt;/span&gt;
shares of common stock authorized for issuance under the Company&#x2019;s 2020 Equity Incentive Plan, or the 2020 Plan, at the
Company&#x2019;s 2022 Annual Meeting of Stockholders. The increase was approved at the Company&#x2019;s 2022 Annual Meeting of
Stockholders held in September 2022. The Director Compensation Policy provides for a grant of stock options or $50,000 worth of RSUs
at the beginning of each fiscal year for current non-employee directors then serving on the Board and for a grant of stock options
or $75,000 worth of RSUs for a newly elected non-employee director, with each RSU priced at the average for the closing prices for
the five days preceding and including the date of grant, or $14.60 per share as of April 1, 2022. The two then-current eligible
directors each was granted a contingent RSU in the amount of&#160;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220401__20230331__srt--CounterpartyNameAxis__custom--EligibleDirectorsEachMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwdwUaUuBhXj" title="Number of shares granted"&gt;3,425&lt;/span&gt;&#160;shares
under the 2020 Plan and the then newly appointed director received a contingent RSU grant for&#160;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220401__20230331__srt--CounterpartyNameAxis__custom--NewlyAppointedDirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z27Oait3b3sg" title="Number of shares granted"&gt;5,137&lt;/span&gt;&#160;shares
under the 2020 Plan. &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkNdEif6y3yg" title="Terms of awards"&gt;The
RSUs were subject to vesting in three installments, 50% on September 30, 2022, and 25% on each of December 31, 2022, and March 31,
2023, subject to the recipient's continued service with the Company on each such vesting date.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;There were &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_do_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z36BBhBqzApc" title="Unvested stock outstanding"&gt;no&lt;/span&gt; vested RSUs outstanding as of
March 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;WARRANTS:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We did not issue any warrants during the fiscal years
ended March 31, 2024 and 2023.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;A summary of the aggregate warrant activity for the years ended March 31,
2024 and 2023 is presented below:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zjrRuohhDUZk" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - EQUITY TRANSACTIONS (Details - Warrant activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BD_zc64ZANAi60f" style="display: none"&gt;Schedule of warrant activity&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Fiscal Year Ended March 31,&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted &lt;br/&gt;
Average&lt;br/&gt;
Exercise Price&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted &lt;br/&gt;
Average&lt;br/&gt;
Exercise Price&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 40%"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding, beginning of year&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zErRFHQtOS21" style="width: 12%; text-align: right" title="Warrants outstanding, beginning balance"&gt;&lt;span style="font-size: 10pt"&gt;32,676&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z73szTak1zCc" style="width: 12%; text-align: right" title="Weighted average exercise price, outstanding"&gt;&lt;span style="font-size: 10pt"&gt;20.09&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zQWlbkhmxtlg" style="width: 12%; text-align: right" title="Warrants outstanding, beginning balance"&gt;&lt;span style="font-size: 10pt"&gt;57,678&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z1NQWo5Bdd2h" style="width: 12%; text-align: right" title="Weighted average exercise price, outstanding"&gt;&lt;span style="font-size: 10pt"&gt;112.11&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcLK0okqnZQ" style="text-align: right" title="Warrants granted"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zdvrFbnbF6o7" style="text-align: right" title="Warrants granted"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di0_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zX2mxOoxuLv8" style="text-align: right" title="Warrants exercised"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zCiBQp6KJlj9" style="text-align: right" title="Warrants exercised"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Cancelled/Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di0_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z3c4VtgFLfHa" style="border-bottom: black 1pt solid; text-align: right" title="Warrants cancelled/forfeited"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;N/A &lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zxVFX3lREgN8" style="border-bottom: black 1pt solid; text-align: right" title="Warrants cancelled/forfeited"&gt;&lt;span style="font-size: 10pt"&gt;(25,002&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zPmmYV2OC7Gf" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price, cancelled/forfeited"&gt;&lt;span style="font-size: 10pt"&gt;232.38&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Outstanding, end of year&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zBdSgpfERaJ7" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants outstanding, ending balance"&gt;&lt;span style="font-size: 10pt"&gt;32,676&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zft8EZaaOf6j" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price, outstanding"&gt;&lt;span style="font-size: 10pt"&gt;20.09&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z1JkEI0bVAQf" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants outstanding, ending balance"&gt;&lt;span style="font-size: 10pt"&gt;32,676&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zaQ0UdOwhNPg" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price, outstanding"&gt;&lt;span style="font-size: 10pt"&gt;20.09&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Exercisable, end of year&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zoZawamDWMV6" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants exercisable"&gt;&lt;span style="font-size: 10pt"&gt;32,676&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLAmPpU8JRH4" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price, exercisable"&gt;&lt;span style="font-size: 10pt"&gt;20.09&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zDD5qMxpkLBi" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants exercisable"&gt;&lt;span style="font-size: 10pt"&gt;32,676&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8Q5GDlVIf24" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price, exercisable"&gt;&lt;span style="font-size: 10pt"&gt;20.09&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Weighted average estimated fair value of warrants granted&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_zLiLKhbjjWL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The detail of the warrants outstanding and exercisable as of March 31,
2024 is as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--SummaryOfWarrantActivityExercisableAndOutstandingTableTextBlock_zCTkxJUWeQs8" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - EQUITY TRANSACTIONS (Details - Warrants outstanding and exercisable)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B9_zRfmV7tr2YLh" style="display: none"&gt;Schedule of warrant activity exercisable and outstanding&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Warrants Outstanding&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Warrants Exercisable&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Range of &lt;br/&gt;
Exercise Prices&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Number &lt;br/&gt;
Outstanding&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted&lt;br/&gt;
Average &lt;br/&gt;
Remaining &lt;br/&gt;
Life (Years)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted &lt;br/&gt;
Average &lt;br/&gt;
Exercise Price&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Number &lt;br/&gt;
Outstanding&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted &lt;br/&gt;
Average &lt;br/&gt;
Exercise Price&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 40%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$18.75 or Below&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice1Member_zqVRgg23Ku0f" style="width: 9%; text-align: right" title="Warrants Outstanding"&gt;&lt;span style="font-size: 10pt"&gt;20,217&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice1Member_zxZg2KrpRJj" title="Weighted Average Remaining Life (Years)"&gt;.71&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice1Member_ziqa6anj7fQf" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding"&gt;&lt;span style="font-size: 10pt"&gt;15.66&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--WarrantsExercisable_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice1Member_zFx0z2cqYgza" style="width: 9%; text-align: right" title="Warrants Exercisable"&gt;&lt;span style="font-size: 10pt"&gt;20,217&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice1Member_z2XU9erpREGg" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;&lt;span style="font-size: 10pt"&gt;15.66&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$25.00 - $27.50&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice2Member_zKQs5Q6KgJzl" style="border-bottom: black 1pt solid; text-align: right" title="Warrants Outstanding"&gt;&lt;span style="font-size: 10pt"&gt;12,459&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice2Member_z7BLNbV4s0R5" title="Weighted Average Remaining Life (Years)"&gt;.81&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice2Member_zrMMlxTPuJU5" style="text-align: right" title="Weighted Average Exercise Price, Outstanding"&gt;&lt;span style="font-size: 10pt"&gt;27.28&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--WarrantsExercisable_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice2Member_zgXpqLYI943a" style="border-bottom: black 1pt solid; text-align: right" title="Warrants Exercisable"&gt;&lt;span style="font-size: 10pt"&gt;12,459&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice2Member_zR38fdz1F1jf" style="text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;&lt;span style="font-size: 10pt"&gt;27.28&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_c20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRT14IUA1Drf" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants Outstanding"&gt;&lt;span style="font-size: 10pt"&gt;32,676&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--WarrantsExercisable_c20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4puQseb3ni3" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants Exercisable"&gt;&lt;span style="font-size: 10pt"&gt;32,676&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The detail of the warrants outstanding and exercisable as of March 31,
2023 is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - EQUITY TRANSACTIONS (Details - Warrants outstanding and exercisable)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Warrants Outstanding&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Warrants Exercisable&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Range of &lt;br/&gt;
Exercise Prices&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Number &lt;br/&gt;
Outstanding&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted&lt;br/&gt;
Average &lt;br/&gt;
Remaining &lt;br/&gt;
Life (Years)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted &lt;br/&gt;
Average &lt;br/&gt;
Exercise Price&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Number &lt;br/&gt;
Outstanding&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted &lt;br/&gt;
Average &lt;br/&gt;
Exercise Price&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 40%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$18.75 or Below&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice1Member_zMDn1beQPOq2" style="width: 9%; text-align: right" title="Warrants Outstanding"&gt;&lt;span style="font-size: 10pt"&gt;20,217&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice1Member_zNj195r1vayi" title="Weighted Average Remaining Life (Years)"&gt;1.71&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice1Member_zh5a5LmGMCJk" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding"&gt;&lt;span style="font-size: 10pt"&gt;15.66&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--WarrantsExercisable_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice1Member_zCXbCCFc65C8" style="width: 9%; text-align: right" title="Warrants Exercisable"&gt;&lt;span style="font-size: 10pt"&gt;20,217&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice1Member_zytkwLEoRzB6" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;&lt;span style="font-size: 10pt"&gt;15.66&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$25.00 - $27.50&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice2Member_zE7764lhzJe7" style="border-bottom: black 1pt solid; text-align: right" title="Warrants Outstanding"&gt;&lt;span style="font-size: 10pt"&gt;12,459&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice2Member_zC2arOIZVZd8" title="Weighted Average Remaining Life (Years)"&gt;1.81&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice2Member_zxx0lRcBfui7" style="text-align: right" title="Weighted Average Exercise Price, Outstanding"&gt;&lt;span style="font-size: 10pt"&gt;27.28&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--WarrantsExercisable_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice2Member_zqrRWurBd0q6" style="border-bottom: black 1pt solid; text-align: right" title="Warrants Exercisable"&gt;&lt;span style="font-size: 10pt"&gt;12,459&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice2Member_zHWwfxaMLRi4" style="text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;&lt;span style="font-size: 10pt"&gt;27.28&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zTIPr7Rlv5m8" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants Outstanding"&gt;&lt;span style="font-size: 10pt"&gt;32,676&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--WarrantsExercisable_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zFJOcWyvolee" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants Exercisable"&gt;&lt;span style="font-size: 10pt"&gt;32,676&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AB_z6RqhSv5NpJ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;STOCK-BASED COMPENSATION:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;2020 EQUITY INCENTIVE PLAN&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In September 2020, our stockholders approved the adoption
of the 2020 Plan, to provide incentives to attract, retain and motivate employees, directors and consultants, whose present and potential
contributions are important to our success, by offering them an opportunity to participate in our future performance through awards of
options, the right to purchase common stock, stock bonuses and stock appreciation rights and other awards. We initially authorized a total
of 168,182 common shares for issuance under the 2020 Plan pursuant to stock option grants, RSUs or other forms of stock-based compensation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In September 2022, our stockholders approved an increase
in the number of shares of common stock authorized for issuance under the 2020 Plan by &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20220901__20220930_zI8C9t6Jyyuh" title="Additional shares authorized for issuance during period"&gt;180,000&lt;/span&gt; shares. As of March 31, 2024, there were
&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20240331_zfQTqb6ARUK7" title="Shares available for grant"&gt;200,948&lt;/span&gt; shares available under the 2020 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;NON-EMPLOYEE DIRECTOR COMPENSATION POLICY&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company maintains the Director Compensation Policy
which provides for cash and equity compensation for persons serving as non-employee directors of the Company. Under this policy, each
new non-employee director receives either stock options or a grant of RSUs upon appointment/election, as well as either an annual grant
of stock options or of RSUs at the beginning of each fiscal year. The (i) stock options are subject to vesting and (ii) RSUs are subject
to vesting and represent the right to be issued on a future date shares of our common stock upon vesting.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Please see above under the heading "Equity Transactions
in the Fiscal Year Ended March 31, 2024&#x2014;RSU Grants to Non-Employee Directors" for disclosure regarding equity awards under
the Director Compensation Policy during the fiscal year ended March 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;STOCK OPTION ACTIVITY&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the fiscal year ended March 31, 2024, we
did not issue stock option grants. The assumptions used in estimating the fair value of stock options in the fiscal year ended
March 31, 2023 included volatility ranging from &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20220401__20230331_zYkakYHYZg79" title="Volatility rate minimum"&gt;136.1&lt;/span&gt;%
to &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_c20220401__20230331_zFU5MSpsgwNa" title="Volatility rate maximum"&gt;140&lt;/span&gt;%,
a &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20220401__20230331_zWtcPVL8yQh3" title="Dividend rate"&gt;0&lt;/span&gt;%
dividend rate, and risk-free rates between &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_c20220401__20230331_zLAes0DMOtm5" title="Risk-free rate minimum"&gt;1.49&lt;/span&gt;%
and &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_c20220401__20230331_zWR1rsy1N2Lh" title="Risk-free rate maximum"&gt;2.14&lt;/span&gt;%.
The weighted average expected volatility was &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_dp_c20220401__20230331_z54Wq3uOv63g" title="Weighted average expected volatility"&gt;138.07&lt;/span&gt;%&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Options outstanding that were vested as of March 31,
2024 and options that are expected to vest subsequent to March 31, 2024 are as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_zeQfQoHkAvCi" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - EQUITY TRANSACTIONS (Details - Option outstanding)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B3_z9WBEuvaNlz6" style="display: none"&gt;Schedule of options outstanding that have vested and are expected to
    vest&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Number of&lt;br/&gt;
Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Remaining&lt;br/&gt;
Contractual&lt;br/&gt;
Term in&lt;br/&gt;
Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 58%"&gt;&lt;span style="font-size: 10pt"&gt;Vested&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zzSCXSgVNxQ5" style="width: 11%; text-align: right" title="Number of options, vested"&gt;&lt;span style="font-size: 10pt"&gt;57,813&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zjOOQHqmjxCa" style="width: 11%; text-align: right" title="Weighted average exercise price options vested"&gt;&lt;span style="font-size: 10pt"&gt;19.41&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zWxejGs86AMi" title="Weighted average remaining contractual term options vested"&gt;6.96&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Expected to vest&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zkzaRkcuZq2b" style="border-bottom: black 1pt solid; text-align: right" title="Number of options, expected to vest"&gt;&lt;span style="font-size: 10pt"&gt;28,653&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z8qYt28MfGK1" style="text-align: right" title="Weighted average exercise price options expected to vest"&gt;&lt;span style="font-size: 10pt"&gt;15.01&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zUEVRtYqLVB" title="Weighted average remaining contractual term options expected to vest"&gt;7.78&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zYzaPiy3Sgi2" style="border-bottom: black 2.25pt double; text-align: right" title="Total options outstanding"&gt;&lt;span style="font-size: 10pt"&gt;86,466&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A3_zo7oB9dbzxpb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following is a summary of the stock options outstanding
at March 31, 2024 and 2023 and the changes during the years then ended:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zAo9W5bWaQ0l" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - EQUITY TRANSACTIONS (Details - Option activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BE_zvYTHa5c8m37" style="display: none"&gt;Schedule of stock option activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;Fiscal Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted&lt;br/&gt; Average &lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Outstanding, beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zJ6BZbcgH0r2" style="width: 11%; text-align: right" title="Stock options outstanding, beginning balance"&gt;171,825&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zd9Lr6oXWk16" style="width: 11%; text-align: right" title="Weighted average exercise price, beginning price"&gt;22.4&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z7EL3WVVghjg" style="width: 11%; text-align: right" title="Stock options outstanding, beginning balance"&gt;166,595&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z9XtW264Q9Di" style="width: 11%; text-align: right" title="Weighted average exercise price, beginning price"&gt;23.1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z3mpFvi4AlL5" style="text-align: right" title="Stock options granted"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zF535IQpTae" style="text-align: right" title="Weighted average exercise price, granted"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z27kKhcJaq2d" style="text-align: right" title="Stock options granted"&gt;12,222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zONZZJ2JADQ9" style="text-align: right" title="Weighted average exercise price, granted"&gt;9.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Cancelled/Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zPO14r3CVAO6" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options cancelled/forfeited"&gt;(85,359&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zKct4XVQNeIa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, cancelled/forfeited"&gt;26.89&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zYAOAZMnbTm8" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options cancelled/forfeited"&gt;(6,992&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z074cgoVFI5i" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, cancelled/forfeited"&gt;17.70&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Outstanding, end of year&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zMDsfI9BwkYk" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options outstanding, ending balance"&gt;86,466&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_ziPnJ37rutOk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending price"&gt;17.95&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zh9hPJnRIDW7" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options outstanding, ending balance"&gt;171,825&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zC2LJB2Eh9w6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending price"&gt;22.4&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Exercisable, end of year&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zGWMPGA3CeW4" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options exercisable"&gt;57,813&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zSaAAn4FBf8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"&gt;19.41&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20230331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zFnqDcZdr0Yc" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options exercisable"&gt;75,554&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zfhFqQX5Lyjh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"&gt;24.5&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Weighted average estimated fair value of options granted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zJvUGQFKBEh6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;There were &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_do_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zx5gQYvnXAG2" title="Stock option grants"&gt;no&lt;/span&gt; stock option grants during the fiscal year ended March 31,
2024. There were &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zNhBHato4vql" title="Stock option grants"&gt;12,222&lt;/span&gt; stock options granted during the fiscal year ended March 31, 2023. The weighted average grant date fair value
of stock options granted during the fiscal year ended March 31, 2023 was $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220401__20230331_zTs7A57P6cCg" title="Weighted average grant date fair value of stock options granted"&gt;61,146&lt;/span&gt;. There were &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230401__20240331_zSUu9ggeU4q6" title="RSUs issued"&gt;54,428&lt;/span&gt; RSUs granted during the fiscal year ended
March 31, 2024. The weighted average grant date fair value of RSUs granted during the fiscal year ended March 31, 2024 was $&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230401__20240331__us-gaap--AwardTypeAxis__custom--RSUMember_zOx5GVhiss4l" title="Weighted average grant date fair value ofRSUs stock options granted"&gt;58,333&lt;/span&gt;. There
were &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20230401__20240331_z9Wtqeb9Ji8c" title="Stock option exercises"&gt;&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20220401__20230331_zJLQKG57Xtlf" title="Stock option exercises"&gt;no&lt;/span&gt;&lt;/span&gt; stock option exercises during the fiscal years ended March 31, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The table below summarizes nonvested stock options  as of March
31, 2024 and changes during the year ended March 31, 2024.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_zl1QTeytm0pg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - EQUITY TRANSACTIONS (Details - Nonvested shares)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B0_zZ1fRm6Q6Lwb" style="display: none"&gt;Schedule of  nonvested shares&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted Average Grant Date Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%"&gt;Nonvested stock options  at April 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20230401__20240331_zMTjRNzFKiq8" style="width: 13%; text-align: right" title="Nonvested shares outstanding, beginning balance"&gt;96,273&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230401__20240331_zWKHgOemzkt1" style="width: 13%; text-align: right" title="Weighted average grant date fair value nonvested shares outstanding, beginning balance"&gt;19.99&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20230401__20240331_zEXXPRjxnxHh" style="text-align: right" title="Options vested"&gt;(21,934&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20230401__20240331_zlrfBxDHrQ9c" style="text-align: right" title="Weighted average grant date fair value nonvested shares outstanding, vested"&gt;1.59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_di_c20230401__20240331_zjn8WPNypCfi" style="border-bottom: Black 1pt solid; text-align: right" title="Options forfeited"&gt;(45,686&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c20230401__20240331_zSlkZLqDL0A8" style="padding-bottom: 1pt; text-align: right" title="Weighted average grant date fair value nonvested shares outstanding, forfeited"&gt;2.55&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Nonvested stock options at March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20230401__20240331_z6YrQr3yxHGc" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested shares outstanding, ending balance"&gt;28,653&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A0_zjmxK3E30udc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The detail of the options outstanding and exercisable as of March 31, 2024
is as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zM4VSKyttegi" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - EQUITY TRANSACTIONS (Details - Options exercisable)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_8B7_zj2Z90QzmWpb" style="display: none"&gt;Schedule of detail of options outstanding and exercisable by exercise
    price&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Exercise Prices&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Number &lt;br/&gt;
Outstanding&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted &lt;br/&gt;
Average &lt;br/&gt;
Remaining &lt;br/&gt;
Life (Years)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted &lt;br/&gt;
Average &lt;br/&gt;
Exercise &lt;br/&gt;
Price&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Number &lt;br/&gt;
Outstanding&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted &lt;br/&gt;
Average &lt;br/&gt;
Exercise &lt;br/&gt;
Price&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 18%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$6.90 - $16.80&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zGq4gqX9uNP" style="width: 13%; text-align: right" title="Stock options outstanding"&gt;&lt;span style="font-size: 10pt"&gt;62,204&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zUOqqKRLAEy4" title="Weighted average remaining life (years)"&gt;7.48&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zmR3wP7meMvi" style="width: 13%; text-align: right" title="Weighted average exercise price, outstanding"&gt;&lt;span style="font-size: 10pt"&gt;13.24&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zklPUYSbuolc" style="width: 13%; text-align: right" title="Stock options exercisable"&gt;&lt;span style="font-size: 10pt"&gt;38,589&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z8zB7Z5oNx6b" style="width: 13%; text-align: right" title="Weighted average exercise price, exercisable"&gt;&lt;span style="font-size: 10pt"&gt;13.48&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$25.20&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zf6AbHdu0sHd" style="text-align: right" title="Stock options outstanding"&gt;&lt;span style="font-size: 10pt"&gt;24,178&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zs0V3d0utOTa" title="Weighted average remaining life (years)"&gt;6.76&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zzmqv2jt834k" style="text-align: right" title="Weighted average exercise price, outstanding"&gt;&lt;span style="font-size: 10pt"&gt;25.20&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_z3eOYSRcQDM7" style="text-align: right" title="Stock options exercisable"&gt;&lt;span style="font-size: 10pt"&gt;19,140&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zfcqfSE7r7cj" style="text-align: right" title="Weighted average exercise price, exercisable"&gt;&lt;span style="font-size: 10pt"&gt;25.20&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&lt;span style="font-size: 10pt"&gt;$1,425.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_z2EWuX0eYv5g" style="border-bottom: black 1pt solid; background-color: #EEEEEE; text-align: right" title="Stock options outstanding"&gt;&lt;span style="font-size: 10pt"&gt;84&lt;/span&gt;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_zolJGhzJuR0b" title="Weighted average remaining life (years)"&gt;.18&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_zAunCcU3Z8qa" style="background-color: #EEEEEE; text-align: right" title="Weighted average exercise price, outstanding"&gt;&lt;span style="font-size: 10pt"&gt;1,425.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_zw1u7z5Yx3B3" style="border-bottom: black 1pt solid; background-color: #EEEEEE; text-align: right" title="Stock options exercisable"&gt;&lt;span style="font-size: 10pt"&gt;84&lt;/span&gt;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_zDtLLYeO1f4a" style="background-color: #EEEEEE; text-align: right" title="Weighted average exercise price, exercisable"&gt;&lt;span style="font-size: 10pt"&gt;1,425.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zNmjB7LVkcmh" style="border-bottom: black 2.25pt double; background-color: white; text-align: right" title="Stock options outstanding"&gt;&lt;span style="font-size: 10pt"&gt;86,466&lt;/span&gt;&lt;/td&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zurW7KowimCg" style="border-bottom: black 2.25pt double; background-color: white; text-align: right" title="Stock options exercisable"&gt;&lt;span style="font-size: 10pt"&gt;57,813&lt;/span&gt;&lt;/td&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A9_zKl10aJdrByf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We recorded stock-based compensation expense related
to RSU issuances and to options granted totaling $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_c20230401__20240331_zTfDHCiCdVu" title="Stock based compensation expense"&gt;1,219,370&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensation_c20220401__20230331_zY3qt1U2pTG1" title="Stock based compensation expense"&gt;1,051,898&lt;/span&gt; for the fiscal years ended March 31, 2024 and 2023, respectively.
These expenses were recorded as stock compensation included in payroll and related expenses in the accompanying consolidated statement
of operations for the years ended March 31, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The table below summarizes restricted stock units
as of March 31, 2024 and changes during the year ended March 31, 2024.&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zrpEZOKJv1L4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details - RSU activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B3_z6vEdDb7F7le"&gt;&lt;b style="display: none"&gt;Schedule of RSUs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Nonvested RSUs at April 1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_d0_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGLH8q5Pc8ml" style="text-align: right" title="RSUs nonvested"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 83%"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3epeXihfsG7" style="width: 14%; text-align: right" title="RSU's granted"&gt;54,428&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di0_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zn5EcXh0jUQi" style="text-align: right" title="RSU's vested"&gt;(34,378&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Tax withholding payments or tax equivalent payments for net share settlement of restricted stock units&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_iN_di0_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAIWv3cO7XV3" style="border-bottom: Black 1pt solid; text-align: right" title="Tax withholding payments, shares"&gt;(15,165&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Nonvested RSUs at March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_d0_c20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUebWn6wZEN9" style="border-bottom: Black 2.5pt double; text-align: right" title="RSUs nonvested"&gt;4,885&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our total stock-based compensation for fiscal years
ended March 31, 2024 and 2023 included the following:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z7xqw0eos203" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - EQUITY TRANSACTIONS (Details - Stockbased compensation)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B7_z6GOuQbHNVy4" style="display: none"&gt;Schedule of stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Fiscal Year Ended&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Vesting of restricted stock units&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSYmKPhONQO5" style="width: 13%; text-align: right" title="Stock based compensation"&gt;206,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensation_pp0p0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeVj2W3NXfE1" style="width: 13%; text-align: right" title="Stock based compensation"&gt;175,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Vesting of stock options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zyOaQGVH8Qw7" style="border-bottom: Black 1pt solid; text-align: right" title="Stock based compensation"&gt;1,013,120&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensation_pp0p0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zuStMwefgWch" style="border-bottom: Black 1pt solid; text-align: right" title="Stock based compensation"&gt;876,898&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total Stock-Based Compensation&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20240331_z1RTdnLlBhXi" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation"&gt;1,219,370&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensation_pp0p0_c20220401__20230331_zeMoSTRPB7z3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation"&gt;1,051,898&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zLDnbT5mictj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We review share-based compensation on a quarterly
basis for changes to the estimate of expected award forfeitures based on actual forfeiture experience. The cumulative effect of adjusting
the forfeiture rate for all expense amortization is recognized in the period the forfeiture estimate is changed. The effect of forfeiture
adjustments for the fiscal year ended March 31, 2024 was insignificant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 31, 2024, our outstanding stock options had
no intrinsic value since the closing price on that date of $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_c20230401__20240331_z190PjfMmfL1" title="Intrinsic value per share"&gt;1.68&lt;/span&gt; per share was below the weighted average exercise price of our outstanding
stock options.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2024, there was approximately $&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20230401__20240331_z9RisB52uBvi" title="Unrecognized compensation cost to share based"&gt;400,002&lt;/span&gt;
of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted average period of
&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230401__20240331_zfWwYl4JMokc" title="Weighted average period"&gt;1.57&lt;/span&gt; years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;













</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2023-10-032023-10-04" id="Fact000661">&#160;1-for-10</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000663"
      unitRef="Shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <aemd:AggregateOfferingPrice
      contextRef="From2022-03-232022-03-24_custom_ATM2022AgreementMember"
      decimals="0"
      id="Fact000669"
      unitRef="USD">15000000</aemd:AggregateOfferingPrice>
    <aemd:AggregateOfferingPrice
      contextRef="From2022-09-282022-09-29_custom_ATM2022AgreementMember"
      decimals="0"
      id="Fact000671"
      unitRef="USD">6625000</aemd:AggregateOfferingPrice>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2024-03-31_custom_ATM2022AgreementMember"
      decimals="0"
      id="Fact000673"
      unitRef="USD">5302617</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-04-012024-03-31_custom_ATM2022AgreementMember"
      decimals="0"
      id="Fact000675"
      unitRef="USD">1322383</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2023-04-012024-03-31_custom_ATM2022AgreementMember_custom_HcWainwrightMember"
      decimals="0"
      id="Fact000677"
      unitRef="USD">34118</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2023-04-012024-03-31_custom_ATM2022AgreementMember"
      decimals="0"
      id="Fact000679"
      unitRef="USD">8202</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-012024-03-31_custom_ATM2022AgreementMember"
      decimals="INF"
      id="Fact000681"
      unitRef="Shares">296056</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <aemd:SharesIssuedPricePerShare1
      contextRef="From2023-04-012024-03-31_custom_ATM2022AgreementMember"
      decimals="INF"
      id="Fact000683"
      unitRef="USDPShares">4.47</aemd:SharesIssuedPricePerShare1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-04-012024-03-31_custom_Director1Member_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000685"
      unitRef="Shares">11628</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-04-012024-03-31_custom_Director2Member_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000687"
      unitRef="Shares">11628</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-04-012024-03-31_custom_Director3Member_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000689"
      unitRef="Shares">11628</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
      contextRef="From2023-04-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact000691">The RSUs are subject to vesting in four equal installments,
with 25% of the restricted stock units vesting on each of June 30, 2023, September 30, 2023, December 31, 2023, and March 31, 2024, subject
in each case to the director&#x2019;s Continuous Service (as defined in the 2020 Plan), through such dates. Vesting will terminate upon
the director&#x2019;s termination of Continuous Service prior to any vesting date.&#160;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000693"
      unitRef="Shares">4885</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-04-012023-03-31_custom_ATM2022AgreementMember"
      decimals="0"
      id="Fact000695"
      unitRef="USD">8927211</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2022-04-012023-03-31_custom_ATM2022AgreementMember_custom_HcWainwrightMember"
      decimals="0"
      id="Fact000697"
      unitRef="USD">229610</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2022-04-012023-03-31_custom_ATM2022AgreementMember"
      decimals="0"
      id="Fact000699"
      unitRef="USD">27153</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-04-012023-03-31_custom_ATM2022AgreementMember"
      decimals="INF"
      id="Fact000701"
      unitRef="Shares">748084</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <aemd:SharesIssuedPricePerShare1
      contextRef="From2022-04-012023-03-31_custom_ATM2022AgreementMember"
      decimals="INF"
      id="Fact000703"
      unitRef="USDPShares">11.90</aemd:SharesIssuedPricePerShare1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2022-04-012023-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000709"
      unitRef="Shares">1800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2022-04-012023-03-31_custom_EligibleDirectorsEachMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000711"
      unitRef="Shares">3425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2022-04-012023-03-31_custom_NewlyAppointedDirectorMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000713"
      unitRef="Shares">5137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
      contextRef="From2022-04-012023-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact000715">The
RSUs were subject to vesting in three installments, 50% on September 30, 2022, and 25% on each of December 31, 2022, and March 31,
2023, subject to the recipient's continued service with the Company on each such vesting date.&#160;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000717"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000719">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zjrRuohhDUZk" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - EQUITY TRANSACTIONS (Details - Warrant activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BD_zc64ZANAi60f" style="display: none"&gt;Schedule of warrant activity&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Fiscal Year Ended March 31,&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted &lt;br/&gt;
Average&lt;br/&gt;
Exercise Price&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted &lt;br/&gt;
Average&lt;br/&gt;
Exercise Price&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 40%"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding, beginning of year&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zErRFHQtOS21" style="width: 12%; text-align: right" title="Warrants outstanding, beginning balance"&gt;&lt;span style="font-size: 10pt"&gt;32,676&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z73szTak1zCc" style="width: 12%; text-align: right" title="Weighted average exercise price, outstanding"&gt;&lt;span style="font-size: 10pt"&gt;20.09&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zQWlbkhmxtlg" style="width: 12%; text-align: right" title="Warrants outstanding, beginning balance"&gt;&lt;span style="font-size: 10pt"&gt;57,678&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z1NQWo5Bdd2h" style="width: 12%; text-align: right" title="Weighted average exercise price, outstanding"&gt;&lt;span style="font-size: 10pt"&gt;112.11&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcLK0okqnZQ" style="text-align: right" title="Warrants granted"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zdvrFbnbF6o7" style="text-align: right" title="Warrants granted"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di0_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zX2mxOoxuLv8" style="text-align: right" title="Warrants exercised"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zCiBQp6KJlj9" style="text-align: right" title="Warrants exercised"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Cancelled/Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di0_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z3c4VtgFLfHa" style="border-bottom: black 1pt solid; text-align: right" title="Warrants cancelled/forfeited"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;N/A &lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zxVFX3lREgN8" style="border-bottom: black 1pt solid; text-align: right" title="Warrants cancelled/forfeited"&gt;&lt;span style="font-size: 10pt"&gt;(25,002&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zPmmYV2OC7Gf" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price, cancelled/forfeited"&gt;&lt;span style="font-size: 10pt"&gt;232.38&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Outstanding, end of year&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zBdSgpfERaJ7" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants outstanding, ending balance"&gt;&lt;span style="font-size: 10pt"&gt;32,676&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zft8EZaaOf6j" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price, outstanding"&gt;&lt;span style="font-size: 10pt"&gt;20.09&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z1JkEI0bVAQf" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants outstanding, ending balance"&gt;&lt;span style="font-size: 10pt"&gt;32,676&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zaQ0UdOwhNPg" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price, outstanding"&gt;&lt;span style="font-size: 10pt"&gt;20.09&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Exercisable, end of year&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zoZawamDWMV6" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants exercisable"&gt;&lt;span style="font-size: 10pt"&gt;32,676&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLAmPpU8JRH4" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price, exercisable"&gt;&lt;span style="font-size: 10pt"&gt;20.09&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zDD5qMxpkLBi" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants exercisable"&gt;&lt;span style="font-size: 10pt"&gt;32,676&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8Q5GDlVIf24" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price, exercisable"&gt;&lt;span style="font-size: 10pt"&gt;20.09&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Weighted average estimated fair value of warrants granted&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000721"
      unitRef="Shares">32676</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000723"
      unitRef="USDPShares">20.09</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000725"
      unitRef="Shares">57678</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000727"
      unitRef="USDPShares">112.11</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-04-012024-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000729"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2022-04-012023-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000731"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2023-04-012024-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000733"
      unitRef="Shares">-0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-04-012023-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000735"
      unitRef="Shares">-0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2023-04-012024-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000737"
      unitRef="Shares">-0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2022-04-012023-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000739"
      unitRef="Shares">25002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2022-04-012023-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000741"
      unitRef="USDPShares">232.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000743"
      unitRef="Shares">32676</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000745"
      unitRef="USDPShares">20.09</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000747"
      unitRef="Shares">32676</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000749"
      unitRef="USDPShares">20.09</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber
      contextRef="AsOf2024-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000751"
      unitRef="Shares">32676</aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber>
    <aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000753"
      unitRef="USDPShares">20.09</aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice>
    <aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber
      contextRef="AsOf2023-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000755"
      unitRef="Shares">32676</aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber>
    <aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000757"
      unitRef="USDPShares">20.09</aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice>
    <aemd:SummaryOfWarrantActivityExercisableAndOutstandingTableTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000763">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--SummaryOfWarrantActivityExercisableAndOutstandingTableTextBlock_zCTkxJUWeQs8" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - EQUITY TRANSACTIONS (Details - Warrants outstanding and exercisable)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B9_zRfmV7tr2YLh" style="display: none"&gt;Schedule of warrant activity exercisable and outstanding&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Warrants Outstanding&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Warrants Exercisable&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Range of &lt;br/&gt;
Exercise Prices&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Number &lt;br/&gt;
Outstanding&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted&lt;br/&gt;
Average &lt;br/&gt;
Remaining &lt;br/&gt;
Life (Years)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted &lt;br/&gt;
Average &lt;br/&gt;
Exercise Price&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Number &lt;br/&gt;
Outstanding&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted &lt;br/&gt;
Average &lt;br/&gt;
Exercise Price&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 40%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$18.75 or Below&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice1Member_zqVRgg23Ku0f" style="width: 9%; text-align: right" title="Warrants Outstanding"&gt;&lt;span style="font-size: 10pt"&gt;20,217&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice1Member_zxZg2KrpRJj" title="Weighted Average Remaining Life (Years)"&gt;.71&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice1Member_ziqa6anj7fQf" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding"&gt;&lt;span style="font-size: 10pt"&gt;15.66&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--WarrantsExercisable_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice1Member_zFx0z2cqYgza" style="width: 9%; text-align: right" title="Warrants Exercisable"&gt;&lt;span style="font-size: 10pt"&gt;20,217&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice1Member_z2XU9erpREGg" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;&lt;span style="font-size: 10pt"&gt;15.66&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$25.00 - $27.50&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice2Member_zKQs5Q6KgJzl" style="border-bottom: black 1pt solid; text-align: right" title="Warrants Outstanding"&gt;&lt;span style="font-size: 10pt"&gt;12,459&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice2Member_z7BLNbV4s0R5" title="Weighted Average Remaining Life (Years)"&gt;.81&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice2Member_zrMMlxTPuJU5" style="text-align: right" title="Weighted Average Exercise Price, Outstanding"&gt;&lt;span style="font-size: 10pt"&gt;27.28&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--WarrantsExercisable_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice2Member_zgXpqLYI943a" style="border-bottom: black 1pt solid; text-align: right" title="Warrants Exercisable"&gt;&lt;span style="font-size: 10pt"&gt;12,459&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice2Member_zR38fdz1F1jf" style="text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;&lt;span style="font-size: 10pt"&gt;27.28&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_c20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRT14IUA1Drf" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants Outstanding"&gt;&lt;span style="font-size: 10pt"&gt;32,676&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--WarrantsExercisable_c20240331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4puQseb3ni3" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants Exercisable"&gt;&lt;span style="font-size: 10pt"&gt;32,676&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The detail of the warrants outstanding and exercisable as of March 31,
2023 is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - EQUITY TRANSACTIONS (Details - Warrants outstanding and exercisable)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Warrants Outstanding&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Warrants Exercisable&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Range of &lt;br/&gt;
Exercise Prices&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Number &lt;br/&gt;
Outstanding&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted&lt;br/&gt;
Average &lt;br/&gt;
Remaining &lt;br/&gt;
Life (Years)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted &lt;br/&gt;
Average &lt;br/&gt;
Exercise Price&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Number &lt;br/&gt;
Outstanding&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted &lt;br/&gt;
Average &lt;br/&gt;
Exercise Price&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 40%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$18.75 or Below&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice1Member_zMDn1beQPOq2" style="width: 9%; text-align: right" title="Warrants Outstanding"&gt;&lt;span style="font-size: 10pt"&gt;20,217&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice1Member_zNj195r1vayi" title="Weighted Average Remaining Life (Years)"&gt;1.71&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice1Member_zh5a5LmGMCJk" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding"&gt;&lt;span style="font-size: 10pt"&gt;15.66&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--WarrantsExercisable_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice1Member_zCXbCCFc65C8" style="width: 9%; text-align: right" title="Warrants Exercisable"&gt;&lt;span style="font-size: 10pt"&gt;20,217&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice1Member_zytkwLEoRzB6" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;&lt;span style="font-size: 10pt"&gt;15.66&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$25.00 - $27.50&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice2Member_zE7764lhzJe7" style="border-bottom: black 1pt solid; text-align: right" title="Warrants Outstanding"&gt;&lt;span style="font-size: 10pt"&gt;12,459&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice2Member_zC2arOIZVZd8" title="Weighted Average Remaining Life (Years)"&gt;1.81&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice2Member_zxx0lRcBfui7" style="text-align: right" title="Weighted Average Exercise Price, Outstanding"&gt;&lt;span style="font-size: 10pt"&gt;27.28&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--WarrantsExercisable_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice2Member_zqrRWurBd0q6" style="border-bottom: black 1pt solid; text-align: right" title="Warrants Exercisable"&gt;&lt;span style="font-size: 10pt"&gt;12,459&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOfExercisePrice2Member_zHWwfxaMLRi4" style="text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;&lt;span style="font-size: 10pt"&gt;27.28&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zTIPr7Rlv5m8" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants Outstanding"&gt;&lt;span style="font-size: 10pt"&gt;32,676&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--WarrantsExercisable_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zFJOcWyvolee" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants Exercisable"&gt;&lt;span style="font-size: 10pt"&gt;32,676&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</aemd:SummaryOfWarrantActivityExercisableAndOutstandingTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice1Member"
      decimals="INF"
      id="Fact000765"
      unitRef="Shares">20217</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2023-04-012024-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice1Member"
      id="Fact000767">P0Y8M15D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice1Member"
      decimals="INF"
      id="Fact000769"
      unitRef="USDPShares">15.66</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <aemd:WarrantsExercisable
      contextRef="AsOf2024-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice1Member"
      decimals="INF"
      id="Fact000771"
      unitRef="Shares">20217</aemd:WarrantsExercisable>
    <aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice1Member"
      decimals="INF"
      id="Fact000773"
      unitRef="USDPShares">15.66</aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice2Member"
      decimals="INF"
      id="Fact000775"
      unitRef="Shares">12459</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2023-04-012024-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice2Member"
      id="Fact000777">P0Y9M21D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice2Member"
      decimals="INF"
      id="Fact000779"
      unitRef="USDPShares">27.28</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <aemd:WarrantsExercisable
      contextRef="AsOf2024-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice2Member"
      decimals="INF"
      id="Fact000781"
      unitRef="Shares">12459</aemd:WarrantsExercisable>
    <aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice2Member"
      decimals="INF"
      id="Fact000783"
      unitRef="USDPShares">27.28</aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000785"
      unitRef="Shares">32676</us-gaap:ClassOfWarrantOrRightOutstanding>
    <aemd:WarrantsExercisable
      contextRef="AsOf2024-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000787"
      unitRef="Shares">32676</aemd:WarrantsExercisable>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice1Member"
      decimals="INF"
      id="Fact000789"
      unitRef="Shares">20217</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2022-04-012023-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice1Member"
      id="Fact000791">P1Y8M15D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice1Member"
      decimals="INF"
      id="Fact000793"
      unitRef="USDPShares">15.66</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <aemd:WarrantsExercisable
      contextRef="AsOf2023-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice1Member"
      decimals="INF"
      id="Fact000795"
      unitRef="Shares">20217</aemd:WarrantsExercisable>
    <aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice1Member"
      decimals="INF"
      id="Fact000797"
      unitRef="USDPShares">15.66</aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice2Member"
      decimals="INF"
      id="Fact000799"
      unitRef="Shares">12459</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2022-04-012023-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice2Member"
      id="Fact000801">P1Y9M21D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice2Member"
      decimals="INF"
      id="Fact000803"
      unitRef="USDPShares">27.28</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <aemd:WarrantsExercisable
      contextRef="AsOf2023-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice2Member"
      decimals="INF"
      id="Fact000805"
      unitRef="Shares">12459</aemd:WarrantsExercisable>
    <aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_us-gaap_WarrantMember_custom_RangeOfExercisePrice2Member"
      decimals="INF"
      id="Fact000807"
      unitRef="USDPShares">27.28</aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000809"
      unitRef="Shares">32676</us-gaap:ClassOfWarrantOrRightOutstanding>
    <aemd:WarrantsExercisable
      contextRef="AsOf2023-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000811"
      unitRef="Shares">32676</aemd:WarrantsExercisable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2022-09-012022-09-30"
      decimals="INF"
      id="Fact000813"
      unitRef="Shares">180000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000815"
      unitRef="Shares">200948</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2022-04-012023-03-31"
      decimals="INF"
      id="Fact000821"
      unitRef="Pure">1.361</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2022-04-012023-03-31"
      decimals="INF"
      id="Fact000823"
      unitRef="Pure">1.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-04-012023-03-31"
      decimals="INF"
      id="Fact000825"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2022-04-012023-03-31"
      decimals="INF"
      id="Fact000827"
      unitRef="Pure">0.0149</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2022-04-012023-03-31"
      decimals="INF"
      id="Fact000829"
      unitRef="Pure">0.0214</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2022-04-012023-03-31"
      decimals="INF"
      id="Fact000831"
      unitRef="Pure">1.3807</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000833">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_zeQfQoHkAvCi" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - EQUITY TRANSACTIONS (Details - Option outstanding)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B3_z9WBEuvaNlz6" style="display: none"&gt;Schedule of options outstanding that have vested and are expected to
    vest&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Number of&lt;br/&gt;
Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Remaining&lt;br/&gt;
Contractual&lt;br/&gt;
Term in&lt;br/&gt;
Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 58%"&gt;&lt;span style="font-size: 10pt"&gt;Vested&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zzSCXSgVNxQ5" style="width: 11%; text-align: right" title="Number of options, vested"&gt;&lt;span style="font-size: 10pt"&gt;57,813&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zjOOQHqmjxCa" style="width: 11%; text-align: right" title="Weighted average exercise price options vested"&gt;&lt;span style="font-size: 10pt"&gt;19.41&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zWxejGs86AMi" title="Weighted average remaining contractual term options vested"&gt;6.96&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Expected to vest&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zkzaRkcuZq2b" style="border-bottom: black 1pt solid; text-align: right" title="Number of options, expected to vest"&gt;&lt;span style="font-size: 10pt"&gt;28,653&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z8qYt28MfGK1" style="text-align: right" title="Weighted average exercise price options expected to vest"&gt;&lt;span style="font-size: 10pt"&gt;15.01&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zUEVRtYqLVB" title="Weighted average remaining contractual term options expected to vest"&gt;7.78&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zYzaPiy3Sgi2" style="border-bottom: black 2.25pt double; text-align: right" title="Total options outstanding"&gt;&lt;span style="font-size: 10pt"&gt;86,466&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2023-04-012024-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000835"
      unitRef="Shares">57813</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000837"
      unitRef="USDPShares">19.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-04-012024-03-31_us-gaap_StockOptionMember"
      id="Fact000839">P6Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000841"
      unitRef="Shares">28653</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000843"
      unitRef="USDPShares">15.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-04-012024-03-31_us-gaap_StockOptionMember"
      id="Fact000845">P7Y9M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000847"
      unitRef="Shares">86466</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000849">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zAo9W5bWaQ0l" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - EQUITY TRANSACTIONS (Details - Option activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BE_zvYTHa5c8m37" style="display: none"&gt;Schedule of stock option activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;Fiscal Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted&lt;br/&gt; Average &lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Outstanding, beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zJ6BZbcgH0r2" style="width: 11%; text-align: right" title="Stock options outstanding, beginning balance"&gt;171,825&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zd9Lr6oXWk16" style="width: 11%; text-align: right" title="Weighted average exercise price, beginning price"&gt;22.4&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z7EL3WVVghjg" style="width: 11%; text-align: right" title="Stock options outstanding, beginning balance"&gt;166,595&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z9XtW264Q9Di" style="width: 11%; text-align: right" title="Weighted average exercise price, beginning price"&gt;23.1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z3mpFvi4AlL5" style="text-align: right" title="Stock options granted"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zF535IQpTae" style="text-align: right" title="Weighted average exercise price, granted"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z27kKhcJaq2d" style="text-align: right" title="Stock options granted"&gt;12,222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zONZZJ2JADQ9" style="text-align: right" title="Weighted average exercise price, granted"&gt;9.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Cancelled/Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zPO14r3CVAO6" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options cancelled/forfeited"&gt;(85,359&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zKct4XVQNeIa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, cancelled/forfeited"&gt;26.89&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zYAOAZMnbTm8" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options cancelled/forfeited"&gt;(6,992&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z074cgoVFI5i" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, cancelled/forfeited"&gt;17.70&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Outstanding, end of year&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zMDsfI9BwkYk" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options outstanding, ending balance"&gt;86,466&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_ziPnJ37rutOk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending price"&gt;17.95&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zh9hPJnRIDW7" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options outstanding, ending balance"&gt;171,825&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zC2LJB2Eh9w6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending price"&gt;22.4&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Exercisable, end of year&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zGWMPGA3CeW4" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options exercisable"&gt;57,813&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zSaAAn4FBf8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"&gt;19.41&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20230331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zFnqDcZdr0Yc" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options exercisable"&gt;75,554&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zfhFqQX5Lyjh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"&gt;24.5&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Weighted average estimated fair value of options granted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-03-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000851"
      unitRef="Shares">171825</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000853"
      unitRef="USDPShares">22.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-03-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000855"
      unitRef="Shares">166595</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-03-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000857"
      unitRef="USDPShares">23.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2023-04-012024-03-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000859"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-04-012024-03-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000861"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2022-04-012023-03-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000863"
      unitRef="Shares">12222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-04-012023-03-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000865"
      unitRef="USDPShares">9.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2023-04-012024-03-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000867"
      unitRef="Shares">85359</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-04-012024-03-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000869"
      unitRef="USDPShares">26.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2022-04-012023-03-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000871"
      unitRef="Shares">6992</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-04-012023-03-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000873"
      unitRef="USDPShares">17.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-03-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000875"
      unitRef="Shares">86466</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000877"
      unitRef="USDPShares">17.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-03-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000879"
      unitRef="Shares">171825</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000881"
      unitRef="USDPShares">22.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-03-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000883"
      unitRef="Shares">57813</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000885"
      unitRef="USDPShares">19.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-03-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000887"
      unitRef="Shares">75554</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000889"
      unitRef="USDPShares">24.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2023-04-012024-03-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000891"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2022-04-012023-03-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000893"
      unitRef="Shares">12222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-04-012023-03-31"
      decimals="INF"
      id="Fact000895"
      unitRef="USDPShares">61146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-04-01to2024-03-31"
      decimals="INF"
      id="Fact000897"
      unitRef="USDPShares">54428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-04-012024-03-31_custom_RSUMember"
      decimals="0"
      id="Fact000899"
      unitRef="USD">58333</aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-04-01to2024-03-31"
      decimals="INF"
      id="Fact000901"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-04-012023-03-31"
      decimals="INF"
      id="Fact000903"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000909">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_zl1QTeytm0pg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - EQUITY TRANSACTIONS (Details - Nonvested shares)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B0_zZ1fRm6Q6Lwb" style="display: none"&gt;Schedule of  nonvested shares&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted Average Grant Date Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%"&gt;Nonvested stock options  at April 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20230401__20240331_zMTjRNzFKiq8" style="width: 13%; text-align: right" title="Nonvested shares outstanding, beginning balance"&gt;96,273&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230401__20240331_zWKHgOemzkt1" style="width: 13%; text-align: right" title="Weighted average grant date fair value nonvested shares outstanding, beginning balance"&gt;19.99&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20230401__20240331_zEXXPRjxnxHh" style="text-align: right" title="Options vested"&gt;(21,934&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20230401__20240331_zlrfBxDHrQ9c" style="text-align: right" title="Weighted average grant date fair value nonvested shares outstanding, vested"&gt;1.59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_di_c20230401__20240331_zjn8WPNypCfi" style="border-bottom: Black 1pt solid; text-align: right" title="Options forfeited"&gt;(45,686&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c20230401__20240331_zSlkZLqDL0A8" style="padding-bottom: 1pt; text-align: right" title="Weighted average grant date fair value nonvested shares outstanding, forfeited"&gt;2.55&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Nonvested stock options at March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20230401__20240331_z6YrQr3yxHGc" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested shares outstanding, ending balance"&gt;28,653&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2023-03-31"
      decimals="INF"
      id="Fact000911"
      unitRef="Shares">96273</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-03-31"
      decimals="INF"
      id="Fact000913"
      unitRef="USDPShares">19.99</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2023-04-01to2024-03-31"
      decimals="INF"
      id="Fact000915"
      unitRef="Shares">21934</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="From2023-04-01to2024-03-31"
      decimals="INF"
      id="Fact000917"
      unitRef="USDPShares">1.59</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="From2023-04-01to2024-03-31"
      decimals="INF"
      id="Fact000919"
      unitRef="Shares">45686</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="From2023-04-01to2024-03-31"
      decimals="INF"
      id="Fact000921"
      unitRef="USDPShares">2.55</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000923"
      unitRef="Shares">28653</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000925">&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zM4VSKyttegi" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - EQUITY TRANSACTIONS (Details - Options exercisable)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_8B7_zj2Z90QzmWpb" style="display: none"&gt;Schedule of detail of options outstanding and exercisable by exercise
    price&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Exercise Prices&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Number &lt;br/&gt;
Outstanding&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted &lt;br/&gt;
Average &lt;br/&gt;
Remaining &lt;br/&gt;
Life (Years)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted &lt;br/&gt;
Average &lt;br/&gt;
Exercise &lt;br/&gt;
Price&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Number &lt;br/&gt;
Outstanding&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Weighted &lt;br/&gt;
Average &lt;br/&gt;
Exercise &lt;br/&gt;
Price&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 18%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$6.90 - $16.80&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zGq4gqX9uNP" style="width: 13%; text-align: right" title="Stock options outstanding"&gt;&lt;span style="font-size: 10pt"&gt;62,204&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zUOqqKRLAEy4" title="Weighted average remaining life (years)"&gt;7.48&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zmR3wP7meMvi" style="width: 13%; text-align: right" title="Weighted average exercise price, outstanding"&gt;&lt;span style="font-size: 10pt"&gt;13.24&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zklPUYSbuolc" style="width: 13%; text-align: right" title="Stock options exercisable"&gt;&lt;span style="font-size: 10pt"&gt;38,589&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z8zB7Z5oNx6b" style="width: 13%; text-align: right" title="Weighted average exercise price, exercisable"&gt;&lt;span style="font-size: 10pt"&gt;13.48&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$25.20&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zf6AbHdu0sHd" style="text-align: right" title="Stock options outstanding"&gt;&lt;span style="font-size: 10pt"&gt;24,178&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zs0V3d0utOTa" title="Weighted average remaining life (years)"&gt;6.76&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zzmqv2jt834k" style="text-align: right" title="Weighted average exercise price, outstanding"&gt;&lt;span style="font-size: 10pt"&gt;25.20&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_z3eOYSRcQDM7" style="text-align: right" title="Stock options exercisable"&gt;&lt;span style="font-size: 10pt"&gt;19,140&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zfcqfSE7r7cj" style="text-align: right" title="Weighted average exercise price, exercisable"&gt;&lt;span style="font-size: 10pt"&gt;25.20&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&lt;span style="font-size: 10pt"&gt;$1,425.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_z2EWuX0eYv5g" style="border-bottom: black 1pt solid; background-color: #EEEEEE; text-align: right" title="Stock options outstanding"&gt;&lt;span style="font-size: 10pt"&gt;84&lt;/span&gt;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_zolJGhzJuR0b" title="Weighted average remaining life (years)"&gt;.18&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_zAunCcU3Z8qa" style="background-color: #EEEEEE; text-align: right" title="Weighted average exercise price, outstanding"&gt;&lt;span style="font-size: 10pt"&gt;1,425.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_zw1u7z5Yx3B3" style="border-bottom: black 1pt solid; background-color: #EEEEEE; text-align: right" title="Stock options exercisable"&gt;&lt;span style="font-size: 10pt"&gt;84&lt;/span&gt;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #EEEEEE"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_zDtLLYeO1f4a" style="background-color: #EEEEEE; text-align: right" title="Weighted average exercise price, exercisable"&gt;&lt;span style="font-size: 10pt"&gt;1,425.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zNmjB7LVkcmh" style="border-bottom: black 2.25pt double; background-color: white; text-align: right" title="Stock options outstanding"&gt;&lt;span style="font-size: 10pt"&gt;86,466&lt;/span&gt;&lt;/td&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zurW7KowimCg" style="border-bottom: black 2.25pt double; background-color: white; text-align: right" title="Stock options exercisable"&gt;&lt;span style="font-size: 10pt"&gt;57,813&lt;/span&gt;&lt;/td&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: white; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-03-31_us-gaap_OptionMember_custom_ExercisePrice1Member"
      decimals="INF"
      id="Fact000927"
      unitRef="Shares">62204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-04-012024-03-31_us-gaap_OptionMember_custom_ExercisePrice1Member"
      id="Fact000929">P7Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_OptionMember_custom_ExercisePrice1Member"
      decimals="INF"
      id="Fact000931"
      unitRef="USDPShares">13.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-03-31_us-gaap_OptionMember_custom_ExercisePrice1Member"
      decimals="INF"
      id="Fact000933"
      unitRef="Shares">38589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_OptionMember_custom_ExercisePrice1Member"
      decimals="INF"
      id="Fact000935"
      unitRef="USDPShares">13.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-03-31_us-gaap_OptionMember_custom_ExercisePrice2Member"
      decimals="INF"
      id="Fact000937"
      unitRef="Shares">24178</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-04-012024-03-31_us-gaap_OptionMember_custom_ExercisePrice2Member"
      id="Fact000939">P6Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_OptionMember_custom_ExercisePrice2Member"
      decimals="INF"
      id="Fact000941"
      unitRef="USDPShares">25.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-03-31_us-gaap_OptionMember_custom_ExercisePrice2Member"
      decimals="INF"
      id="Fact000943"
      unitRef="Shares">19140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_OptionMember_custom_ExercisePrice2Member"
      decimals="INF"
      id="Fact000945"
      unitRef="USDPShares">25.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-03-31_us-gaap_OptionMember_custom_ExercisePrice3Member"
      decimals="INF"
      id="Fact000947"
      unitRef="Shares">84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-04-012024-03-31_us-gaap_OptionMember_custom_ExercisePrice3Member"
      id="Fact000949">P0Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_OptionMember_custom_ExercisePrice3Member"
      decimals="INF"
      id="Fact000951"
      unitRef="USDPShares">1425.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-03-31_us-gaap_OptionMember_custom_ExercisePrice3Member"
      decimals="INF"
      id="Fact000953"
      unitRef="Shares">84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_OptionMember_custom_ExercisePrice3Member"
      decimals="INF"
      id="Fact000955"
      unitRef="USDPShares">1425.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-03-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000957"
      unitRef="Shares">86466</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-03-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000959"
      unitRef="Shares">57813</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000961"
      unitRef="USD">1219370</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000963"
      unitRef="USD">1051898</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000965">&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zrpEZOKJv1L4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details - RSU activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B3_z6vEdDb7F7le"&gt;&lt;b style="display: none"&gt;Schedule of RSUs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Nonvested RSUs at April 1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_d0_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGLH8q5Pc8ml" style="text-align: right" title="RSUs nonvested"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 83%"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3epeXihfsG7" style="width: 14%; text-align: right" title="RSU's granted"&gt;54,428&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di0_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zn5EcXh0jUQi" style="text-align: right" title="RSU's vested"&gt;(34,378&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Tax withholding payments or tax equivalent payments for net share settlement of restricted stock units&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_iN_di0_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAIWv3cO7XV3" style="border-bottom: Black 1pt solid; text-align: right" title="Tax withholding payments, shares"&gt;(15,165&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Nonvested RSUs at March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_d0_c20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUebWn6wZEN9" style="border-bottom: Black 2.5pt double; text-align: right" title="RSUs nonvested"&gt;4,885&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000967"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-04-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000969"
      unitRef="Shares">54428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2023-04-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000971"
      unitRef="Shares">34378</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="From2023-04-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000973"
      unitRef="Shares">15165</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000975"
      unitRef="Shares">4885</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact000977">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z7xqw0eos203" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - EQUITY TRANSACTIONS (Details - Stockbased compensation)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B7_z6GOuQbHNVy4" style="display: none"&gt;Schedule of stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Fiscal Year Ended&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Vesting of restricted stock units&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSYmKPhONQO5" style="width: 13%; text-align: right" title="Stock based compensation"&gt;206,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensation_pp0p0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeVj2W3NXfE1" style="width: 13%; text-align: right" title="Stock based compensation"&gt;175,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Vesting of stock options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zyOaQGVH8Qw7" style="border-bottom: Black 1pt solid; text-align: right" title="Stock based compensation"&gt;1,013,120&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensation_pp0p0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zuStMwefgWch" style="border-bottom: Black 1pt solid; text-align: right" title="Stock based compensation"&gt;876,898&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total Stock-Based Compensation&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20240331_z1RTdnLlBhXi" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation"&gt;1,219,370&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensation_pp0p0_c20220401__20230331_zeMoSTRPB7z3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation"&gt;1,051,898&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-04-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact000979"
      unitRef="USD">206250</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-04-012023-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact000981"
      unitRef="USD">175000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-04-012024-03-31_us-gaap_OptionMember"
      decimals="0"
      id="Fact000983"
      unitRef="USD">1013120</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-04-012023-03-31_us-gaap_OptionMember"
      decimals="0"
      id="Fact000985"
      unitRef="USD">876898</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000987"
      unitRef="USD">1219370</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000989"
      unitRef="USD">1051898</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
      contextRef="From2023-04-01to2024-03-31"
      decimals="INF"
      id="Fact000991"
      unitRef="USDPShares">1.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact000993"
      unitRef="USD">400002</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2023-04-01to2024-03-31" id="Fact000995">P1Y6M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact001002">&lt;p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zXzFo02h0Km8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;5. &lt;span id="xdx_823_z3YoTzrCTcv2"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;DUE TO RELATED PARTIES&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;For the fiscal year ended
March 31, 2024 we accrued unpaid fees of $&lt;span id="xdx_906_ecustom--AccruedDirectorFees_iI_c20240331__srt--CounterpartyNameAxis__custom--NonEmployeeDirectorsMember_z2Yx90Q7Q1k3" title="Accrued director fees"&gt;68,250&lt;/span&gt;&#160;owed to our non-employee directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;As a result of entering
into a Separation Agreement effective November 27, 2023 with our former Chief Executive Officer, or CEO, Charles J. Fisher, M.D., or
the Separation Agreement, we paid out accrued vacation of $&lt;span id="xdx_904_eus-gaap--SeveranceCosts1_c20230401__20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Dr.FisherMember__us-gaap--TypeOfArrangementAxis__custom--SeparationAgreementMember_zwrQCWDa0Efb"&gt;53,076&lt;/span&gt;
to Dr. Fisher in the fiscal year ended March 31, 2024. That accrued vacation was previously recorded in the due to related parties
account. In addition, pursuant to the terms of Dr. Fisher&#x2019;s Executive Employment Agreement, we accrued $&lt;span id="xdx_90C_eus-gaap--SeveranceCosts1_c20231201__20240331__us-gaap--TypeOfArrangementAxis__custom--SeparationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Dr.FisherMember_zxIVA3rQtFtd"&gt;435,378 &lt;/span&gt;for
cash severance payments payable monthly and COBRA payments to be paid monthly over a 12-month period that began on December 1,
2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Additionally, $&lt;span id="xdx_90C_eus-gaap--DeferredCompensationLiabilityCurrent_iI_c20240331_zp2xMdvt0E2j" title="Accrued stock-based compensation"&gt;393,139&lt;/span&gt;
of stock-based compensation was recorded during the fiscal year ended March 31, 2024 for the acceleration of vesting for 50% of then outstanding
options held by Dr. Fisher at the time of his separation from the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;Amounts
due to related parties were comprised of the following items:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zj8M4CoQqLfa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RELATED PARTY TRANSACTIONS (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8B9_zJTXDMWKaWH4" style="display: none"&gt;Schedule of amounts
due to related parties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, &#160;&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Accrued Board fees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--DueToRelatedPartiesCurrent1_iI_c20240331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedBoardFeesMember_z3BAoXbanhT3" style="width: 13%; text-align: right" title="Total due to related parties"&gt;68,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--DueToRelatedPartiesCurrent1_iI_c20230331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedBoardFeesMember_zIfHf7bbzvBg" style="width: 13%; text-align: right" title="Total due to related parties"&gt;57,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued vacation to all employees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--DueToRelatedPartiesCurrent1_iI_c20240331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedVacationToAllEmployeesMember_z2sADtbisxN" style="text-align: right" title="Total due to related parties"&gt;167,973&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--DueToRelatedPartiesCurrent1_iI_c20230331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedVacationToAllEmployeesMember_zyqmR5c2SgUj" style="text-align: right" title="Total due to related parties"&gt;157,221&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accrued separation expenses for former executive&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--DueToRelatedPartiesCurrent1_iI_c20240331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedSeparationExpensesForFormerExecutiveMember_zqhcYvMzHLRd" style="border-bottom: Black 1pt solid; text-align: right" title="Total due to related parties"&gt;310,211&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--DueToRelatedPartiesCurrent1_iI_d0_c20230331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedSeparationExpensesForFormerExecutiveMember_zJ7Egt01PYl" style="border-bottom: Black 1pt solid; text-align: right" title="Total due to related parties"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total due to related parties&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--DueToRelatedPartiesCurrent1_iI_c20240331_zbM3YRV2iSOf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total due to related parties"&gt;546,434&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--DueToRelatedPartiesCurrent1_iI_c20230331_zNbNL4Ohriqa" style="border-bottom: Black 2.5pt double; text-align: right" title="Total due to related parties"&gt;214,221&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <aemd:AccruedDirectorFees
      contextRef="AsOf2024-03-31_custom_NonEmployeeDirectorsMember"
      decimals="0"
      id="Fact001004"
      unitRef="USD">68250</aemd:AccruedDirectorFees>
    <us-gaap:SeveranceCosts1
      contextRef="From2023-04-012024-03-31_custom_Dr.FisherMember_custom_SeparationAgreementMember"
      decimals="0"
      id="Fact001005"
      unitRef="USD">53076</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="From2023-12-012024-03-31_custom_SeparationAgreementMember_custom_Dr.FisherMember"
      decimals="0"
      id="Fact001006"
      unitRef="USD">435378</us-gaap:SeveranceCosts1>
    <us-gaap:DeferredCompensationLiabilityCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001008"
      unitRef="USD">393139</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact001010">&lt;table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zj8M4CoQqLfa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RELATED PARTY TRANSACTIONS (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8B9_zJTXDMWKaWH4" style="display: none"&gt;Schedule of amounts
due to related parties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, &#160;&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Accrued Board fees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--DueToRelatedPartiesCurrent1_iI_c20240331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedBoardFeesMember_z3BAoXbanhT3" style="width: 13%; text-align: right" title="Total due to related parties"&gt;68,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--DueToRelatedPartiesCurrent1_iI_c20230331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedBoardFeesMember_zIfHf7bbzvBg" style="width: 13%; text-align: right" title="Total due to related parties"&gt;57,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued vacation to all employees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--DueToRelatedPartiesCurrent1_iI_c20240331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedVacationToAllEmployeesMember_z2sADtbisxN" style="text-align: right" title="Total due to related parties"&gt;167,973&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--DueToRelatedPartiesCurrent1_iI_c20230331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedVacationToAllEmployeesMember_zyqmR5c2SgUj" style="text-align: right" title="Total due to related parties"&gt;157,221&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accrued separation expenses for former executive&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--DueToRelatedPartiesCurrent1_iI_c20240331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedSeparationExpensesForFormerExecutiveMember_zqhcYvMzHLRd" style="border-bottom: Black 1pt solid; text-align: right" title="Total due to related parties"&gt;310,211&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--DueToRelatedPartiesCurrent1_iI_d0_c20230331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedSeparationExpensesForFormerExecutiveMember_zJ7Egt01PYl" style="border-bottom: Black 1pt solid; text-align: right" title="Total due to related parties"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total due to related parties&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--DueToRelatedPartiesCurrent1_iI_c20240331_zbM3YRV2iSOf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total due to related parties"&gt;546,434&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--DueToRelatedPartiesCurrent1_iI_c20230331_zNbNL4Ohriqa" style="border-bottom: Black 2.5pt double; text-align: right" title="Total due to related parties"&gt;214,221&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <aemd:DueToRelatedPartiesCurrent1
      contextRef="AsOf2024-03-31_custom_AccruedBoardFeesMember"
      decimals="0"
      id="Fact001012"
      unitRef="USD">68250</aemd:DueToRelatedPartiesCurrent1>
    <aemd:DueToRelatedPartiesCurrent1
      contextRef="AsOf2023-03-31_custom_AccruedBoardFeesMember"
      decimals="0"
      id="Fact001014"
      unitRef="USD">57000</aemd:DueToRelatedPartiesCurrent1>
    <aemd:DueToRelatedPartiesCurrent1
      contextRef="AsOf2024-03-31_custom_AccruedVacationToAllEmployeesMember"
      decimals="0"
      id="Fact001016"
      unitRef="USD">167973</aemd:DueToRelatedPartiesCurrent1>
    <aemd:DueToRelatedPartiesCurrent1
      contextRef="AsOf2023-03-31_custom_AccruedVacationToAllEmployeesMember"
      decimals="0"
      id="Fact001018"
      unitRef="USD">157221</aemd:DueToRelatedPartiesCurrent1>
    <aemd:DueToRelatedPartiesCurrent1
      contextRef="AsOf2024-03-31_custom_AccruedSeparationExpensesForFormerExecutiveMember"
      decimals="0"
      id="Fact001020"
      unitRef="USD">310211</aemd:DueToRelatedPartiesCurrent1>
    <aemd:DueToRelatedPartiesCurrent1
      contextRef="AsOf2023-03-31_custom_AccruedSeparationExpensesForFormerExecutiveMember"
      decimals="0"
      id="Fact001022"
      unitRef="USD">0</aemd:DueToRelatedPartiesCurrent1>
    <aemd:DueToRelatedPartiesCurrent1
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001024"
      unitRef="USD">546434</aemd:DueToRelatedPartiesCurrent1>
    <aemd:DueToRelatedPartiesCurrent1
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact001026"
      unitRef="USD">214221</aemd:DueToRelatedPartiesCurrent1>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact001028">&lt;p id="xdx_807_eus-gaap--OtherLiabilitiesDisclosureTextBlock_zYEugq0TOhwe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;6. &lt;span id="xdx_82B_zRhllrMutL4g"&gt;OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Other current liabilities were comprised of the following items:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zvtquUdNM57b" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OTHER CURRENT LIABILITIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8BC_za5mGk7Sp6j8" style="display: none"&gt;Schedule of other current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240331_z8TUYRKPoTs1" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230331_z8DqaMkyRnG8" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maOLCzgCt_z0gYTssShTI4" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Accrued professional fees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;215,038&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;184,472&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--AccruedCommissionLiability_iI_pp0p0_d0_maOLCzgCt_zdOUX9uWyzn2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accrued commission liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;404,120&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OtherLiabilitiesCurrent_iTI_pp0p0_mtOLCzgCt_zIZbY8R15PF1" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total other current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;215,038&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;588,592&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During 2017 through 2020, the Company incorrectly
recorded accrued commission liability of approximately $404,000. The Company reversed accrued commission liability of approximately $404,000
during the year ended March 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact001030">&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zvtquUdNM57b" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OTHER CURRENT LIABILITIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8BC_za5mGk7Sp6j8" style="display: none"&gt;Schedule of other current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240331_z8TUYRKPoTs1" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230331_z8DqaMkyRnG8" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maOLCzgCt_z0gYTssShTI4" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Accrued professional fees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;215,038&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;184,472&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--AccruedCommissionLiability_iI_pp0p0_d0_maOLCzgCt_zdOUX9uWyzn2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accrued commission liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;404,120&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OtherLiabilitiesCurrent_iTI_pp0p0_mtOLCzgCt_zIZbY8R15PF1" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total other current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;215,038&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;588,592&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001032"
      unitRef="USD">215038</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact001033"
      unitRef="USD">184472</us-gaap:AccruedProfessionalFeesCurrent>
    <aemd:AccruedCommissionLiability
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001035"
      unitRef="USD">0</aemd:AccruedCommissionLiability>
    <aemd:AccruedCommissionLiability
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact001036"
      unitRef="USD">404120</aemd:AccruedCommissionLiability>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001038"
      unitRef="USD">215038</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact001039"
      unitRef="USD">588592</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact001041">&lt;p id="xdx_804_eus-gaap--IncomeTaxDisclosureTextBlock_zcsMpX9UmJU8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;7. &lt;span id="xdx_829_zcut8WBupfce"&gt;INCOME TAXES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the years ended March 31, 2024 and 2023, we had
no income tax expense due to our net operating losses and 100% deferred tax asset valuation allowance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2024 and 2023, we had net deferred tax
assets as detailed below. These deferred tax assets are primarily composed of capitalized research and development costs and tax net operating
loss carryforwards. Due to uncertainties surrounding our ability to generate future taxable income to realize these assets, a 100% valuation
allowance has been established to offset the net deferred tax assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Significant components of our net deferred tax assets
at March 31, 2024 and 2023 are shown below:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zoLLJ0sLPNBa" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - INCOME TAXES (Details - Deferred tax assets)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B3_zgF3kcWb5tVg" style="display: none"&gt;Schedule of deferred tax assets&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240331_z4VaK1Wx75hi" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230331_z2PwwUFcRSjl" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;YEAR ENDED MARCH 31,&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNetAbstract_iB" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_maDTAGzgu3_zWmy1WzIoTpa" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 68%"&gt;&lt;span style="font-size: 10pt"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,442,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,442,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_d0_maDTAGzgu3_zdSeixhkk9j2" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;646,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;519,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzgu3_zfcDQE15kE9f" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Net operating loss carryforwards&lt;sup id="xdx_F45_ztCw7rmSw7Ge"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;26,927,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;24,158,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_maDTAGzgu3_zRMO5kCzz6uc" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,244,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,903,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzgu3_maDTANzQ3M_zCWb1Bw0SBP6" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;33,259,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;30,022,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxLiabilities_iI_d0_zhNrlTbAq5Wk" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_zFTUMaiX59ge" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;33,259,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;30,022,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzQ3M_z4YAdZXxDEJ3" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(33,259,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(30,022,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iI_d0_mtDTANzQ3M_zLjwOD9IdBHh" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;______________&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 2%"&gt;&lt;span id="xdx_F04_zPTN1fUPFNWd" style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; width: 98%"&gt;&lt;span id="xdx_F1E_zuxC2VzOtnie" style="font-size: 10pt"&gt;Pursuant to Internal Revenue Code Section 382, use of
    our tax net operating loss carryforwards may be limited. The amount of the annual limitation, if any, will be determined based on the value of the Company immediately
prior to an ownership change. Subsequent ownership changes may further affect the limitation in future years. If and when the Company
utilizes the NOL carryforwards in a future period, it will perform an analysis to determine the effect, if any, of these loss limitation
rules on the NOL carryforward balances.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A9_zZ8Fw1pqBmLk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2024, we had tax net operating loss carryforwards
for federal and state purposes approximating $&lt;span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pn6n6_c20240331__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_zgrQTlg39uWk" title="Net operating loss carryforward"&gt;98&lt;/span&gt; million and $&lt;span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_pn6n6_c20240331__us-gaap--IncomeTaxAuthorityAxis__custom--StateMember_zu4dcesZ6ZPg" title="Net operating loss carryforward"&gt;91&lt;/span&gt; million, respectively, portions of which began to expire in the year
2021. The indefinite position is approximately $&lt;span id="xdx_902_ecustom--UnrecognizedTaxBenefitsIndefiniteTaxPosition_iI_pn6n6_c20240331_za3rWde7uUwg" title="Indefinite position amount"&gt;36&lt;/span&gt; million. Research and Development credits begin to expire in 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The provision for income taxes on earnings subject
to income taxes differs from the statutory federal rate for the years ended March 31, 2024 and 2023 due to the following:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zgLbNogOlGy7" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - INCOME TAXES (Details - Provision for income taxes)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BE_zJVYfwDIQXka" style="display: none"&gt;Schedule of provision for income taxes&lt;/span&gt; &lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230401__20240331_z5qnv41gDEv7" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220401__20230331_z1IsodZwyyha" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzXSL_zECZnihdl8ye" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 68%"&gt;&lt;span style="font-size: 10pt"&gt;Income taxes (benefit) at federal statutory rate of 21.00%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(2,564,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(2,526,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_maITEBzXSL_zwz6UjVUUiVh" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Tax effect on non-deductible expenses and credits&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--TrueUpItems_msITEBzXSL_zBOZR8I2qmu" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;True up items&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(29,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;57,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--NetOperatingLossCarryforwardsExpiration_maITEBzXSL_zwLWD6CdLWsc" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Expiration of net operating loss carryforwards &lt;sup id="xdx_F4C_zQzmbEhF0Mw3"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;204,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;353,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzXSL_zFvJQU2QOeH2" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,387,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,114,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_iT_d0_mtITEBzXSL_zm192IICrDCi" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Income Tax Expense (Benefit)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;______________&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 2%"&gt;&lt;span id="xdx_F09_zFFeg7ThfXM8" style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 98%"&gt;&lt;span id="xdx_F10_z0hhl1v5txw5" style="font-size: 10pt"&gt;Pursuant to Internal Revenue Code Section 382, use of our tax net operating loss carryforwards may be limited.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A5_zgTPoOiglQm" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;ASC 740, &#x201c;Income Taxes&#x201d;, clarifies the
accounting for uncertainty in income taxes recognized in an entity's financial statements, and prescribes recognition thresholds and measurement
attributes for financial statement disclosure of tax positions taken or expected to be taken on a tax return. Under ASC 740, the impact
of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to
be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than
a 50% likelihood of being sustained. Additionally, ASC 740 provides guidance on derecognition, classification, interest and penalties,
accounting in interim periods, disclosure and transition. Our practice is to recognize interest and/or penalties related to income tax
matters in income tax expense. During the years ended March 31, 2024 and 2023, we did not recognize any interest or penalties relating
to tax matters.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At and for the years ended March 31, 2024 and 2023,
management does not believe the Company has any uncertain tax positions. Accordingly, there are &lt;span id="xdx_909_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20240331_zU1llxWn8EP6" title="Unrecognized tax benefits"&gt;&lt;span id="xdx_90F_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20230331_zOu9sRW2U4Qk" title="Unrecognized tax benefits"&gt;no&lt;/span&gt;&lt;/span&gt; unrecognized tax benefits at&#160;March
31, 2024 or March 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our tax returns remain open for examination by the
applicable authorities, generally 3 years for federal and 4 years for state. We are currently not under examination by any taxing authorities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact001047">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zoLLJ0sLPNBa" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - INCOME TAXES (Details - Deferred tax assets)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B3_zgF3kcWb5tVg" style="display: none"&gt;Schedule of deferred tax assets&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240331_z4VaK1Wx75hi" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230331_z2PwwUFcRSjl" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;YEAR ENDED MARCH 31,&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNetAbstract_iB" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_maDTAGzgu3_zWmy1WzIoTpa" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 68%"&gt;&lt;span style="font-size: 10pt"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,442,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,442,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_d0_maDTAGzgu3_zdSeixhkk9j2" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;646,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;519,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzgu3_zfcDQE15kE9f" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Net operating loss carryforwards&lt;sup id="xdx_F45_ztCw7rmSw7Ge"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;26,927,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;24,158,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_maDTAGzgu3_zRMO5kCzz6uc" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,244,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,903,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzgu3_maDTANzQ3M_zCWb1Bw0SBP6" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;33,259,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;30,022,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxLiabilities_iI_d0_zhNrlTbAq5Wk" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_zFTUMaiX59ge" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;33,259,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;30,022,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzQ3M_z4YAdZXxDEJ3" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(33,259,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(30,022,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iI_d0_mtDTANzQ3M_zLjwOD9IdBHh" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;______________&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 2%"&gt;&lt;span id="xdx_F04_zPTN1fUPFNWd" style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; width: 98%"&gt;&lt;span id="xdx_F1E_zuxC2VzOtnie" style="font-size: 10pt"&gt;Pursuant to Internal Revenue Code Section 382, use of
    our tax net operating loss carryforwards may be limited. The amount of the annual limitation, if any, will be determined based on the value of the Company immediately
prior to an ownership change. Subsequent ownership changes may further affect the limitation in future years. If and when the Company
utilizes the NOL carryforwards in a future period, it will perform an analysis to determine the effect, if any, of these loss limitation
rules on the NOL carryforward balances.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001052"
      unitRef="USD">3442000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact001053"
      unitRef="USD">3442000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001055"
      unitRef="USD">646000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact001056"
      unitRef="USD">519000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001058"
      unitRef="USD">26927000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact001059"
      unitRef="USD">24158000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001061"
      unitRef="USD">2244000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact001062"
      unitRef="USD">1903000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001064"
      unitRef="USD">33259000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact001065"
      unitRef="USD">30022000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001067"
      unitRef="USD">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact001068"
      unitRef="USD">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001070"
      unitRef="USD">33259000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact001071"
      unitRef="USD">30022000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001073"
      unitRef="USD">33259000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact001074"
      unitRef="USD">30022000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001076"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact001077"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-03-31_custom_FederalMember"
      decimals="-6"
      id="Fact001080"
      unitRef="USD">98000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-03-31_custom_StateMember"
      decimals="-6"
      id="Fact001082"
      unitRef="USD">91000000</us-gaap:OperatingLossCarryforwards>
    <aemd:UnrecognizedTaxBenefitsIndefiniteTaxPosition
      contextRef="AsOf2024-03-31"
      decimals="-6"
      id="Fact001084"
      unitRef="USD">36000000</aemd:UnrecognizedTaxBenefitsIndefiniteTaxPosition>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact001086">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zgLbNogOlGy7" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - INCOME TAXES (Details - Provision for income taxes)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BE_zJVYfwDIQXka" style="display: none"&gt;Schedule of provision for income taxes&lt;/span&gt; &lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230401__20240331_z5qnv41gDEv7" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220401__20230331_z1IsodZwyyha" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzXSL_zECZnihdl8ye" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 68%"&gt;&lt;span style="font-size: 10pt"&gt;Income taxes (benefit) at federal statutory rate of 21.00%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(2,564,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(2,526,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_maITEBzXSL_zwz6UjVUUiVh" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Tax effect on non-deductible expenses and credits&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--TrueUpItems_msITEBzXSL_zBOZR8I2qmu" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;True up items&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(29,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;57,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--NetOperatingLossCarryforwardsExpiration_maITEBzXSL_zwLWD6CdLWsc" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Expiration of net operating loss carryforwards &lt;sup id="xdx_F4C_zQzmbEhF0Mw3"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;204,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;353,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzXSL_zFvJQU2QOeH2" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,387,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,114,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_iT_d0_mtITEBzXSL_zm192IICrDCi" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Income Tax Expense (Benefit)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;______________&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 2%"&gt;&lt;span id="xdx_F09_zFFeg7ThfXM8" style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 98%"&gt;&lt;span id="xdx_F10_z0hhl1v5txw5" style="font-size: 10pt"&gt;Pursuant to Internal Revenue Code Section 382, use of our tax net operating loss carryforwards may be limited.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact001088"
      unitRef="USD">-2564000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact001089"
      unitRef="USD">-2526000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact001091"
      unitRef="USD">2000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact001092"
      unitRef="USD">2000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <aemd:TrueUpItems
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact001094"
      unitRef="USD">-29000</aemd:TrueUpItems>
    <aemd:TrueUpItems
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact001095"
      unitRef="USD">57000</aemd:TrueUpItems>
    <aemd:NetOperatingLossCarryforwardsExpiration
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact001097"
      unitRef="USD">204000</aemd:NetOperatingLossCarryforwardsExpiration>
    <aemd:NetOperatingLossCarryforwardsExpiration
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact001098"
      unitRef="USD">353000</aemd:NetOperatingLossCarryforwardsExpiration>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact001100"
      unitRef="USD">2387000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact001101"
      unitRef="USD">2114000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact001103"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact001104"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001111"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact001113"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact001115">&lt;p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zPViucQLJSM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;8. &lt;span id="xdx_82B_zhvoG53SdgWc"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;CONTRACTUAL OBLIGATIONS AND COMMITMENTS&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We have had the following material changes to our
contractual obligations and commitments outside the ordinary course of business during the fiscal year ended March 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;LEASE COMMITMENTS&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Office, Lab and Manufacturing Space Leases&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_903_eus-gaap--LesseeOperatingLeaseDescription_c20230401__20240331__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeAndLaboratorySpaceMember_zPRLCT1Vva0d" title="Lease description"&gt;In December 2020, we entered into an agreement to
lease approximately 2,823 square feet of office space and 1,807 square feet of laboratory space located at 11555 Sorrento Valley Road,
Suite 203, San Diego, California 92121 and 11575 Sorrento Valley Road, Suite 200, San Diego, California 92121, respectively. The agreement
carries a term of 63 months and we took possession of the office space effective October 1, 2021.&lt;/span&gt; We took possession of the laboratory
space effective January 1, 2022. &lt;span id="xdx_908_eus-gaap--LesseeOperatingLeaseDescription_c20230401__20240331__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--ManufacturingSpaceMember_zwVa3vynt6gc" title="Lease description"&gt;In October 2021, we entered into another lease for approximately 2,655 square feet of space to house
our manufacturing operations located at 11588 Sorrento Valley Road, San Diego, California 92121. The term is for 55 months and we took
possession of the manufacturing space in August 2022.&lt;/span&gt; The current &lt;span id="xdx_90E_eus-gaap--DebtInstrumentFrequencyOfPeriodicPayment_c20230401__20240331__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeAndLaboratorySpaceMember_zGNfDIkCnzZ9" title="Lease frequency of periodic payment"&gt;monthly&lt;/span&gt; base rent under the office and laboratory component of the lease
is $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentPeriodicPayment_c20230401__20240331__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeAndLaboratorySpaceMember_zXoWXfaL3EA1" title="Lease periodic payment"&gt;14,158&lt;/span&gt;. The current &lt;span id="xdx_909_eus-gaap--DebtInstrumentFrequencyOfPeriodicPayment_c20230401__20240331__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--ManufacturingSpaceMember_zQWUZfyfOACi" title="Lease frequency of periodic payment"&gt;monthly&lt;/span&gt; base rent under the manufacturing component of the lease is $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentPeriodicPayment_c20230401__20240331__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--ManufacturingSpaceMember_z9W30M9IcDOc" title="Lease periodic payment"&gt;12,452&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The office, lab and manufacturing leases are coterminous
with a remaining term of &lt;span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20240331__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeLabAndManufacturingLeasesMember_zXfDJaekMsAh" title="Remaining lease term"&gt;36&lt;/span&gt; months. The weighted average discount rate is &lt;span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20240331__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeLabAndManufacturingLeasesMember_zSrjkfmnqMXi" title="Lease weighted average discount rate"&gt;4.25&lt;/span&gt;%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of our March 31, 2024 balance sheet, we have a
right-of-use lease asset of $&lt;span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAsset_pp0p0_c20240331_zWrAGczgnHYc" title="Right of use lease asset"&gt;883,054&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table presents a maturity analysis of
expected undiscounted cash flows for operating leases on an annual basis for the next three fiscal years. All of our leases conterminously
expire during the fiscal year ending March 31, 2027.&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zK4nAp4l8dSa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B7_z7FhDgCC9Swc" style="display: none"&gt;Schedule of lease maturity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240331_z6dhqMaZyu0b" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Fiscal Years Ended March 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zJMuWIbaSDc6" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 84%; text-align: justify"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;323,812&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zcA9W1YWXw7j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;333,462&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_zeLx8eLzJLcg" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;343,352&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_zHLmsSGMMUxf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,000,626&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zZkWdfJS7Spk" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Less amount representing imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(60,310&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_zOr0NYHjjAq6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Present value of minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;940,316&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Mobile Clean Room&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition, we rented a mobile clean room on a short
term, month-to-month basis, where we housed our manufacturing operations until our permanent manufacturing space was completed. The mobile
clean room was located on leased land near our office and lab and we paid $2,000 per month for the right to locate it there. The arrangement
was terminated in September 2022 and the mobile clean room was returned to the vendor that leased it to us.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Overall, our rent expense, which is included in general
and administrative expenses, approximated $&lt;span id="xdx_90C_eus-gaap--OperatingLeaseExpense_pp0p0_c20230401__20240331_zpzu4perRGn2" title="Operating lease expense"&gt;420,353&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--OperatingLeaseExpense_pp0p0_c20220401__20230331_zlRjQZad4Ksi" title="Operating lease expense"&gt;519,000&lt;/span&gt; for the fiscal years ended March 31, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;LEGAL MATTERS&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;From time to time, claims are made against us in the
ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties
and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or more
products or engaging in other activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The occurrence of an unfavorable outcome in any specific
period could have a material adverse effect on our results of operations for that period or future periods. We are not presently a party
to any pending or threatened legal proceedings.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="From2023-04-012024-03-31_custom_OfficeAndLaboratorySpaceMember"
      id="Fact001117">In December 2020, we entered into an agreement to
lease approximately 2,823 square feet of office space and 1,807 square feet of laboratory space located at 11555 Sorrento Valley Road,
Suite 203, San Diego, California 92121 and 11575 Sorrento Valley Road, Suite 200, San Diego, California 92121, respectively. The agreement
carries a term of 63 months and we took possession of the office space effective October 1, 2021.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="From2023-04-012024-03-31_custom_ManufacturingSpaceMember"
      id="Fact001119">In October 2021, we entered into another lease for approximately 2,655 square feet of space to house
our manufacturing operations located at 11588 Sorrento Valley Road, San Diego, California 92121. The term is for 55 months and we took
possession of the manufacturing space in August 2022.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment
      contextRef="From2023-04-012024-03-31_custom_OfficeAndLaboratorySpaceMember"
      id="Fact001121">monthly</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2023-04-012024-03-31_custom_OfficeAndLaboratorySpaceMember"
      decimals="0"
      id="Fact001123"
      unitRef="USD">14158</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment
      contextRef="From2023-04-012024-03-31_custom_ManufacturingSpaceMember"
      id="Fact001125">monthly</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2023-04-012024-03-31_custom_ManufacturingSpaceMember"
      decimals="0"
      id="Fact001127"
      unitRef="USD">12452</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="AsOf2024-03-31_custom_OfficeLabAndManufacturingLeasesMember"
      id="Fact001129">P36M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-03-31_custom_OfficeLabAndManufacturingLeasesMember"
      decimals="INF"
      id="Fact001131"
      unitRef="Pure">0.0425</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001133"
      unitRef="USD">883054</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact001135">&lt;table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zK4nAp4l8dSa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B7_z7FhDgCC9Swc" style="display: none"&gt;Schedule of lease maturity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240331_z6dhqMaZyu0b" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Fiscal Years Ended March 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zJMuWIbaSDc6" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 84%; text-align: justify"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;323,812&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zcA9W1YWXw7j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;333,462&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_zeLx8eLzJLcg" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;343,352&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_zHLmsSGMMUxf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,000,626&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zZkWdfJS7Spk" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Less amount representing imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(60,310&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_zOr0NYHjjAq6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Present value of minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;940,316&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001137"
      unitRef="USD">323812</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001139"
      unitRef="USD">333462</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001141"
      unitRef="USD">343352</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001143"
      unitRef="USD">1000626</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001145"
      unitRef="USD">60310</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001147"
      unitRef="USD">940316</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2023-04-01to2024-03-31"
      decimals="0"
      id="Fact001153"
      unitRef="USD">420353</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact001155"
      unitRef="USD">519000</us-gaap:OperatingLeaseExpense>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-04-01to2024-03-31" id="Fact001157">&lt;p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zfPiGqGVIelg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;9. &lt;span id="xdx_820_zOLpW8Cho4G8"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management has evaluated events subsequent to March
31, 2024 through the date that the accompanying consolidated financial statements were filed with the Securities and Exchange Commission
for transactions and other events which may require adjustment of and/or disclosure in such financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Public Offering&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 17, 2024, we closed a public offering pursuant
to which we sold an aggregate of: (i) 2,450,000 shares of our common stock and accompanying Class A warrants to purchase up to 2,450,000
shares of common stock and Class B warrants to purchase up to 2,450,000 shares of common stock, at a combined public offering price of
$0.58 per share and accompanying warrants; and (ii) in lieu of common stock, pre-funded warrants to purchase 5,650,000 shares of common
stock and accompanying Class A warrants to purchase up to 5,650,000 shares of common stock and Class B warrants to purchase up to 5,650,000
shares of common stock, at a combined public offering price of $0.579 per pre-funded warrant and accompanying warrants, which is equal
to the public offering price per share of common stock, and accompanying warrants less the $0.001 per share exercise price of each such
pre-funded warrant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Class A and Class B warrants each have an exercise
price of $0.58 per share, are immediately exercisable, and, in the case of Class A warrants, will expire on May 17, 2029, and in the case
of Class B warrants, will expire on May 19, 2025. The exercise price of the Class A and Class B warrants is also subject to adjustment
for stock splits, reverse splits, and similar capital transactions as described in such warrants. Maxim Group LLC acted as the exclusive
placement agent for the offering.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The gross proceeds from the offering, before deducting
the placement agent&#x2019;s fees and other offering expenses, were approximately $4.7 million. The Company intends to use the net proceeds
from this offering for general corporate purposes, which may include clinical trial expenses, research and development expenses, capital
expenditures and working capital.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In June 2024, holders of Class A and Class B warrants
exercised 295,000 shares and 2,875,000 shares, respectively, for total proceeds of $1,838,600.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;RSU Grants&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In April 2024, the Board approved, pursuant to the
terms of the Director Compensation Policy, the grant of the annual RSUs under the Director Compensation Policy to each of the four non-employee
directors of the Company then serving on the Board. The Director Compensation Policy provides for a grant of stock options or $50,000
worth of RSUs at the beginning of each fiscal year for current non-employee directors then serving on the Board, and for a grant of stock
options or $75,000 worth of RSUs for a newly elected non-employee director, with each RSU priced at the average for the closing prices
for the five days preceding and including the date of grant, or $1.52 per share for the April 2024 RSU grants. As a result, in April 2024
the four eligible directors were each granted an RSU in the amount of 32,894 shares under the 2020 Plan. The RSUs are subject to vesting
in four equal installments, with 25% of the restricted stock units vesting on each of June 30, 2024, September 30, 2024, December 31,
2024, and March 31, 2025, subject in each case to the director&#x2019;s Continuous Service (as defined in the 2020 Plan), through such
dates. Vesting will terminate upon the director&#x2019;s termination of Continuous Service prior to any vesting date.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact001058"
          xlink:label="Fact001058"
          xlink:type="locator"/>
        <link:footnote id="Footnote001078" xlink:label="Footnote001078" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Pursuant to Internal Revenue Code Section 382, use of
    our tax net operating loss carryforwards may be limited. The amount of the annual limitation, if any, will be determined based on the value of the Company immediately
prior to an ownership change. Subsequent ownership changes may further affect the limitation in future years. If and when the Company
utilizes the NOL carryforwards in a future period, it will perform an analysis to determine the effect, if any, of these loss limitation
rules on the NOL carryforward balances.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001058"
          xlink:to="Footnote001078"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001059"
          xlink:label="Fact001059"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001059"
          xlink:to="Footnote001078"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001097"
          xlink:label="Fact001097"
          xlink:type="locator"/>
        <link:footnote id="Footnote001105" xlink:label="Footnote001105" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Pursuant to Internal Revenue Code Section 382, use of our tax net operating loss carryforwards may be limited.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001097"
          xlink:to="Footnote001105"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001098"
          xlink:label="Fact001098"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001098"
          xlink:to="Footnote001105"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
